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8 
Introduction and aim of the thesis 
 
Cellular communication is essential for the thriving of an organism as a whole. Behavioral 
cues for individual cells come from the cellular microenvironment as well as other cells or 
soluble mediators. A wide range of surface receptors is responsible for relaying these cue, 
including G-protein coupled receptors, tyrosine kinase-associated receptors and integrins. 
Activation of these receptors by their ligands triggers cellular effects through activation of 
intracellular signal transduction pathways, which in turn relies heavily on post-translational 
modification of proteins. In particular protein phosphorylation is a pivotal modification 
mechanism, based on fast and reversible covalent binding of a phosphoryl moiety to specific 
amino acid residues in proteins (Tamura et al, 2004; Jailkhani et al, 2011). The class of 
enzymes known as kinases is able to transfer a phosphate group onto a protein, generally 
derived from and at the expense of an adenosine triphosphate (ATP) molecule, while the class 
of phosphatases is able to remove this phosphate group through hydrolysis, resulting in the 
generation of water (Figure 1). Phosphorylation of a protein may have several consequences: 
it might create new recognition sites to allow protein-protein interaction; it can control protein 
stability and, most importantly, might regulate enzymatic activity of phosphorylated proteins. 
As such, the overall tyrosine, serine and threonine phosphorylation, carefully balanced by 
kinases and phosphatase, plays a major role in signaling to lead to survival, proliferation, 
differentiation and cell death (Jailkhani et al, 2011). In the specific case of cell proliferation 
and survival signaling, integrins and tyrosine kinase-associated receptors have been 
highlighted as major players for cell growth signaling (Butti et al, 2018). The tyrosine kinase-
associated receptors include many growth factor receptors, which promote activation of 
mitogenic-activated protein kinase (MAPK) and phosphatidyl-inositol 3’-OH kinase 
(PI3K)/AKT pathways. The MAPK family members include the effector kinases p38, JNK 
and Erk. In general, p38 and JNK activate apoptosis and inflammatory pathways upon 
activation by stress signals from extracellular environment, while Erk signal transduction is 
associated with proliferation and cellular differentiation (Yang et al, 2007; Lee et al, 2020; 
Paton et al, 2020). In the same direction, the PI3K/AKT pathway plays an important role in 
cell survival, proliferation, migration and cell cycle initiation. Rather than a protein 
phosphatase, PI3K is a lipid phosphatase able to convert the membrane lipid 
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol 3,4,5-trisphosphate 
(PIP3), which allows recruitment and activation of the protein kinases PDK1 and AKT. The 
main function of AKT is to phosphorylate tuberous sclerosis protein (TSC)-1 and TSC-2, 
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promoting their disassociation and releasing their negative modulation of mTOR kinase, 
thereby allowing protein synthesis (Huang et al, 2018) - (see Figure 2). Signaling through 
integrins is associated with activation of focal adhesion kinase (FAK) and Src family kinases, 
some of the most well-described proteins associated with cell motility and survival (Mitra and 
Schlaepfer, 2006). Most signaling pathways are not completely independent, with many 
molecules associated with one pathway able to activate molecules canonically associated with 
another signaling cascade. For instance, non-canonical MAPK signaling converges on PI3K 
activation, as tyrosine kinase-associated receptors induce KRAS activation, which promotes 
both MAPK and PI3K signaling (Janku et al, 2018). Additionally, FAK is known to activate 
MAPK/PI3K pathways, while Src itself is also a known FAK target able to stimulate 
MAPK/PI3K signaling.  
 
 
Figure 1. General scheme of protein phosphorylation. The protein kinases have the function 
to add a phosphate group (PO4
2-) on protein-specific site, while protein phosphatases are able 
to remove this phosphate group. A fictional: protein is represented with a phosphorylation site 
(brown color). 
 
Protein kinases are classified as serine/threonine, tyrosine, or dual specificity depending on 
the amino acid site that will receive the phosphate group. There are around 520 protein 
kinases in the human genome, emphasizing their importance for cellular functioning. 
Conversely, abnormal activity of these enzymes is seen in a diverse range of diseases, 
including diabetes, obesity, inflammation, neurodegenerative diseases and neoplasia 
(Mustelin et al, 2005; Souza et al, 2009; Jailkhani et al, 2011; Lee et al, 2015), and more than 
300 of the tyrosine kinase genes have been implicated in carcinogenesis (Arena et al, 2005; 
Jacob et al, 2005; Julien et al, 2011; Ferreira-Halder et al, 2019). Indeed, enhanced activation 
of many kinases and receptors is seen in various cancers (Turner and Grose, 2010; Rajaram et 
al, 2017; Roskoski et al, 2018).  
Using cancer as model, several signal transduction pathways have been singled out for their 
contribution to survival and proliferation signaling, with the MAPK and PI3K/AKT pathways 
and their components emerging as arguably two of the most important pathways and 
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therapeutic targets. The MAPK family is associated with cell proliferation signaling, and this 
cascade is frequently rendered constitutively activated (i.e. independent of growth factor 
stimulation) in for instance colorectal cancer, through mutations in KRAS (30%) or BRAF 
(17%) genes (Huang et al, 2018; Tate et al, 2019; Martini et al, 2020). PI3K/AKT pathway 
activation, also associated with cellular survival, is rendered active through for instance 
mutations in the PI3KCA gene (in 15% of colonic cancers) and leads to tumor survival 
advantage (Tate et al, 2019). The principal negative modulator of PI3K/AKT signaling is the 
lipid phosphatase PTEN (Phosphatase and Tensing Homologue deleted on chromosome 10), 
which reverts the actions of PI3K by reverting PIP3 to PIP2, consequently limiting the 
pathway transduction (Keniry and Parsons, 2008; Álvarez-Garcia et al, 2019). Partial or total 
loss-of-function of PTEN is frequently observed in several types of cancer, impacting directly 
on tumorigenesis and cancer progression via PI3K pathway activation (Álvarez-Garcia et al, 
2019). A role for Src in tumorigenesis has also been described, and in fact was the first proto-
oncogene described in animal cells. The Src kinase family is well-known to be over-activated 
in several cancers, where it positively regulates survival and proliferation. For instance, 80% 
of colorectal cancer patients are suggested to have increased Src activity in their tumor cells 
(Chen et al, 2014). Of note, only up to 17% of colorectal cancers harbor activating Src 
mutations indicating that Src activity in tumors may also be a consequence of upstream 
signaling activities. It is of interest to note that the expression of several of the Src kinase 
family members (including Lck, Fyn and Lyn) is restricted to hematopoietic cells. Thus, it is 
perhaps not surprising that Src kinase signaling is of particular importance in hematological 
malignancies. For instance, one of the main characteristics of chronic myeloid leukemia 
(CML) is the presence of a fusion protein, Bcr-Abl, which arises from translocation of 
t(9;22)(q34;q11) chromosomes called Philadelphia chromosome (Mahon et al, 2008). This 
fusion product constitutes a novel, tumor-specific kinase, which activates Src family kinases, 
in addition to the PI3K and other pathways.  
The most advanced treatment development in cancer is based on targeting kinases. Novel 
kinase inhibitors are used in the clinic to improve cancer outcomes (Kannaiyan and 
Mahadevan, 2018), and 52 kinase inhibitors have been approved for cancer treatment by the 
FDA to date (Roskoski, 2019). One striking example is the use of a targeted Bcr-Abl 
inhibitor, imatinib, which has proven immensely successful for the treatment of CML. 
Another example is the use of the BRAF inhibitor vemurafenib. As BRAF mutation has direct 
implications on MAPK and PI3K/AKT activation, the inhibition of these kinases may be a 
strategy to reduce tumor growth (Dankner et al, 2018; Huang et al, 2018). Protein (kinases or 
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receptors) mutations and/or gain-of-function of molecules downstream of the original 
treatment target have been highlighted as a major contribution to therapeutic resistance. For 
instance, the crosstalk between the BcrAbl and Src kinase can lead to a more malignant 
phenotype in CML (Rubbi et al, 2011) impairing the imatinib treatment efficiency (Ferreira et 
al, 2012; Linev et al, 2018). Thus, dual targeting compounds have been investigated and 
therapeutic strategies against both of these kinases have appeared promising over the last 
decade (Quintás-Cardama et al, 2006; Musumeci et al, 2018) Similarly, vemurafenib-treated 
tumors may acquire resistance to the therapy by the acquisition of additional MAPK 
mutations, something that appears to be a frequent occurrence in colorectal cancer (Ahronian 
et al, 2015). Subsequent use of kinase inhibitors targeting the downstream pathways may then 
be of use. But also non-kinase treatments affecting signaling may be used in the clinical 
management of tumors, as in the case of Sonic hedgehog (Shh) pathway inhibitor vismodegib 
(Sekulic et al, 2012), which blocks the Smoothened receptor downstream of Shh signaling. 
Nevertheless, also vismodegib has occasionally been highlighted as ineffective, potentially 
due to activation of additional signaling pathways by Hedgehog signaling.  
Based on the importance of kinases for cellular function and disease, a wish to investigate this 
family of enzymes on a wider scale has risen in the last decades. Kinome profiling has 
emerged as an effective strategy to screen activity of a large amount of kinases 
simultaneously, and investigate how these are differently modulated in several biological 
systems. Using an array-like platform (Peppelenbosch et al, 2016), canonical and non-
canonical pathways associated with specific signals and/or ligands can be investigated, 
including potential targets for overcoming cancer. Using the kinome profiling approach, the 
global upregulation of kinase activity in cancer can be screened and might reveal new 
potential targets to overcome resistance beyond classical targets. 
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Figure 2. The main signal transduction pathways in normal cells, which are often deregulated 
in cancer. Hedgehog, Src Family Kinase, FAK are commonly associated with cell motility 
and survival; PI3K/AKT, Ras-Rac, MAPK pathways play important role in cancer 
progression by sustaining cell motility (migration profile), proliferation and survival events 
together with cell death resistance in colorectal cancer.  
  
Despite the widespread knowledge regarding the role of kinases in cancer, the contribution of 
phosphatases to tumor progression still needs to be largely investigated. While kinases are 
generally seen as positive regulators of signaling and cancer, phosphatases are mostly 
regarded as negative regulators and tumor suppressors. For instance, as described above, 
PTEN loss is commonly seen in cancer, and was associated with energetic metabolism 
rewiring, anoikis resistance, invasion and metastasis. Based on such examples, phosphatases 
were largely associated with tumor suppressors (Ortega-Molina and Serrano, 2013; Ferreira-
Halder et al, 2019). However, the end result of phosphatase activity may depend on whether 
the dephosphorylation site is activating or inhibitory. And thus, phosphatase activity may in 
some context actually activate rather than inhibit downstream signaling. Based on the 
function, structure, sequence, specificity, sensitivity to activators and inhibitors, the 
phosphatases are general classified in three families: serine/threonine phosphatases, tyrosine 
phosphatases and dual-specificity phosphatases (Aoyama et al, 2003). Within the human 
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genome, 107 genes from the tyrosine phosphatase family have been identified (Alonso et al, 
2004; Mustelin et al, 2005; Souza et al, 2009; Caselli et al, 2016), which based on function, 
structure and aminoacid sequence of the catalytic domain, can be classified into four classes 
(I-IV) (He et al, 2014). Abnormal functionality changes on tyrosine phosphatase activity 
contribute to disease progression, including cancer. Indeed, tyrosine phosphatases have been 
described to play an interesting role in tumor progression and metastasis supporting several 
cancer hallmarks events (Ferreira-Halder et al, 2019). Most classical and dual-specificity 
phosphatases belong to class I. Low molecular weight protein tyrosine phosphatase (18 kDa, 
LMWPTP), also known as ACP1, is the only member of the class II of phosphatases, while 3 
CDC25 phosphatases belong to class III and 4 PTPs, which unlike other classes contain 
catalytic aspartic acid residues, belong to class IV (He et al, 2014). In human beings, 
LMWPTP enzymes are encoded by a single ACP1 gene copy on chromosome 2, in which 
transcription can derive four different RNAs by alternative splicing. Of these four LMWPTP 
isoforms, isoforms 1 and isoform 2 were described to be catalytically active and identically 
functional (Modesti et al, 1998; Souza et al, 2009). In particular isoform 1 was described to 
play a major role in cancer aggressiveness and chemoresistance (Ferreira et al, 2012; Hoekstra 
et al, 2015; Ruela-de-Sousa et al, 2016).  
Cellular function of LMWPTP is the dephosphorylation/regulation of many tyrosine kinase 
receptors and other molecules involved in signal transduction (Caselli et al, 2016). Normal 
function of LMWPTP has been associated to (i) cell motility and spreading coordinated by 
FAK dephosphorylation on several Tyr sites, in mouse fibroblast model; (ii) immune response 
modulation by dephosphorylation of Zap-70 Tyr292 (inhibitory site), a member of T-cell 
receptor signaling; (iii) balance between tight cell-cell contacts by co-localization with β-
catenin and inhibition of cell-cell adhesion and clustering by negative modulation of ICAM-1; 
(iv) cytoskeletal remodeling by interaction with EphrinA2 receptor (EphA2) and modulating 
of Ras-MAPK signaling; (v) decrease cell proliferation by negative regulation of Janus kinase 
(JAK)-2, as well as Signal Transducer and Activator of Transcription (STAT) family 
members, such STAT-2, -3 and -5, platelet derived growth factor receptor (PDGFR), and 
fibroblast growth factor receptor (FGFR) – (Chiarugi et al, 1995; Chiarugi et al, 1998; Stein et 
al, 1998; Bottini et al, 2002 a; Kikawa et al, 2002; Taddei et al, 2002; Park et al, 2002; 
Rigacci et al, 2002; Giannoni et al, 2003; Rigacci et al, 2003; Lee et al, 2007; He et al, 2014; 
Hoekstra et al, 2015). Under normal cellular conditions, the function of LMWPTP has been 
extensively characterized in osteoclast and osteoblast cell lines. The contribution of 
LMWPTP to bone metabolism was first associated with osteoblast differentiation by 
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modulating Src phosphorylation status. Indeed, LMWPTP expression decreased in a time-
dependent fashion during osteoblastic differentiation. The same pattern of activity was 
observed for the antioxidant glutathione (GSH) suggesting a crosstalk between redox status 
and LMWPTP activity (Zambuzzi et al, 2008; de Souza Malaspina et al, 2009). Besides that, 
LMWPTP activity also coordinates the cellular adhesion process by transient 
dephosphorylation of FAK Tyr397 and Src Tyr416, both activator sites, in osteoblasts 
(Fernandes et al, 2014). FAK itself also plays a major role in bone integrity and its activity 
was described to be modulated by secreted phosphoprotein 1 (SPP1)-induced LMWPTP 
expression (Kusuyama et al, 2017). Further, under cellular architecture modifying 
hyperosmotic conditions, LMWPTP in keratinocytes was suggested to effect selective Src 
Tyr416 dephosphorylation, rather than Tyr527 (inhibitory site). This mechanism might be 
associated with LMWPTP phosphorylation on Tyr132, which increases its affinity to 
substrates (for LMWPTP regulation modulation, see Souza et al, 2009). On the other hand, a 
mutual Src/LMWPTP activation during osteoblast differentiation has also been described 
(Bucciantini et al, 1999; den Hertog et al, 2008; Zambuzzi et al, 2008; Silva et al, 2015).  
Besides its importance in normal processes, LMWPTP has been described to play a role in 
metabolic diseases, such obesity, diabetes, and cancer. In metabolic diseases, a higher 
expression of LMWPTP was associated with a protective effect on hypertriglyceridemia 
(Bottini et al, 2002 b). Indeed, the tyrosine phosphatases LMWPTP and Protein Tyrosine 
Phosphatase 1B (PTP1B) might coordinate lipid overload, and LMWPTP inhibition provoked 
lipid-induced apoptosis in liver cells (Bourebaba et al, 2020). On the other hand, high 
LMWPTP levels appear to be less favorable for diabetes, as LMWPTP overexpression leads 
to insulin resistance in mouse models of obesity (Stanford et al, 2017). Additionally, 
LMWPTP knockdown in mice was associated with prevention of cardiomyopathy through 
decreasing cardiac remodeling, fibrosis and hypertrophy (Wade et al, 2015). In the cancer 
field, LMWPTP was first described as negative regulator of the PDGFR, consequently 
inhibiting cell growth (Shimizu et al, 2001; Fiaschi et al, 2001). In normal cells, the increase 
of LMWPTP expression was associated to lower PDGFR phosphorylation and 90% reduction 
of mitogenic capacity (Ramponi and Stefani, 1997). Indeed, LMWPTP was able to 
dephosphorylate PDGFR at Tyr857 which was important for catalytic site regulation 
(Chiarugi et al, 2002). Taking this information together, it was expected that LMWPTP would 
play a major role as a tumor suppressor. Instead, LMWPTP has since been described as a 
positive modulator of Ras-MAPK, FGFR and Eph receptor signaling (Stein et al, 1998; Park 
et al, 2002). Indeed, LMWPTP activates several cancer-associated signal pathway mediators, 
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and its enhanced expression prompts cell transformation and is highly associated with tumor 
development and progression. For instance, LMWPTP overexpression was associated with 
higher oncogenic activity of the EphA2 receptor (Kikawa et al, 2002; Chiarugi et al, 2004; 
Locard-Paulet et al, 2016), as well as to invasive profile and positive coordination of primary 
sarcoma formation in nude mice (Chiaguri et al, 2004). Overexpression of LMWPTP has now 
been described in breast, colonic, lung and neuroblastoma cancers (Malentacchi et al, 2005) 
and has been associated with specific clinical-pathological characteristics from each cancer 
type. One of the major challenges in the treatment of cancer is the development of drug 
resistance in cancer, as this remains one of the major risks associated with treatment failure. A 
higher activity and expression of LMWPTP are associated with a multidrug resistance profile 
in CML including supporting Src kinase and Bcr-Abl activation. In CML, knockdown of 
LMWPTP decreased Src activation which was associated with sensitization of drug resistant 
leukemia cells to treatments. The LMWPTP and Src down-regulation enhanced the sensitivity 
to vincristine and imatinib (the standard treatment for chronic myeloid leukemia) (Ferreira et 
al, 2012). 
The research groups of Prof. Dr. Ferreira-Halder and Prof. Dr. Peppelenbosch, together with  
Dr. Fuhler, have been collaborating to better understand the contribution of LMWPTP to 
cancer biology (Ferreira et al, 2006; Bispo de Jesus et al, 2008; Souza et al, 2009; Ferreira et 
al, 2012; de Abrantes et al, 2013; Hoekstra et al, 2015; Ruela-de Sousa et al, 2016). In this 
context, these groups have pointed out the relevance of LMWPTP for chemoresistance and 
metastasis in several tumor models: chronic myeloid leukemia (Ferreira et al, 2012) as 
described before, prostate cancer (Ruela-de-Sousa et al, 2016) and colorectal cancer (Hoekstra 
et al, 2015). In solid tumors, they also described that LMWPTP overexpression in patient 
samples is associated with cancer malignancy and patient survival. LMWPTP emerged as a 
poor prognostic and development stage biomarker, as a correlation between proportional 
expression of LMWPTP to higher degree of dysplasia and liver metastasis was observed for 
colorectal cancer (Hoekstra et al, 2015).  
Despite the advances in our knowledge regarding kinase and phosphatase signaling in cancer 
in recent years, several knowledge gaps remain. While aspects of kinases and phosphatases in 
several cellular aspects of cancer have been investigated, most notably migration and 
proliferation, several other characteristics, including interaction of tumor cells with stromal 
cells and their role in chemoresistance, remain underexplored. Further elucidation of the role 
of kinase and phosphatase signaling in cancerous processes requires further attention in order 
to develop secondary lines of treatment. 
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Outline of the thesis  
Treatment and survival of cancer has improved remarkably over the last decades. In particular 
the advent of targeted therapies, including cell cycle inhibitors, kinase inhibitors and others, 
have improved outcomes of several types of cancer. However, tumor relapse due to resistance 
acquisition is often observed and a better understanding of cancer signaling in order to devise 
novel targeted treatment strategies is thus still required. The aim of this thesis was to further 
investigate phosphorylation events in different malignancies and determine whether 
LMWPTP could potentially be a target for treatment. 
In CHAPTER 2, we employed kinome profiling to investigate phosphoprofiles of cells 
treated with the targeted anti-cancer drug vismodigib. We demonstrate that kinomic activity is 
modulated by this treatment, but that non-canonical pathways exist which may render cancer 
cells unsusceptible to these treatments. Thus, finding alternative treatment targets remains 
imperative. In CHAPTER 3, we turn our attention to the phosphatase class of enzymes. The 
phosphatase LMWPTP is highly overexpressed in malignant hematopoietic cells. Again 
employing kinome profiling, we demonstrate that this phosphatase modulates phosphoprofiles 
in hematopoietic cancer cells, which confers metabolic changes associated with increased 
drug resistance and survival of cells, and in CHAPTER 4, we link these metabolic changes to 
LMWPTP-dependent autophagy modulation. Our data suggest that LMWPTP may enhance 
this interaction, which confers further survival and growth advantage to tumor cells. After 
introducing the concept of platelets as tumor-promoting aging-dependent agents in 
CHAPTER 5, we further investigate the role of LMWPTP in tumor-platelet interactions in 
CHAPTER 6. We demonstrate that LMWPTP is overexpressed in gastric and colonic 
cancers. In addition, our data suggest that LMWPT may enhance the interaction between 
cancer cells and platelets, which confers further survival and growth advantage to tumor cells. 
In CHAPTER 7, we review signal transduction events in platelets themselves. As for cancer 
cells, much is known regarding the role of kinase activities in platelets, while phosphatases 
have been relatively less well studied. In CHAPTER 8, we show for the first time that in 
platelets contain active LMWPTP enzyme, which is modulated by platelet agonists and 
arguably plays a role in their activation as we demonstrate that the platelet antagonist 3-
bromopyruvate inhibits enzymatic activity of LMWPTP.   
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Abstract 
Hedgehog proteins are pivotal morphogens acting through canonical pathway involving first 
activation of ligand binding to Patched followed by alleviation of Smoothened receptors 
inhibition, leading to activation of Gli transcription factors. Noncanonical Hedgehog signaling 
remains poorly characterized, but is thought to be mainly dependent on Smoothened. 
However, Smoothened inhibitors have yielded only partial success in combating Hedgehog 
signal transduction–dependent cancer, suggesting that noncanonical Smoothened-independent 
pathways also are clinically relevant. Moreover, several Smoothened-dependent effects (e.g. 
neurite projection) do not require transcriptional activation, further suggesting biological 
importance of noncanonical Smoothened-dependent pathways. We comprehensive 
characterized the cellular kinome in Hedgehog-challenged murine wildtype and Smoothened-
/- fibroblasts, as well as Smoothened agonist–stimulated cells. A peptide assay–based kinome 
analysis (in which cell lysates are used to phosphorylate specific kinase substrates), along 
with endocytosis, Lucifer yellow–based, and immunoblotting assays, identified an elaborate 
signaling network of both Smoothened-dependent and -independent pathways that mediates 
actin reorganization through Src-like kinases, activates various proinflammatory signaling 
cascades, and concomitantly stimulates Wnt and Notch signaling, while suppressing bone 
morphogenetic protein (BMP) signaling. The contribution of noncanonical Smoothened-
independent signaling to overall effects of Hedgehog on cellular physiology appears to be 
much larger than previously envisioned and may explain the transcriptionally independent 
effects of Hedgehog signaling on cytoskeleton. The observation that Patched-dependent, 
Smoothened-independent, noncanonical Hedgehog signaling increases Wnt/Notch signaling 
provides a possible explanation for the failure of Smoothened antagonists in combating 
Hedgehog-dependent but Smoothened inhibitor–resistant cancer. Our findings suggest that 
inhibiting Hedgehog–Patched interaction could result in more effective therapies as compared 
to conventional Smoothened-directed therapies. 
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Introduction  
Cell fate is determined by morphogens, molecules whose non-uniform distribution governs 
the pattern of tissue development [1,2]. Notable examples of morphogens include Hedgehog, 
Wingless-related integration site (Wnt) and Bone morphogenetic protein (BMP) [3-5]. The 
intracellular signaling resulting from engagement of morphogens with their cognate receptors 
is involved in many physiological and pathophysiological processes, including 
embryogenesis, tissue regeneration, and carcinogenesis. Fully understanding morphogen 
signaling is therefor of the utmost importance [6]. Unfortunately, morphogen signaling is 
often extremely complex, a special case to point being signal transduction initiated by 
Hedgehogs [7]. 
Hedgehog proteins are a highly conserved family of intercellular signalling molecules. 
Originally identified as a Drosophila segment polarity gene required for embryonic 
patterning, several vertebrate homologues have been discovered—Indian (Ihh), Desert (Dhh) 
and Sonic Hedgehog (Shh), the latter being most extensively characterised [8]. Hedgehog 
signals are fundamental regulators of embryonic development, as illustrated by embryological 
malformations seen when accurate timing of Hedgehog signals during gestation is corrupted 
[9]. Hedgehog remains active in the post-embryonic period, maintaining histostasis in a 
variety of tissues, including the gastrointestinal tract and the immune system [10]. Continuous 
hedgehog signalling is an essential permissive factor for many cancers and causative in basal 
cell carcinoma of the skin [11]. In humans, one-allelic loss of the inhibitory hedgehog 
receptor Patched is sufficient to produce the so-called Gorlin syndrome [12], which is 
associated with rhabdomyosarcoma and the development of multiple basal cell carcinomas.  
Despite the importance of Hedgehog signalling for human physiology and pathophysiology, 
the molecular details underlying this signalling pathway remain only partly characterized. The 
primary receptor for Hedgehogs is Patched, an unconventional receptor, as it does not convey 
the Hedgehog signal to the intracellular components of the pathway itself. Rather, binding of 
Hedgehog to Patched alleviates the inhibitory effect of Patched on another membrane 
receptor, Smoothened. The Patched inhibition alleviation is probably caused by 
internalization of Patched following Hedgehog binding, but the signaling mechanisms 
involved remain obscure [13]. Subsequently, Smoothened mediates the activation of the latent 
transcription factor glioma-associated oncogene (Gli) via a process which involves the kinase 
Fused (Fu), the Suppressor of Fused protein (Su(Fu)) [14, 15] and inhibition of Gli 
proteolysis. Gli proteins are considered the final transcriptional effectors of Hedgehog 
signaling, both in normal vertebrate development as well as oncological disease [16]. 
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Together this signalling cascade may be termed the canonical hedgehog pathway. It is 
obvious that enhanced knowledge of the signaling elements involved in this pathway should 
prove exceeding useful in defining novel rational therapy directed at disease emanating from 
aberrant activation of canonical Hedgehog signaling. 
In addition to canonical Hedgehog signalling, a role for transcription-independent signalling 
via Hedgehog has also been suggested [17-19]. Tantalizingly, the presence of canonical and 
non-canonical Hedgehog signaling opens the theoretical possibility to uncouple the anti-
cancer effect of Hedgehog signaling on cancer in general [20] and the trophic effect of 
Hedgehog signaling on specifically cancer stem cells. In the absence, however, of knowledge 
on the molecular pathways that mediate these non-canonical effects of Patched-dependent but 
Smoothened-independent Hedgehog signaling, this possibility remains hypothetical only. In 
an effort to address this issue, here we endeavor to characterize the signaling pathways 
involved. 
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Results  
Hedgehog stimulation provokes rapid and marked reorganization of the cellular kinome  
We set out to characterize the kinase activities associated with Hedgehog challenge in 
general, as well as those specifically associated with Patched activation or Smoothened 
activation in isolation. To this end we exploited the power of peptide array-based kinome 
profiling, which allows the generation of comprehensive descriptions of cellular kinase 
activities [21-23]. The general approach to this study, both technically and biologically is 
provided through Figure 1. We characterized the kinase signatures associated with Hedgehog 
stimulation of mouse embryonic fibroblasts (MEFs), which we have recently shown to 
constitute a powerful model for delineating signal transduction events [24]. We established 
that under our experimental conditions, these cells do not endogenously release Hedgehog 
(not shown). Cells were incubated for 10 min with either 2 µg/mL Shh or a vehicle control, 
and the cell lysates were employed for in vitro phosphorylation of peptide arrays using 33P-γ-
ATP. Arrays consisted of 1024 different undecapeptides, of which 48 are various technical 
controls, whereas the remaining 976 peptides provide kinase substrate consensus sequences 
spanning the entire mammalian kinome and which we have shown earlier to provide 
comprehensive insight in cellular signal transduction [25]. On each separate carrier, the array 
was spotted three times, to allow assessment of possible variability in substrate 
phosphorylation. As a control for the specificity of the reaction 33P-α-ATP was used; no 
incorporation of radioactivity was seen (data not shown). We then calculated the mean 
phosphorylation level for all substrates before and after the treatment (total number of data 
points is 9 for each group). The technical quality of the profiles was good, and we only 
allowed experiments in which the Pearson product moment correlation coefficient was more 
as 0.95 for the technical replicas. Results were collapsed on elective signal transduction 
categories (see experimental procedures and [25]).  
 
 
 
 
(Legend on next page) 
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Figure 1. Outline of the study. A. Technical approach – kinome profiling. In this study we 
aim to comprehensively characterize cellular kinase enzymatic activities. To this end 
appropriately stimulated cell cultures are washed with ice-cold PBS and lysed in a non-
denaturing complete lysis buffer so as to solubilize cellular kinases. Lysates are the 
transferred to arrays consisting of a substrate peptide library, spotted in triplicate to assess 
technical reproducibility, which are spotted on a hydrogel-coated glass carrier. Upon addition 
of radioactive ATP and an activation mix, kinases –if enzymatically active- will 
phosphorylate substrate peptides. Incorporation of radioactive ATP into a substrate peptide is 
taken as measure of enzymatic kinase activity towards a particular substrate. The broad 
variation in specific substrates used (see also supplementary data) allows obtaining a more-or-
less complete description of cellular signaling, the so-called kinome. B. Biological approach. 
In this study we first generate a description of the effects of Shh challenge on cellular 
signaling in general by comparing kinome profiling results of cultures challenged and not 
challenged by the morphogen. To identify signal transduction events that are downstream of 
Ptc but do not involve Smo, the Hedgehog provoked effects on the cellular kinome are studied 
in fibroblasts genetically deficient for Smo. Finally, to identify events that are solely 
dependent on the activation of Smo, we study the effects of the Smo agonist purmorphamine 
(purm). Several kinome profiling results are subsequently validated using a second approach, 
in which MEFs were stimulated with Shh and subjected to Western blot analysis. To simulate 
Ptc-dependent effects, cells are treated with the Smoothened inhibitor (Vismodegib) prior to 
Shh stimulation. To simulate Smo-dependent effects, cells are treated with the Smoothened 
agonist SAG.  
 
The results are shown in Figure 2A and detailed in Supplementary table 1. They show that 
Hedgehog challenge provokes fast and substantial remodeling of cellular signaling. 
Particularly notable is the upregulation of mTOR signaling. mTOR is a key component of 
Hedgehog signaling and is a putative target for treating Hedgehog-driven cancers [26]. Other 
interesting points include an upregulation of G-protein-coupled receptor kinase enzymatic 
activity, which is able to control Smoothened activity [27, 28]. This is also in line with the 
fact that Smoothened itself is such a receptor and the observation that PKC enzymatic activity 
is upregulated, conform the canonical mode of action of G-protein coupled receptors. Strong 
regulation of PKA, a proposed regulator of Hedgehog signaling [29], is also seen. We 
observed activation of a variety of pro-inflammatory signaling modules (including Lyn, Fyn 
and peptides that are consensus substrates for Bruton’s tyrosine kinase), but as embryonic 
fibroblasts are not immunological cells, the importance of this observation is uncertain. In our 
untransformed epithelial model system, Hedgehog stimulation reduced Wnt signaling. These 
data are in line with studies shown that Hedgehog acts as an inhibitor of Wnt signaling in 
colon cells [30] although an activating role for Hedgehog on Wnt signaling has been proposed 
in cancer stem cells [31]. Lastly, the upregulation of substrate peptides for p21-activated 
kinase (Pak) activity and related molecules indicates that Hedgehog stimulation stimulates 
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actin reorganization and morphological changes. Together, these data show that the effect of 
Hedgehog on the cellular kinome is rapid and profound.  
 
 
Figure 2. Effects of Hedgehog stimulation on cellular signaling as determined by kinome 
profiling. (A) Murine fibroblasts were stimulated with 2 µg/mL Shh. Subsequently cells were 
lysed and the resulting lysates were used to phosphorylate arrays of different kinase substrates 
employing 33P-γ-ATP and radioactivity incorporated in the different substrates was 
determined. Peptide substrates were allotted to elective signal transduction elements. The 
picture depicts the number of peptides significantly phosphorylated (which means the number 
of peptides that received a Markov “on” call - see experimental procedures) for each element. 
A darker color reflects more kinase activity towards substrate elements and the results reveal 
the effects of Hedgehog stimulation on cellular signal transduction, thus a black color means 
all peptides were significantly phosphorylated, whereas a white color means that no peptides 
allotted to this signal transduction in this experimental condition were phosphorylated. 
Results were first statistically tested by a dichotomal analysis based on the number of Markov 
“on” calls observed in vehicle-and Shh-stimulated cultures. If statistically significant 
differences were noted the signal transduction category is highlighted with a red border and 
the level of significance observed is indicated in red. For signal transduction elements in 
which this very robust analysis fails to detect a statistically significant difference, a parametric 
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test was performed. If this proved significant, the category is highlighted with an orange color 
and corresponding level of significance is depicted as well. The results provide a wealth of 
data on the effects of Hedgehog stimulation on cellular signaling. (B) MEFs were grown in 6 
wells plates. To simulate Smo and Ptc-dependent signaling, cells were treated with Shh (2 
μg/mL) for 10 minutes and compared to unstimulated cells. Cells were lysed and proteins 
resolved by SDS-PAGE followed by blotting to PVDF and incubation of membrane with 
antibodies against the indicated phosphorylated proteins. Blots were reprobed with antibodies 
against ß-Actin to confirm equal loading.  
 
Despite the great sensitivity and efficiency of array kinome profiling, we validated several of 
the key pathways by western blot (Figure 2B). Consistent with canonical Shh signaling, 
phosphorylation of PKC was observed (intentsity of α-phosho-PKCδ/θ increased by a factor 
1.22), showing the validity of these models. Secondly, we show an increased activity of the 
mTOR-PKB/Akt-S6 pathway upon Shh stimulation (intentsity of α-phosho-Akt staining 
increased by a factor 1.75, p<0.05). Furthermore, in agreement with the Shh-induced 
cytoskeletal remodeling seen in kinome experiments, we observed an increase in Cofilin 
(intentsity of α-phosho-cofilin staining increased by a factor 1.86, p<0.05) and Src family 
phosphorylation (intentsity of α-phosho-Src staining increased by a factor 1.19). Although 
these changes in phosphorylation are more modest as those observed in the kinome array, they 
do support the peptide array data. As Western blot measures the sum of kinase and 
phosphatase activity, whereas the kinome array measures only kinase activity the Western 
blot data indicate the presence of compensatory mechanisms counteracting increased 
phosphorylation of substrate proteins. Hence, these data validate the robustness and validity 
of the kinome data.  
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Figure 3. Effects of Hedgehog on endocytosis and the influence of Smoothened inhibition 
thereon. (A) Fibroblast cultures were grown in twenty-four-wells plates and incubated in a 1 
mL containing 200 nCi of [3H]-sucrose in the presence or absence of either 1 µg/mL Shh and 
10 µM cyclopamine or appropriate vehicle control. At the end of the experiment cells were 
extensively washed with ice-cold PBS and lysed in NP-40 for subsequent scintillation 
counting. As sucrose can only enter cells through fluid phase uptake, this provides a reliable 
measure of cellular endocytosis. We observe that Hedgehog stimulates fluid phase uptake and 
this effect does not require Smoothened as it is not sensitive to the Smoothened inhibitor 
cyclopamine. (B) Similarly, fluorescence spectrophotometry indicated that fibroblasts grown 
in 96 wells plates and treated with Shh (2 μg/mL) for 6 hours still show uptake of Luciferin 
Yellow (35 μM) even in the presence of the smoothened inhibitor Vismodigib (50 μM), 
indicative of a Ptc-dependent, Smo-independent cellular process.   
 
Patched-dependent Smoothened-independent effects on cellular kinase activity 
The existence of Patched-dependent Smoothened-independent signal transduction is 
supported by various observations [32] and appears highly relevant in that it is essential for 
cancer stem cell survival in colorectal cancer [31]. To test whether such signaling is present in 
our model system, we incubated embryonic fibroblasts with 3H-sucrose (which is membrane 
impermeable and is only taken up via endocytosis in most cell types) and challenged the cells 
with either a vehicle control or 2 µg/mL Shh, in the presence or absence of the Smoothened 
inhibitor cyclopamine (Figure 3A). We observed strong accumulation of radioactivity in 
Hedgehog-challenged cells, as well as in cells challenged with Hedgehog in the presence of 
cyclopamine, indicating that Smoothened-independent cellular function is present in 
Hedgehog-stimulated fibroblasts. As a control tomatidine (an alkaloid similar to cyclopamine 
that has no action on Smo) was used but no effect was observed (not shown). To confirm our 
observation using a more specific, clinically relevant Shh signaling inhibitor, we used 
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Vismodegib. Vismodegib is described to be a specific Smoothened inhibitor and was FDA 
approved in 2012 for the use of advanced basal-cell carcinoma [33]. Vismodigib-treated cells 
were stimulated with Shh (2µg/mL), and incubated with Lucifer Yellow, a classic fluorescent 
molecule that can be used to quantify pinocytosis [44]. Lucifer Yellow uptake in the presence 
of Shh was not decreased by inhibition of Smoothened (Figure 3B). We thus concluded that 
endocytosis following Hedgehog stimulation does not require Smoothened activity and that 
hence our model system was suitable for investigating at least certain aspects of Smoothened-
independent signal transduction. 
To further characterize these aspects we performed kinome profiling of Smoothened-/- 
fibroblasts (originally obtained from Drs. James Chen and Philip Beachy and previously 
described by Varajosalo et al [35]), challenged with either a vehicle control or 2 µg/mL Shh 
for 10 min. The results are summarized in Figure 4A and Supplementary table 1 and reveal 
that the influence of Smoothened-independent Hedgehog-induced signaling on cellular kinase 
activity is substantial. Lacking however, is G protein-coupled receptor-associated signal 
transduction, which is obviously in line with the absence of Smoothened-dependent events. In 
particular, activation of cytoskeletal remodeling is seen following addition of Hedgehog, 
which correlates with a reduced activity of the negative Src activity regulator, Csk. This may 
relate to the observed Smoothened-independent effects of Hedgehog on endocytosis described 
above, especially as kinase enzymatic activity directed against FAK-responsive peptides is 
observed to be co-activated in our profiles, which fits canonical signaling on endocytosis [36]. 
Another prominent effect upon Hedgehog in Smoothened-/- fibroblasts is increased mTOR 
activation, whereas inflammatory signal transduction was also activated. Hedgehog in wild 
type fibroblasts provokes similar effects (see above) and thus these effects of Hedgehog 
signaling appear at least partially to stem from Smoothened-independent signaling. Similarly, 
activation of Wnt and Notch signaling is also seen and thus this aspect of Hedgehog signaling 
seems also independent of Smoothened. Interestingly, in the absence of Smoothened, 
Hedgehog activates rather than inhibits PKA, and it is tempting to speculate that this effect 
may relate to activating phosphorylation of Smoothened by PKA that has been described in 
Hedgehog signaling [37]. In conjunction, these results reveal that an unexpectedly large 
proportion of Hedgehog signal transduction towards the cellular kinome is mediated though 
non-canonical Patched-dependent Smoothened-independent signaling. 
To simulate these Patched-dependent, smoothened independent effects, we also treated cells 
with Vismodigib in the presence and absence of Shh (Figure 1, 4B), and show that Wnt 
signaling (as measured by β-Catenin activity) was also indeed activated independently of 
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smoothened in this system, as were PAK and S6 phosphorylation. Although the changes in 
phosphorylation observed on Western blot are more modest as those observed in the kinome 
array, they do support the peptide array data. As Western blot measures the sum of kinase and 
phosphatase activity, whereas the kinome array measures only kinase activity the Western 
blot data indicate the presence of compensatory mechanisms counteracting increased 
phosphorylation of substrate proteins.  In addition we verified the nature of the Smoothened-/- 
fibroblasts by Western blot (Figure 4C). 
These results, demonstrating the presence of a Smoothened-independent activation, suggest 
that treatment with Smoothened inhibitors may lack the potential to attenuate full Shh 
signaling and may provide some explanation as to why, while efficacious in some tumor 
types, the use of Vismodigib in other Shh-activated tumors (e.g. prostate cancer) shows less 
promise [38]. 
 
 
(Legend on next page) 
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Figure 4. Effects of Hedgehog stimulation on cellular signaling in Smo-deficient 
fibroblasts. Murine Smo-/- fibroblasts were stimulated with 2 µg/mL Shh. Subsequently cells 
were lysed and the resulting lysates were used to phosphorylate arrays of different kinase 
substrates employing 33P-γ-ATP and radioactivity incorporated in the different substrates was 
determined. Peptide substrates were allotted to elective signal transduction elements and a 
darker color reflects more kinase activity towards substrate elements and the results reveal the 
effects of Hedgehog stimulation on cellular signal transduction. Results were first statistically 
tested by a dichotomal analysis based on the number of Markov “on” calls observed in 
vehicle-and Shh-stimulated cultures (highlighted with a red border). For signal transduction 
elements in which this very robust analysis fails to detect a statistically significant difference, 
a parametric test was performed (highlighted in orange). The results reveal an intricate web of 
Patched-dependent Smoothened-independent non-canonical signal transduction events. (B) 
Smo-independent signaling was investigated by treating cells in the presence of both Shh (2 
μg/mL) and the Smoothened inhibitor Vismodigib (50 μM, 30 minutes pre-incubation). Cells 
were lysed and proteins resolved by SDS-PAGE followed by blotting to PVDF and 
incubation of membrane with antibodies against the indicated phosphorylated proteins. Blots 
were reprobed with antibodies against ß-Actin to confirm equal loading. C. Validation of the 
nature of the Smo-/- culture. BxPC3 cells were used as Smo+/+ control. Cells were lysed and 
proteins resolved by SDS-PAGE followed by blotting to PVDF and incubation of membrane 
with an antibody against Smo. Blots were reprobed with antibodies against ß-Actin to confirm 
equal loading. 
 
Cellular kinase response to selective Smoothened activation  
Next, we decided to investigate the effects of selective Smoothened activation in MEFs. To 
this end we challenged cells with purmorphamine, a purine derivative that acts as a direct 
agonist of Smoothened [39]. The results are provided through Figure 5A and Supplementary 
table 1. We observe that purmorphamine results in inhibition of PKA. As Hedgehog 
stimulation in both WT and Smoothened-/- cells was increased, PKA activity appears 
dominated by Patched-dependent, Smoothened independent signaling. Intriguingly, 
purmorphamine results in a downregulation of ROCK, which is important for a variety of 
cellular processes, but in particular for cytoskeletal reorganization [40]. It was earlier 
established that Smoothened is a powerful mediator of chemotactic responses, but only so 
when not located at the primary cilium [30]. At the primary cilium, Smoothened loses its 
capacity to stimulate chemotaxis. The apparent downregulation of ROCK activity following 
purmorphamine stimulation is thus best explained by a purmorphamine-dependent 
recruitment of Smoothened to the primary cilium. The strong canonical responses to 
purmorphamine stimulation observed by others would agree with this notion, as would the 
marked downregulation of PKA activity in our profiles. We also employed the Smoothened 
agonist SAG to confirm some of these effects by Western blot analysis (Figure 5B). While 
generally lower than Shh (Figure 5B), SAG induced Src, Pak, PKB/S6 and Wnt signaling in 
MEFs. Although these changes in phosphorylation observed on Western blot are more modest 
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as those observed in the kinome array, they do support the peptide array data. As Western blot 
measures the sum of kinase and phosphatase activity, whereas the kinome array measures 
only kinase activity the Western blot data indicate the presence of compensatory mechanisms 
counteracting increased phosphorylation of substrate proteins. 
In some aspects, the rapid Smoothened-independent effects and rapid Smoothened-dependent 
effects on cellular kinase activities studied in our experimental set up, are similar, as both 
provoke mTOR activation and, in our model system, activation of Wnt signaling. In this 
sense, non-canonical signaling downstream of Patched and Smoothened may converge to 
produce the final phenotype. It is important to stress that our set up does not allow for 
studying the effects of canonical Hedgehog signaling, which requires transcriptional 
responses. Generally speaking canonical signaling and non-canonical signaling by 
morphogens counteract each other and the effects observed in this study partially substantiate 
that notion for Hedgehog signaling as well. Not seen downstream of specific Smoothened 
stimulation were strong pro-inflammatory responses, which therefore seem mainly Patched-
dependent. Generally speaking, Patched-specific signaling events (i.e. the effects of 
Hedgehog stimulation on Smoothened-/- fibroblasts) were more pronounced as those 
provoked by purmorphamine stimulation as also evident from the number of peptides that 
became significantly phosphorylated (see experimental procedures), i.e. 180 peptides in 
Hedgehog-stimulated Smoothened-/- fibroblasts and 134 in purmorphamine-stimulated wild 
type fibroblasts. It thus appears that the major branch of non-canonical Hedgehog signaling is 
downstream of Patched but not of Smoothened (See Figure 6 and Table 1 for overview). 
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Figure 5. Effects of selective Smoothened activation by purmorphamine stimulation on 
cellular signaling in fibroblasts. (A) Murine fibroblasts were stimulated with 
purmorphamine. Subsequently cells were lysed and the resulting lysates were used to 
phosphorylate arrays of different kinase substrates employing 33P-γ-ATP and radioactivity 
incorporated in the different substrates was determined. Peptide substrates were allotted to 
elective signal transduction elements and a darker color reflects more kinase activity towards 
substrate elements and the results reveal the effects of Hedgehog stimulation on cellular signal 
transduction. Results were first statistically tested by a dichotomal analysis based on the 
number of Markov “on” calls observed in vehicle-and Shh-stimulated cultures (highlighted 
with a red border). For signal transduction elements in which this very robust analysis fails to 
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detect a statistically significant difference, a parametric test was performed (highlighted in 
orange). The results reveal a web of Smoothened-dependent signal transduction events clearly 
distinct from Patched-dependent signaling. (B) To investigate Ptc-independent signaling, cells 
were subjected to treatment with the Smo agonist SAG (100 nM) for 10 minutes. Cells were 
lysed and proteins resolved by SDS-PAGE followed by blotting to PVDF and incubation of 
membrane with antibodies against the indicated phosphorylated proteins. Blots were reprobed 
with antibodies against ß-Actin to confirm equal loading.  
 
 
 
 
Figure 6.  Selected kinome profiling-detected Shh-provoked signal transduction events 
and the role of Patched and Smoothened therein. Blue elements are confirmed, whereas 
gray elements showed a trend but did not reach Bonferoni-corrected statistical significance. 
The results reveal that the role of Patched-dependent Smoothened-independent signal 
transduction is more prominent in transcription-independent cellular effects of Hedgehog as 
previously thought. 
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Discussion 
Hedgehog signal transduction is highly unusual, containing many features unique to this 
signaling system (e.g. [41, 42]). Apart from canonical Hedgehog signaling, Hedgehog 
effects in physiology and pathophysiology also depend on so-called non-canonical signaling. 
For most morphogens, non-canonical signaling has been identified and effects observed are in 
general contrasting the effects derived from canonical signaling. An example is BMP 
signaling, which generally acts as a tumor suppressor in the colon [5]. In the presence of 
canonical BMP-signaling abrogating SMAD4 mutations, a non-canonical BMP-induced 
signaling pathway becomes evident that stimulates epithelial-to-mesenchymal transition and 
metastasis via activation of Rho and ROCK and furthers the colon cancer process [9]. 
Likewise, non-canonical Wnt signal transduction mediates important aspects of the action of 
this morphogen in the body through activation of small GTPases like Rac, Rho and Cdc42 to 
regulate the activity of ROCK, MAPK and JNK as well as Ca2+ signaling, also an effect 
important for colon cancer metastasis [43]. For Hedgehog also various modes of non-
canonical signaling have been described, both downstream of Patched and independent of 
Smoothened as well as downstream of Smoothened. The most prominent example of the 
former concerns colorectal cancer stem cells [31]. Whereas canonical Gli-dependent 
Hedgehog signaling negatively regulates Wnt signaling in the normal intestine and intestinal 
tumors [30], Hedgehog signaling in colon cancer stem cells activates a non-canonical 
Patched-dependent but Smoothened-independent signaling that is required for survival of 
these cancer stem cells.  
Apart from Patched-dependent Smoothened-independent non-canonical Hedgehog signaling, 
Smoothened-dependent Gli-independent non-canonical Hedgehog signaling has also been 
described and likewise the molecular mechanisms involved are only partly understood. The 
interaction of Hedgehog with Patched stimulates the translocation of Smoothened to the 
primary cilium, which is required for the transcriptional Hedgehog response [26]. This 
translocation involves activation of phospholipase A2 following Smoothened activation and 
results in the enzymatic release of arachidonic acid from plasma membrane phospholipids. 
Arachidonic acid metabolites are powerful actin cytoskeleton remodeling agents [44] and 
while located outside the primary cilium, Smoothened also mediates transcription-
independent actin reorganization and chemotactic responses through the production of these 
metabolites [17-19]. The physiological importance of this non-canonical response to 
Hedgehog signaling is illustrated by its pivotal role in Hedgehog effects in directing neurite 
projection [18]. It has been shown that non-canonical Hedgehog effects on axonal guidance 
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involve activation of Src-like kinases [19], and our data now yield a plethora of information 
regarding the signaling pathways contributing the non-canonical signaling induced by 
Hedgehog.  The changes in kinase activity measured may derive from either altered 
expression of kinases or altered activity of the individual kinase enzymes involved. As the 
stimulation period of the experiments is very short (10 minutes) we feel the latter explanation 
the most probably but until experiments in the presence of translation inhibitors have been 
performed, other possibilities should be kept in mind. Similarly, it should be noted that there 
is a disconnect between effect size on Western blot and kinome array, suggesting that part of 
the kinase effects observed are counteracted by compensatory phosphatase activity, thus the 
importance of our observations for phenotypic cellular activities such as proliferation, 
viability, migration will remain to be investigated in other studies. Nevertheless, the final 
effect of Hedgehog in physiology and pathophysiology is resultant from the integration of 
both canonical and non-canonical Hedgehog signaling [32]. The potential of pharmacological 
inhibitors of Hedgehog signaling in the treatment of disease has received substantial attention 
and various trials employing pharmacological inhibitors of Hedgehog signaling have been 
conducted. Especially Vismodegib and Sonidegib have met with success in diseases driven by 
canonical Hedgehog signaling, in particular dermatological cancer [33]. Despite the evidence, 
however, that Hedgehog signaling is important for many gastrointestinal cancers [46], trials in 
this type of disease have not yet proven successful. In view of our data presented above that 
Patched and not Smoothened is a major mediator of non-canonical Hedgehog signaling and 
the momentum-gaining notion that especially non-canonical Hedgehog signaling may be 
important for maintaining gastrointestinal cancer [31], this may not be surprising. Vismodegib 
and Sonidegib target Hedgehog signaling at the level of Smoothened and leave Patched-
dependent non-canonical Hedgehog signaling unaffected. Especially in view of the Patched-
dependent Smoothened-independent Wnt signaling, one can easily imagine that especially the 
non-canonical branch of Hedgehog signaling is important in supporting growth in the 
gastrointestinal compartment. An implication of our results is thus that future Hedgehog-
based therapy with respect to gastrointestinal cancer should be directed at counteracting the 
interaction of Patched with Hedgehog rather than the current strategy of targeting 
Smoothened. Obviously, proof of this notion awaits experimentation in cancer cells that are 
insensitive to Smoothened inhibitors but require extracellular Hedgehog.  
 
 
 
 
41 
Conclusions 
Here we characterise the non-canonical aspect of Hedgehog signaling. We observe that such 
non-canonical signaling mainly involves Patched-dependent Smoothened-independent 
signaling, with especially activation of cytoskeletal remodeling and the activation of Wnt 
signaling being prominent elements. Thus, for efficient targeting of Hedgehog-dependent 
signaling it may prove essential to target such signaling at the level of Patched and not 
Smoothened. 
 
  
 
42 
Experimental procedures 
Materials 
Cyclopamine was from Biomol (Hamburg, Germany). Purmorphamine was from EMD 
Biochemicals (Darmstadt, Germany) and was dissolved in ethanol (final concentration 0.2 %). 
Recombinant Sonic Hedgehog was from R&D Systems (Minnesota, USA). Sonic Hedgehog 
inhibitor Vismodegib (GDC-0449) was from Selleck Chemicals (Texas, USA) and 
reconstituted in DMSO (final concentration 0.025%). Shh agonist SAG (SML1314-1MG; 
#14454) was from Sigma-Aldrich (Missouri, USA) and Recombinant Murine Sonic 
Hedgehog (Shh) (315-22, 0513521) was from PeproTech, Inc. 
 
Cell culture 
Smoothened–/– fibroblasts (provided by Dr. Taipale) and wild-type mouse embryonic 
fibroblast (provided by Dr. Scott) were cultured in Dulbecco's modified Eagle's medium 
(DMEM, Invitrogen, California, USA) supplemented with 10% fetal calf serum (FCS, 
Invitrogen, California, USA), and propagated at 37°C in a 5% CO2 humidified atmosphere. 
For experiments a confluence of 50% cells was allowed to grow in six-wells plates. 
Stimulations were done, if appropriate, with 2 µg/mL Shh for 10 minutes. Each experiment 
consisted of three biological replicas of experiments containing three technical replicas.  
 
Kinome Profiling  
For peptide array analysis, we employed the Pepchip kinomics array. The protocol and 
associated analysis has been described in detail elsewhere [25] and is based on the original 
protocol of van Baal et al. [47]. In short, cells were washed in ice-cold PBS and lysed in a 
non-denaturing complete lysis buffer (cells were lysed in 50μL lysis buffer (20mM Tris-HCl 
pH 7.5, 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM sodium 
pyrophosphate, 1mM MgCl2, 1mM glycerophosphate, 1mM Na3VO4, 1mM NaF,1μg/mL 
Leupeptin, 1μg/mL Aprotinin, 1mM PMSF). Subsequently the cell lysates were cleared by 
centrifugation and peptide array incubation mix was produced by adding 10 µL of activation 
mix (50% glycerol, 50 µM ATP, 0.05% v/v Brij-35, 0.25 mg/ml bovine serum albumin) and 2 
µL [γ-33P] ATP (approx. 1000 kBq (Amersham AH9968). Next, the peptide array mix was 
added onto the chip, and the chip was kept at 37°C in a humidified stove for 90 minutes. 
Subsequently the peptide array was washed twice with Tris-buffered saline with Tween 20, 
twice in 2M NaCl, and twice in demineralised H2O and then air-dried. The chips were 
exposed to a phosphor screen for 72 h, and the density of the spots was measured and 
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analyzed with array software (ScanAnalyze). Using grid tools, spot density and individual 
background were corrected and spot intensities and background intensities were analyzed. 
Data from at least 9 independent data points were exported to an excel sheet for further 
analysis. Control spots on the array were analyzed for validation of spot intensities between 
the different samples. Inconsistent data (i.e., SD between the different data points >1.96 of the 
mean value) were excluded from further analysis. For each peptide the  average  and  standard  
deviation  of  phosphorylation  was  determined  and  plotted  in  an  amplitude‐based 
hierarchical  fashion. For data analysis, first every peptide was given an “on” call or “off” call 
(Markov state analysis). To this end, first an average signal was calculated for each peptide 
using the three biological replicates (each consisting of two technical replicates) yielding an 
aggregate dataset for each the hematopoietic subsets. Subsequently, for each of the aggregate 
datasets, either “on” calls or “off” calls were given to each peptide substrate (Markov state 
analysis). In order to do this, we assumed that the subset of signals representing the 1-e-1 
fraction of peptides having the lowest phosphorylation of all peptides contained pure noise 
and did represent meaningful phosphorylation. The distribution of this noise was fitted as a 
single exponent, using the amplitude-sorted row number of these substrates as the X domain 
of the distribution and this single exponent was assumed to describe noise for the entire 
dataset. Now for all data points within the subset, when the actual amplitude observed minus 
1,96 the standard deviation was in excess of the value expected from distribution describing 
the noise, a substrate was given an “on” cal (p < 0.05) in this Markov analysis. Subsequently 
results were collapsed on elective signal transduction categories and subjected to dichotomal 
significance analysis, contrasting Shh-stimulated cultures to parallel vehicle cultures or 
Purmorphamine-stimulated cultures to parallel unstimulated cultures. If a significant result (p 
< 0.05) was detected, we considered the result as robust evidence of differential activation of 
signal transduction between Hedgehog-stimulated and unstimulated cultures and in the 
depiction of results the corresponding signal transduction categories have been highlighted 
with a red border. For those signal transduction categories in which using this dichotomal 
testing based on number of Markov state “on” peptides did not result in statistical 
significance, the relative levels of phosphorylation were also tested using a paired T test, 
directly parametrically comparing phosphorylation of the corresponding spots. As we 
considered thus-discovered statistically significant differences between the relevant 
experimental conditions less robust, in the depiction of the results they have been highlighted 
with an orange border. Note that due to differences in the number of peptides allotted to the 
signal transduction categories apparently large differences in phosphorylation not always 
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yield statistically significant results, while smaller differences can produce such results if the 
number of substrates in such categories is large. 
 
Endocytosis assay 
Cells were grown on 24-well plates to 70% confluence and were stimulated with either 1 
μg/mL Shh or vehicle control (0.1% BSA/PBS) and or cyclopamine (Biomol, Plymouth 
Meeting, Pennsylvania, United States) for 1 hour. After extensive washing with ice-cold PBS, 
cells were lysed in 1% Nonidet P-40 and the lysate was transferred to 4 mL of scintillation 
fluid and activity was determined on a Packard Tri-Carb scintillation counter (PerkinElmer, 
Wellesley, Massachusetts, United States). Values were corrected for solvent control treated 
cells on ice.  
 
Lucifer Yellow assay 
Mouse embryonic fibroblast were plated at a density of 3.5x103cells/well. After 24 hours, 
Vismodegib was added (50µM DMSO 0.25%) for 15 minutes, followed by Shh treatment at 
2µg/mL for 15 minutes. Stock solution of Lucifer Yellow CH dilithium salt (Sigma Aldrich, 
Germany) was prepared in PBS, and working solution in culture medium. The assay was 
performed using 35mM of Lucifer Yellow, incubated for 6 hours, at 37°C, 5% CO2. After 
that, the supernatant was removed and the Lucifer Yellow fluorescence was measured by 
spectrophotometer CytoFluor MultiWell Plate 4000 (PerSeptive Biosystems, USA) with 
excitation 430nm and emission at 530nm. The concentration was calculated using a Lucifer 
Yellow curve.  
 
MEF treatment 
MEFs were seeded at 1x103 cells/well and the next day, cells were incubated with 
Vismodegib (50µM DMSO 0.25%) for 1 hour. After, Shh at 4µg/mL and SAG at 100nM 
were added for 7 minutes, and western blot samples were prepared, as described below. 
 
Western blot 
After treatment, the samples were prepared by adding 2X Laemmli buffer (100 mM Tris–HCl 
(pH 6.8), 200 mM dithiothreitol, 4% SDS, 0.1% bromophenol blue and 20% glycerol) and 
samples were boiled for 95°C, 10 minutes. Cell extracts were resolved by SDS–PAGE and 
transferred to polyvinylidene difluoride membranes (Merck chemicals BV, Amsterdam, the 
Netherlands). Membranes were blocked in 50% Odyssey Blocking Buffer (LI-COR 
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Biosciences, Lincoln, NE) in TBS and incubated overnight at 4°C with primary antibody. 
Primary antibodies: From Cell Signalling: phospho-Akt (Ser473) (#4060S); phospho-PKA C 
(Thr197) (#4781); phospho-Src Family (Tyr416) (#2101); phospho-PKCδ/θ (Thr638/641) 
(#9376); phospho-S6K Ribosomal (Ser235/236) (#4858); phospho-β-Catenin (Ser675) 
(#9567); phospho-PAK2 (Ser20) (#2607). From Santa Cruz: β-Actin (C4) (sc-47778). From 
SignalWay: phospho-cofilin (Ser3) (#11139) and phospho-ROCK2 (Ser1379) (#13005). Goat 
polyclonal anti-Smo C-17 was obtained from Santa Cruz. After washing in TBS-T, 
membranes were incubated with IRDye® antibodies (LI-COR Biosciences, Lincoln, NE) for 
1 hour. Detection was performed using Odyssey reader and analyzed using manufacturers 
software. 
 
Statistical analysis  
Statistical analysis details for each experiment are described at the legend. Furthermore, 
statistical methods were: a) unpaired and paired t-student, confidence interval at 95%, two-
tailed and b) one-way ANOVA repeated measures test, significance level alpha 0.05 (95% 
confidence interval), followed by post-test Turkey, (*, **) indicates significance P<0.05. 
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TABLE 1. Summary of pathways analyzed using kinome. Cross comparison as a short 
description of kinome profiling showing the major pathways and statistical comparing the 
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Smoothened-dependent – Smo-). 
Pathway Shh canonical Statistics Ptc-dependent Statistics Smo-dependent Statistics 
Survival + <0.01 + 0.03 
  
Mitogenic 
      
2nd messenger + <0.01 
  
+ 0.01 
Nutrient 
      
Cytoskeletal + <0.01 + 0.04 
  
Mitosis - 0.02 
    
Inflamatory 
  
+ 0.01 
  
Stemness 
  
+ 0.05 
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Abstract 
In chemoresistant leukemia cells (Lucena-1), the low molecular weight protein tyrosine 
phosphatase (LMWPTP) is about 20-fold more active than in their susceptible counterpart 
(K562). We found this phosphatase ensures the activated statuses of Src and Bcr-Abl. Since 
phosphorylation and dephosphorylation of proteins represent a key post-translational 
regulation of several enzymes, we also explored the kinome. We hereby show that LMWPTP 
superactivation, together with kinome reprogramming, cooperate towards glucose addiction. 
Resistant leukemia cells present lower levels of oxidative metabolism, in part due to 
downexpression of the following mitochondrial proteins: pyruvate dehydrogenase subunit 
alpha 1, succinate dehydrogenase and voltage-dependent anion channel. Those cells displayed 
higher expression levels of glucose transporter 1 and higher production of lactate. In addition, 
Lucena-1 siRNA LMWPTP cells showed lower expression levels of glucose transporter 1 and 
lower activity of lactate dehydrogenase. On the other hand, K562 cells overexpressing 
LMWPTP presented higher expression/activity of both proteins. In this study, we show that 
LMWPTP is a pivotal mediator of metabolic reprogramming that confers survival advantages 
to leukemia cells against death stimuli. 
 
 
Keywords: Chemoresistant leukemia cells; Kinome; LMWPTP; ACP1, Glycolytic 
metabolism 
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Introduction 
Among major problems in dealing with leukemic disease is the build-up of resistance against 
therapy [Martelli et. al., 2003; O’Hare et. al., 2006; Diehl et. al., 2007; Wieczorek et. al., 
2016]. This may include resistance associated with decreased drug accumulation in the cell, 
altered intracellular drug distribution, increased detoxification, diminished drug-target 
interaction, increased DNA repair, altered cell-cycle regulation and uncoupling of pathways 
linking cellular damage with programmed cell death [Branger et. al., 2002; Kondo et. al., 
2005]. In this context, increased expression of P-gp, encoded by the MDR1 gene, is a well-
characterized mechanism for chemoresistance in cancer cells. However, the biochemical 
mechanism behind drug resistance has yet to be fully understood. Therefore, a better 
understanding of the mechanisms mediating resistance and novel targets for improved 
therapeutic options are required. Cellular functions are under tight control of the balance 
between protein phosphorylation and dephosphorylation. Kinases and phosphatases that 
control these processes are, therefore, essential regulators of processes such as cell 
proliferation, adhesion, migration and death. The widespread nature of protein 
phosphorylation/dephosphorylation underscores its key role in cell-signaling metabolism. In 
fact, cells are able to give a specific response towards diverse changes in their 
microenvironment through integrated networks of intracellular signaling pathways. These acts 
via cascades of sequential phosphorylation or dephosphorylation reactions, which are 
governed by protein kinases and phosphatases, respectively. Previous studies have revealed 
that oncosignaling under stress conditions can lead to metabolic reprogramming. Glucose 
metabolism is reprogrammed in many malignancies as shown by accelerated glycolysis and 
by the active truncated tricarboxylic acid (TCA) cycle [Liberti and Locasale, 2016]. In 
addition, glycolysis is also favored in some tumor cells in response to metabolic stress. In the 
present study, we focus our attention on LMWPTP and its association to a metabolic switch 
responsible for drug resistance in leukemia. Over the last decade, it has become clear that 
many protein tyrosine phosphatases are involved in different diseases, including cancer. 
Specifically, the LMWPTP family, also known as acid phosphatase locus 1 (ACP1), is shown 
to be upregulated in various human cancers [Malentacchi et. al., 2005; Marzocchini et. al., 
2008; Hoekstra et. al., 2015; Ruela-de-Sousa  et. al., 2016] and to play a role in leukemia 
resistance [Ferreira et. al., 2012]. We now show that LMWPTP, together with kinases such as 
Pyruvate dehydrogenase kinase 1 (PDK1), Src and mTOR, are involved in glucose 
metabolism reprogramming in resistant leukemia cells providing survival advantages to these 
cells towards death stimuli. 
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Materials & methods 
Cell line and Antibodies 
K562 cells were purchased from the American Type Culture Collection and Lucena-1 cells 
(counterpart of K562 cells with multiresistant phenotype) were provided by Rumjanek et. al. 
(2001). Anti-sheep, anti-rabbit, anti-goat and anti-mouse peroxidase-conjugated antibodies 
were purchased from Cell Signaling Technology. HIF-1α (28b) (sc-13515) and LDHA (H160) 
(sc33781) antibodies were obtained from Santa Cruz Biotechnology, Inc.. p-mTOR (Ser2448) 
(gtx50258) was purchased from GeneTex Inc.. LMWPTP (ACP1) (ab26232), mTOR 
(ab63480) and Glut-1 (ab15309) antibodies were obtained from Abcam. PKM2 (#3198), p-
PKM2 (#3827), p-Erk1/2 (Thr202/Tyr204) (#9101S), p-P38 (Thr180/Tyr182) (#92165), p-
Pax (Tyr118) (#2541) p-JNK (Thr183/Tyr185) (#46685), p-Src (Tyr416) (#2101S), Pyruvate 
dehydrogenase subunit α1  (C54G1) (#3205), SDHA (D6J9M) (#11998) and VDAC 
(D73D12) (#4661), p-LDHA (Tyr10) (#8176S), Insulin Receptor β (4B8) (#3025), p-Insulin 
Receptor β (Tyr1345) (14A4) (#3026), Pan Actin (D18C11) (#8456), β-Tubulin (9F3) 
(#2128) antibodies were purchased from Cell Signaling Technology.  
 
Cell Culture 
K562 and Lucena-1 cells were routinely grown in suspension in Roswell Park Memorial 
Institute 1640 medium supplemented with 2mM glutamine, 100U/mL penicillin, 100µg/ml 
streptomycin and 10% heat-inactivated fetal bovine serum (FBS), at 37°C in a 5% CO2 
humidified atmosphere. 
 
Kinome 
Kinome arrays were performed essentially as described before [Diks et. al., 2004; Lowenberg 
et. al., 2006; van Baal et. al., 2006]. Briefly, cells (2.5x105) were washed in PBS and lysed in 
a non-denaturing complete lysis buffer. The peptide arrays (Pepscan), containing up to 1024 
different kinase substrates in triplicate, were incubated with cell lysates for 2 hours in a 
humidified incubator at 37ºC. Subsequently, the arrays were washed in 2M NaCl, 1% Triton-
X-100, PBS, 0.1% Tween and water. Thereafter slides were exposed to a phospho-imaging 
screen for 24-72 hours and scanned on a phospho-imager (Fuji). The level of incorporated 
radioactivity, which reflects the extent of phosphorylation, was quantified with specific array 
software (EisenLab ScanAlyze, version 2.50). Datasets from chips were then analyzed 
statistically using PepMatrix, as described by Milani et. al. (2010). Basically, spot replications 
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were scrutinized for consistency using two indexes: one being the standard deviation:average 
(SD/A) ratio and the other being the ratio between the average and the median (A/M) of all 
three replications for each chip. Parameters applied to the indexes were SD/A<50% and 
80%<A/M<120%. The fold change in phosphorylation between control and experiment cells 
was assessed using Student's t-test, with p<0.05 indicating significance. 
 
Western blotting analysis 
Cells (3x107) were lysed in 200µL of lysis buffer (50mM Tris–HCl pH 7.4, 1% Tween 20, 
0.25% sodium deoxycholate, 150mM NaCl, 1mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA), 1mM Na3VO4, 1mM NaF and protease inhibitors [1µg/ml 
aprotinin, 10µg/ml leupeptin, and 1mM 4-(2-aminoethyl) benzenesulfonyl-fluorid-
hydrochloride] for 2 hours on ice. Protein extracts were cleared by centrifugation and protein 
concentrations were determined using the Bradford reagent (Sigma-Aldrich). Twice the 
volume of sodium dodecyl sulfate (SDS) gel loading buffer (100mM Tris–HCl pH 6.8), 
200mM DTT, 4% SDS, 0.1% bromophenol blue and 20% glycerol) was added to the samples, 
which were subsequently boiled for 5 minutes. Cell extracts were resolved by SDS-
polyacrylamide gel (12%) electrophoresis (PAGE) and transferred to polyvinylidene 
difluoride (PVDF) membranes. Membranes were blocked in 5% fat-free dried milk or bovine 
serum albumin (BSA) in Tris-buffered saline (TBS)-Tween 20 (0.05%) and incubated 
overnight at 4°C with the appropriate primary antibody at 1:1000 dilution. After washing in 
TBS-Tween 20 (0.05%), membranes were incubated with anti-rabbit, anti-mouse and anti-
goat horseradish peroxidase-conjugated secondary antibodies, at 1:5000 dilutions, in BSA 1% 
in TBS-Tween 20 (0.05%) for 2 hours. Proteins were detected using enhanced 
chemiluminescence in Alliance 6.7 (UVITEC). 
 
Isolation and preparation of mitochondria for western blotting analysis 
For mitochondria isolation, 2x107 cells (K562 and Lucena-1) were washed with saline 
solution (0.9% NaCl) in triplicate using a centrifuge tube at 850×g for 2 minutes each wash at 
4°C. Afterwards, the procedure consisted in following the protocol of the mitochondria 
isolation kit (Thermo Scientific). Briefly, after the last centrifugation, the supernatant was 
discarded and the cell pellet was re-suspended in 800µL of Mitochondria Isolation Reagent A, 
mixed using a vortex mixer at medium speed for 5 seconds and incubated on ice for no longer 
than 2 minutes. Then, 10µL of Mitochondria Isolation Reagent B was added and mixed again 
for 5 seconds at maximum speed. The tube was kept on ice for 5 minutes repeating the mixing 
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for each minute at maximum speed. On the next step, the addition of 800µL of Mitochondria 
Isolation Reagent C was done followed by the inversion of the tube several times to mix 
(without vortexing). The mixture was then centrifuged at 700×g for 10 minutes at 4°C. The 
supernatant was transferred to a new tube and centrifuged at 3,000×g for 15 minutes and 4°C. 
At this point, the supernatant is the cytosolic fraction and the pellet contains isolated 
mitochondria. The pellet was then re-suspended in 500µL of Mitochondria Isolation Reagent 
C and centrifuged at 12,000×g for 5 minutes at 4°C. For western blotting assays the 
mitochondria was lysed with 50 mM Tris pH 8, 2mM MgCl2, 1mM EGTA pH 8, 1mM DTT, 
10% glycerol, 0.2% NP-40. Reagents A, C and lysis buffer were supplemented with Halt 
Protease Inhibitor Cocktail, EDTA-Free (Thermo Scientific). Protein concentrations of 
mitochondria and cytosol fractions were determined using the Lowry method (DC Protein 
Assay, Bio-Rad). 
 
Oxygen consumption 
The oxygen consumption assay of non-permeabilized cells was performed in Krebs-Ringer 
buffer (Sigma-Aldrich) pH 7.4 at 37ºC in the presence of glucose (25mmol/L) and HEPES 
(10mmol/L). After, we added viable cells (3x106 cells/mL) and signal stabilization, the 
chamber was closed and O2 flow (Jo) recorded. The ATP synthase inhibitor oligomycin A 
(1µg/mL) and the mitochondrial uncoupler CCCP (Carbonyl cyanide m-
chlorophenylhydrazone – 1µM) were used as internal control [Pesta and Gnaiger, 2011; 
Teodoro et. al., 2014]. 
 
Cell Viability 
Cells were plated at 1x105 cells/mL and treated with H2O2 for 24 hours. After treatment, cell 
viability was assessed by trypan blue dye exclusion. 
 
MTT assay 
1x105 cells/well was seeded into a 12-wells plate for 48 hours and the medium was removed 
from the cells after each incubation period. 1mL of MTT (Sigma Aldrich) solution (0.5mg/mL 
in FBS free culture medium) was added to each well. After incubating for 3 hours at 37°C, the 
MTT solution was removed and the formed formazan crystals were solubilized in 100μL of 
ethanol. The plate was shaken for 10 minutes and the absorbance was measured at λ = 570 nm 
with a microplate reader (Synergy HT, BioTek). 
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Lactate assay 
The medium was collected from cells after each incubation period and used for extracellular 
lactate measurement by Lactate kit (BioClin) following manufacturer’s instructions. 
 
Transfection of K562 Cells with LMW-PTP Plasmid 
K562 cells (1x105 cells/mL) were grown for 24 hours and the transfections were done using 
the Effectene transfection kit (QIAGEN) according to the manufacturer’s instructions. 
Briefly, the cells were transfected with 2.4µg of pcDNA3.1/V5-His-TOPO vector with or 
without an insert containing the sequence of human LMWPTP after a cytomegalovirus 
promoter. Overexpression was always verified by western blotting. 
 
Transfection of K562 and Lucena-1 Cells with LMW-PTP siRNA 
Lucena-1 cells (1x105 cells/mL) were grown for 24 hours and subsequently transiently 
transfected with LMWPTP siRNA (QIAGEN). Transfections were done using the Hiperfect 
transfection kit (QIAGEN) according to the manufacturer’s instructions. Briefly, the cells 
were transfected with LMWPTP siRNA (final concentration: 5nM) for 72 hours. The 
efficiency of transfection was assessed based on the expression of LMWPTP by western 
blotting analysis. 
 
Data Analysis 
All experiments were performed in triplicate and results were shown in the graphs as means ± 
standard error of the mean (S.E.M.). Soluble lysates were matched for protein content and 
analyzed by western blotting and all bands were compared with their respective internal 
control. Kinome profile data were assessed using Student's t-test, with p<0.05 considered 
significant. MTT and lactate statistical analyses were analyzed using one-way analysis of 
variance (ANOVA) followed by Tukey posttest, with p<0.05 considered significant. All data 
were analyzed using GraphPad Prism Software, Version 5.0. 
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Results 
Kinome profiling of K562 cells and its multidrug-resistant counterpart Lucena-1 
Erythroleukemic cell line K562 and its derivative line Lucena-1 have been described to be a 
useful model for investigating the acquisition of multidrug resistance, the former being 
sensitive to a variety of chemical agents whereas the latter displays significant resistance to 
such treatment [Queiroz et. al., 2010; Moreira et. al., 2014].  Previously, we have shown that 
LMWPTP is highly expressed in Lucena-1 cells, and that this tyrosine phosphatase is 
essential to keep Src and Bcr-Abl signaling [Ferreira et. al., 2012]. In order to explore to what 
extent signaling pathways were being rewired, we sought to understand the kinome activity of 
K562 and Lucena-1 cells using a kinase array of 1024 consensus peptides [Diks et. al., 2004; 
Lowenberg et. al., 2006; van Baal et. al., 2006]. Profiling quality was considered good as 
technical replicates showed an average Pearson product-moment correlation coefficient of 
0.93 (Figure 1A). Single data analysis of arrays with K562 cell lysates resulted in the 
statistically significant phosphorylation of 78 peptides, whereas lysates of Lucena-1 cells 
resulted in phosphorylation of 107 peptides. Subsequent statistical analysis of signal intensity 
showed that phosphorylation of 30 peptides was significantly altered between Lucena-1 and 
K562 cells (p<0.05) (Figure 1B). In general, all kinases with higher activities in Lucena-1 
cells are involved in signalling pathways responsible for cellular proliferation and survival. 
CK2 and PDK1, in particular, were two of the most activated kinases, and both of them can 
modulate glucose metabolism. Accordingly, an insulin receptor that displays intrinsic kinase 
activity was also more active in Lucena-1 cells. Even though kinome profiling is a robust and 
reproducible technology, western blotting analysis was performed to validate peptide array 
data. As shown in Figure 2, Lucena-1 cells exhibit increased activation of p21Rac targets in 
cytoskeletal remodelling (Src and Paxillin) as well as downstream targets of this GTPase 
including, ERK1/2, p38 and JNK. In addition, a strong activation of mTOR kinase was 
observed. Thus, these results agree with data from kinome profiling and hence confirm that 
the transition from a chemotherapy-sensitive to a chemotherapy-resistant phenotype in 
erythroleukemia is accompanied by a distinct set of changes in the activation status of specific 
signal transduction pathways.  
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Figure 1. Comparison of kinome profiling between K562 and Lucena-1 cells. (A) Scatter 
plots showing the correlation between pepchip array replicates for K562 and Lucena-1 cells. 
(B) Comparison between statistically significant phosphorylated spots in K562 and in Lucena-
1 cells. This graph shows the correlation between fold change and p-values for statistically 
significant phosphorylated spots in both cell lines. Fold changes in Lucena-1 cells were 
assessed using Student's t-test, with p<0.05 indicating significance. Vertical axis is in log-
scale. 
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Figure 2. Validation of kinome profiling. Lysates of K562 and Lucena-1 were submitted to 
western blotting and probed with anti-phosphosite specific antibodies. 
 
A glycolytic switch is related to the maintenance of the drug resistant phenotype  
Accordingly, when we looked at proteins involved in glucose transport and metabolism, we 
detected a) higher expression levels of Glucose transporter 1 (Glut-1) and HIF-1α; b) higher 
activity of Insulin Receptor β and Lactate Dehydrogenase subunit A (LDHA) and c) a strong 
inhibition of PKM2, all of which indicate a higher glycolytic rate in Lucena-1 cells (Figure 
3A). Furthermore, the amount of lactate produced by those cells was also higher (Figure 3B). 
Since it is known that key metabolites, such as NADPH (pentose phosphate pathway), are 
produced by tumor cells via accelerated glycolysis and a truncated TCA cycle [Liberti and 
Locasale, 2016], we investigated whether Lucena-1 and K562 cells would have different 
responses to hydrogen peroxide. Indeed, when both cells were treated with this compound for 
24 hours, we observed that Lucena-1 cells were less sensitive (Figure 3C). 
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Figure 3. Glycolytic metabolism is predominant in resistant leukemia cells. (A) Lysates 
of K562 and Lucena-1 were submitted to western blotting and probed with specific antibodies 
against proteins involved in glucose uptake and regulation of glucose metabolism. (B) Lactate 
production was checked by measuring this metabolite in culture medium. (C) Leukemia cells 
(1 x 105 cells/mL) were treated with 250 µM hydrogen peroxide for 24 hours and viable cells 
quantified by trypan blue. Data are represented as mean ± S.E.M. and one-way analysis of 
variance (ANOVA) followed by Tukey posttest. (#), (*) p<0.01 Lucena-1 vs K562 cells. 
 
After we established that Lucena-1, a cell line that organically acquired resistance to 
chemotherapy, displays high levels of Glut-1 expression and lactate production in comparison 
to K562 cells, we sought to examine the mitochondrial function of those cells. Accordingly, 
we found some mitochondrial proteins (PDHα1, SDH and VDAC) were strongly 
downregulated in Lucena-1 cells (Figure 4A). In addition, when we compared the ability of 
Lucena-1 and K562 in reducing MTT, Lucena-1 cells also were less efficient (Figure 4B). 
Next, we monitored oxygen consumption. As shown in Figure 4C, basal oxygen consumption 
by Lucena-1 was significantly lower when compared to K562. When both cell lines were 
incubated with oligomycin, an FO-ATP synthase inhibitor, Lucena-1 cells consumed 50% less 
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oxygen (Figure 4C). This result suggests that Lucena-1 cells have a lower mitochondrial 
function compared to K562. Also, when Lucena-1 and K562 cells were submitted to CCCP, a 
potent uncoupler of mitochondrial oxidative phosphorylation, Lucena-1 presents a lower 
oxygen consumption rate compared to K562 (Figure 4C). All of these results suggest that the 
oxidative metabolism is not the main energy supplier in resistant cells, mainly due to 
downregulation of key mitochondrial proteins. 
 
LMWPTP contributes to the Warburg effect in resistant human erythrocytic leukemia 
cells  
Previously we reported that inhibition of LMWPTP in Lucena-1 cells culminates in reducing 
both Src and Bcr-Abl activities and increasing chemotherapeutic sensitivity [Ferreira et al, 
2012]. We now show that Lucena-1 cells also display a highly active glycolytic metabolism. 
Therefore, we wondered if LMWPTP could contribute to the Warburg effect. To address this 
question, we silenced LMWPTP and examined the expression and/or activity of proteins 
involved in glucose metabolism. 
Lucena-1 siRNA LMWPTP cells showed lower expression levels of Glut-1 and lower activity 
of LDHA, once this enzyme was less phosphorylated at Tyrosine (Tyr10), an activator 
residue. On the other hand, K562 LMWPTP cells presented higher expression of Glut-1 and 
higher activity of LDHA (Figure 5).  
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Figure 4. Mitochondrial function in leukemia cells. (A) Mitochondrial lysates of K562 and 
Lucena-1 were submitted to western blotting and probed with specific antibodies against 
mitochodrial proteins. (B) Cells were incubated with MTT solution for 3 hours at 37°C. The 
MTT solution was removed and formazan crystals were solubilized in ethanol. Data are 
represented as mean ± S.E.M. and one-way analysis of variance (ANOVA) followed by 
Tukey posttest. (#) p<0.01 Lucena-1 vs K562 cells. (C) Oxygen consumption assay of non-
permeabilized cells (3x106 cells/mL) was performed in Krebs-Ringer buffer, pH 7.4 at 37ºC 
in the presence of glucose (25mM) and HEPES (10mM). After signal stabilization, the 
chamber containing the cell suspension was closed and O2 flow (Jo) recorded. ATP synthase 
inhibitor oligomycin A (1µg/mL) and the mitochondrial uncoupler CCCP (1µM) were used as 
internal controls. Data are represented as mean ± S.E.M. and (*) p>0.05 Lucena-1 vs K562 
cells. 
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Figure 5. Low molecular weight protein tyrosine phosphatase (LMWPTP) contributes to 
the Warburg effect in resistant human erythrocytic leukemia cells. LWMPTP was 
overexpressed in K562 cells and knocked down in Lucena-1 cells. LMWPTP expression was 
checked by western blotting. Lysates of K562 control and K562 LMWPTP, as well as 
Lucena-1 siRNA scramble and Lucena-1 siRNA LMWPTP were submitted to western 
blotting and probed with specific antibodies against Glut-1 and LDHA proteins. 
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Discussion 
Changes in cellular biochemistry associated with acquisition of the multidrug resistant 
phenotype remain only partially understood. Therefore, efforts in building a metabolic atlas to 
better understand cells with the resistant phenotype will open new avenues leading to 
improved therapy. Among the major problems in dealing with leukemic disease is the build-
up of resistance against therapy [Martelli et. al., 2003; O’Hare et. al., 2006; Diehl et. al., 
2007]. The biochemical aspects behind drug resistance are still far from being fully revealed. 
Since metabolic pathways depend on a tightly controlled balance between phosphorylation 
and dephosphorylation of proteins, kinases and phosphatases have a key function in the 
cancer resistance process [Abrantes et. al., 2014]. An earlier report from our group has shown 
a significant association of LMWPTP activity to chemoresistance of leukemia cells [Ferreira 
et. al., 2012], which was partly due to the maintenance of Src and Bcr-Abl activation. 
Therefore, in order to correlate phosphorylation-driven signaling with changes in cellular 
metabolism associated to the resistant phenotype, we evaluated the kinome of K562 cells and 
Lucena-1 cells. Kinome profiling provided us with a global overview of kinase activity that 
accompanies the acquisition of multidrug resistance. A fairly coherent picture emerged in 
which the resistant phenotype exhibits more activity of glycolytic signalling as demonstrated 
by: a) increased activity of the insulin receptor and its downstream mediators Akt/mTOR; b) 
diminished GSK-3 activity; c) activation of p21 Rac, leading to both cytoskeletal responses as 
well as activation of stress-activated kinases JNK, PAK, CK2 and PDK1. Accordingly, 
kinome profiling and pulldown experiments also revealed that PAK1 is more active in 
resistant leukemia cells. It is known that PAK1 also regulates glucose homeostasis by 
stimulating Glut-4 translocation and glucose uptake [Chiang et. al., 2014] and modulating 
Phosphoglycerate mutase (PGM), an enzyme in the lower end of the glycolytic pathway that 
catalyzes the interconversion of 3- and 2-phosphoglycerate. Gururaj and colleagues (2004) 
demonstrated that when PAK1 phosphorylates threonine 466 of PGM, it significantly 
increased its enzymatic activity. Beyond that, kinome profiling showed that PDK1 is more 
active in Lucena-1 cells. PDK1 is a key negative regulator enzyme of glucose metabolism 
through phosphorylation of Pyruvate Dehydrogenase (PDH) [Fan et. al., 2014]. PDH belongs 
to a multienzyme complex that catalyzes the oxidative decarboxylation of pyruvate, 
generating acetyl-CoA and, consequently, favouring the oxidative pathway in mitochondria 
[Saunier et. al., 2016]. Therefore, since PDK1 is more active in Lucena-1 cells, use of 
pyruvate by mitochondria is inhibited. In addition, PDH is inhibited by Src [Jin et. al., 2016], 
a kinase that is much more active in Lucena-1 cells [Ferreira et. al., 2012]. This explains the 
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higher production of lactate observed in those cells. Furthermore, Lucena-1 presents a lower 
enzymatic activity of Pyruvate kinase isoform 2 (PKM2) when compared to K562. Shinohara 
and colleagues (2015) have reported that a higher activity of Src kinase promotes PKM2 
inhibition. Furthermore, PKM2 catalyzes the conversion of phosphoenolpyruvate to pyruvate. 
Higher lactate production in Lucena-1 cells is likely guaranteed by Pyruvate kinase isoform 1 
(PKM1) [Taniguchi et. al., 2016]. Furthermore, the activity of PKM2 determines the level of 
cellular energy, redox homeostasis and proliferating ability [Filipp, 2013; Iqbal et. al., 2013].  
In order to explain the predominance of a glycolytic metabolism in Lucena-1 cells, we 
focused our attention on the investigation of mitochondrial function in both K562 and 
Lucena-1. Glucose metabolism is reprogrammed in many malignancies, as shown by 
accelerated glycolysis rates to provide energy/biosynthetic precursors and by the active 
truncated TCA cycle to produce intermediates for tumor cells. It is already known that 
alterations in glucose metabolism are closely associated with therapeutic resistance and 
clinical outcome [Liberti and Locasale, 2016]. Lucena-1 cells displayed lower oxygen 
consumption, which is in accordance with higher production of lactate. Based on western 
blotting analysis, we also showed that key mitochondrial proteins (SDHA, PDHα1 and 
VDAC) were strongly downregulated. SDHA, Succinate dehydrogenase complex, subunit A, 
belongs to the SDH protein complex of the inner mitochondrial membrane, which catalyzes 
the conversion of succinate to fumarate (TCA reaction) and also takes part on electron 
transport in the mitochondrial complex II. Dysfunctions of SDH have been associated with 
the development of cancer, as the excess of succinate inhibited prolyl hydroxylases dependent 
on α-ketoglutarate, leading to HIF-1α stabilization. Consequently, HIF-1α is able to regulate 
the expression of genes involved in glucose metabolism including Glut-1 [Kirches, 2009; 
Wallace, 2012; Morin et. al., 2014]. HIF-1α and Glut-1 increase glycolysis and decrease 
mitochondrial function in tumors, and this axis is critical for cells to overcome metabolic 
stress. Another important player in the regulation of mitochondrial function is VDAC, which 
constitutes an ionic transport channel protein family that acts as a selective pore for anions 
and cations, like calcium, and promotes the communication between mitochondria and the 
rest of the cell. Therefore, downregulation of this protein in Lucena-1 cells suggests 
mitochondria are not the main energy supplier. Besides, the low concentration of VDAC also 
contributes for lower TCA efficiency, since this protein is important for the uptake of TCA 
subtrates [Maldonado and Lemasters, 2014].  
Our findings so far allow us to propose the following hypothesis: Lucena-1 siRNA LMWPTP 
cells take up less glucose due to the lower expression of Glut-1. All these findings suggest 
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that inhibition of LMWPTP switches cell metabolism from glycolytic to oxidative. 
Furthermore, K562 LMWPTP presented increased Glut-1 expression and also LDHA activity. 
In the last four years, we have reported the importance of the low molecular weight protein 
tyrosine phosphatase for aggressiveness of different tumors (cancer cell lines and patient 
biopsies). Specifically, in relation to chronic myeloid leukemia, high activity of this 
phosphatase correlates to a resistant phenotype, since inhibition of LMWPTP in Lucena-1 
cells culminates in reducing both Src and Bcr-Abl activities and increasing chemotherapeutic 
sensitivity [Ferreira et. al., 2012]. In this study, we show that LMWPTP is a pivotal mediator 
of metabolic reprogramming that confers survival advantages to leukemia cells against death 
stimuli, such as hydrogen peroxide. Indeed, we have observed that Lucena-1 cells (resistant 
phenotype) are much more resistant to the toxic effect of peroxide than K562, its non-resistant 
counterpart. 
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Abstract 
In the last decade, several reports highlight the importance of the low molecular weight 
protein tyrosine phosphatase (LMWPTP) in cancer aggressiveness and resistance. 
Specifically, in chronic myeloid leukemia, we have reported that high expression of the 
LMWPTP maintains Src and Bcr-Abl kinases in an activated status and the glucose 
metabolism is directed to lactate production, and in turn favoring the pentoses pathway (one 
of the key process for antioxidant and protective responses). In this present study, we 
investigated the possible correlation between the LMWPTP and autophagy. In resistant 
chronic myeloid leukemia cells, the antioxidant response is supported by the glycolytic 
metabolism and antioxidant enzymes such as SOD and catalase, both favored by the 
LMWPTP. Therefore, when the cells were challenged by hydrogen peroxide treatment, the 
LMWPTP level goes down as well as SOD, and in turn, autophagy process was stimulated. 
The findings presented here, reveal a novel aspect by which LMWPTP cooperates for the 
resistance of CML towards stressor stimuli. 
 
Keywords: LMWPTP, ACP1, autophagy, leukemia, antioxidant response. 
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Introduction 
Autophagy is a cellular recycling process crucial for homeostasis and stress adaptation. 
Therefore, it can confer protection and promote survival in response to 
metabolic/environmental stress, such as nutrient deprivation, hypoxia, and chemotherapies 
[1]. There is preclinical evidence that targeting autophagy can enhance the efficacy of cancer 
therapies [2, 3]. However, it has been described that autophagy activation seems to be reduced 
in human acute myeloid leukemia blasts and loss of key autophagy genes leads to leukemia 
initiation and progression in mouse models [4, 5, 6, 7]. These observations prompted us to 
investigate whether the LMWPTP could influence the autophagy process in chronic myeloid 
leukemia (CML) cells (K562 and Lucena-1). In the last years, our research group conducted 
several large-scale analyses to identify biochemical differences between two leukemic cells 
lines K562 and a multidrug resistant phenotype Lucena-1 [8, 9, 10]. Based on that, the Low 
Molecular Weight Protein Tyrosine Phosphatase (LMWPTP) was identified overexpressed in 
chemoresistant leukemia cells. LMWPTPs are a group of 18kDa-tyrosine phosphatase class 
II, encoded by ACP1 gene and have been reported to play a major role in leukemia as well as 
solid cancers [8, 9, 11, 12]. We reported that the high expression and activity of the LMWPTP 
in resistant CML cells (Lucena-1 cell line) kept Src and Bcr-Abl active [9]. More recently, we 
showed that the LMWPTP switches the glucose oxidative metabolism off, and in turn, 
favoring a potent antioxidant defense [10]. However, the mechanisms by which this tyrosine 
phosphatase contributes for the basal protection response towards environmental stresses is 
not completely understood. In the present study, we report that in Lucena-1 cells, the basal 
autophagy process is down-modulated which is in part due to the control of autophagy 
mediators and up regulation of the antioxidant response by the LMWPTP. 
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Results 
Crosstalk between the LMWPTP and autophagy in chronic myeloid leukemia cells 
In order to explore the basal autophagy process in CML cells, we analyzed the 
expression/phosphorylation status of protein involved in nucleation phase: beclin and the 
phosphorylated form phospho-beclin (Ser 93/96), in elongation phase: LC3 I and II, Caveolin-
1 and phosphorylated form Caveolin-1 (Tyr14), and in autophagy process execution (UBC3, 
an ubiquitin protein). As it can be seen in Figure 1, cell with higher amount of LMWPTP also 
display higher amount of p62/SQSTM1 and LC3I. In addition, the phospho-caveolin/caveolin 
ratio was much lower in Lucena-1 compare to K562 cells (Figure 1A). These findings indicate 
that autophagy process is not favored in Lucena-1 cells. Accordingly, we do observe a huge 
number of vacuoles in Lucena-1 cells, which might be autophagosomes, that means the 
autophagy process starts but is not completed (Figure 1B). Also, it was observed higher LC3 
accumulation on Lucena-1 cells compared to K562 (Figure 1C), as a confirmation of our 
findings on western blot. We next examined whether LMWPTP silencing in Lucena-1 cells 
would affect intracellular level of P62/SQSTM1 and caveolin-1. Interestingly, p62/SQSTM1 
is lower expressed and Caveolin is more phosphorylated in knockdown cells (Figure 2). 
Caveolin phosphorylation has been reported to be important, among other processes, for 
endosome formation and autophagy activation [13- 15]. 
 
75 
 
(Legend on next page) 
 
76 
Figure 1. Autophagy in CML cells. (A) Low Molecular Weight Protein Tyrosine 
Phosphatase (LMWPTP) expression at chronic myeloid leukemia cells and autophagy-related 
proteins. Lysates of cells were submitted to Western blotting and probed with specific 
antibodies against LMWPTP and proteins involved in autophagy process. β-tubulin was used 
as the internal housekeeping, and the densitometry is represented by histograms on 
Supplemental Figure 1A. The number under the western blot picture is the indication of 
densitometry. The densitometry indicated below the blot is related to the ratio between 
phosphorylated and total protein forms. (B) Electron microscopy showing K562 (1 and 2 – 
zoom from the highlighted area) and Lucena-1 (3 and 4 – zoom from the highlighted area).  
(C) Representation of immunofluorescence microscopy of K562 and Lucena-1 cells targeted 
LC3 (green) expression. Nuclei are stained in blue (DAPI). Representative images are shown 
at 63X, and 4X from 63X magnification.  (D) Immunofluorescence quantification of LC3 on 
K562 and Lucena-1. Statistical analysis: P<0.05 K562 vs. Lucena-1. 
 
 
Figure 2. LMWPTP expression coordinates autophagy. Low Molecular Weight Protein 
Tyrosine Phosphatase (LMWPTP) expression at Lucena-1 control (Scramble) and siRNA 
LMWPTP and autophagy-related proteins. Lysates of cells were submitted to Western 
blotting and probed with specific antibodies against LMWPTP and proteins involved in 
autophagy process. β-tubulin was used as the internal housekeeping, and the densitometry is 
represented by histograms on Supplemental Figure 1B. 
 
Short time challenged Lucena-1 cells with hydrogen peroxide decreases LMWPTP and 
p62/SQSTM1 amounts 
Previously, it has been shown that Lucena-1 cells display high resistance towards hydrogen 
peroxide treatment compared to K562 [10, 16]. Therefore, we decided to check if the 
challenging of Lucena-1 cells with subtoxic concentration of hydrogen peroxide would affect 
the LMWPTP and p62/SQSTM1. In other words, we wonder if the environmental stress 
would favor an extra protective response, for instance by reactivating autophagy. For that, 
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K562 and Lucena-1 cells were treated with 5mM hydrogen peroxide up to 60 minutes. 
Interestingly, autophagy- and antioxidant-associated proteins levels decreased during 
hydrogen peroxide treatment of K562 cells (Figure 3A), while in Lucena-1 cells, LMWPTP 
amount decreased, as well as the total p62/SQSTM1 (Figure 3B). On the other hand, SOD2 
was upregulated at 30 minutes and dramatically downregulated after 60 min of hydrogen 
peroxide treatment, which correlates with catalase downregulation (Figure 3C). These 
findings reinforce that the LMWPTP contributes for autophagy process inhibition in Lucena-1 
cells, which is reverted when these cells are treated with oxidant agent.  
 
 
Figure 3. The antioxidant profile of K562 and Lucena-1. CML cells (1x105/mL) were 
treated with 5mM of H2O2 for 30 and 60 minutes. Lysates of cells K562 (A) and Lucena-1 
(B,C) were submitted to Western blotting. α-tubulin was used as the internal housekeeping, 
and the densitometry is represented by histograms on Supplemental Figure 1C,D. 
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Discussion 
K562 and Lucena-1 cells are useful models of chronic myeloid leukemia which have been 
characterized molecularly [16, 17]. Comparing the both models, our group described that the 
high amount of the LMWPTP in Lucena-1 cells (resistant cells) is important for keeping Src 
and Bcr-Abl activated [9]. Specifically, in relation to antioxidant response, Src has been 
highlighted to promote Warburg effect, which among other effects, stimulates the pentose 
pathway, a key cascade for producing NADPH, essential for antioxidant reaction. Recently, 
Jin and co-workers (2016) reported that the activation of Src decreased pyruvate 
dehydrogenase (PDH) activity, also the generation of reactive oxygen species (ROS) [18]. In 
opposite, Src inhibitors activated PDH and increased cellular ROS levels. PDH has a critical 
role in defining the fate of pyruvate produced by glycolysis pathway, once this enzyme 
catalyzed the conversion of pyruvate in Acetyl-CoA. In other words, PDH is the gatekeeper 
enzyme that strategically links glycolysis to mitochondrial oxidation. Later on, our group 
showed that LMWPTP is also connected to the glycolytic profile of Lucena-1 cells [10], 
which is important for the resistance of these cells towards hydrogen peroxide treatment. 
These findings prompted us to compare the autophagy pathway in Lucena-1 (resistant) and 
K562 (sensitive) cells, once this process contributes to remove the irreversibly oxidized 
biomolecules from cells, and to find out whether there is any connection between the 
LMWPTP and autophagy process. Indeed, the autophagy process is inhibited in Lucena-1 
cells. Hydrogen peroxide treatment of Lucena-1 caused a wave response in LMWPTP, SOD2 
and p62/SQSTM1. These proteins were upregulated at 30 min, followed by downregulation at 
60 minutes. It means that, at first Lucena-1 recruits antioxidant players in order to overcome 
the oxidant stimulus, which it is not sustained for longer hydrogen peroxide exposure. 
Consequently, the autophagy process is required for controlling the ROS excess and/or 
removing damage organelles and macromolecules. On the same direction, K562 cell line, 
which has lower LMWPTP expression, has lower antioxidant capacity, as it was observed on 
catalase and SOD2 amount along hydrogen peroxide treatment time frame. These findings 
suggested that Lucena-1 cells do not keep autophagy process activated under basal condition. 
The explanation for that might be, in part, due to an efficient antioxidant response supported 
by: glycolytic metabolism that guarantees NADPH production [19]. However, when these 
cells were challenged with an oxidant agent, the LMWPTP, SOD and p62/SQSTM1 amount 
dropped. Consequently, this redox imbalance favors autophagy occurrence (Figure 4). It has 
been reported that autophagy triggered by reactive oxygen species (ROS) is prevented in the 
presence of ROS scavengers [20, 21].  
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Overall, we showed, for the first time, that the LMWPTP is also linked to cell redox stasis and 
autophagy regulation, kinds of cellular strategies to withstand an unfavorable environment. In 
addition, the findings presented here brought out new aspect of LMWPTP relevance for 
leukemia resistance, once keeping Src kinase active enables resistant leukemia cells to 
counteract the harmful effect of hydrogen peroxide. 
 
 
 
 
Figure 4. LMWPTP supports antioxidant defense in Lucena-1 cells. LMWPTP for an 
effective antioxidant arsenal and consequently autophagy process is not favored. However, 
when Lucena-1 cells are treated with H2O2, the LMWPTP amount goes down, and in turn 
autophagy can occurs. 
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Supplemental figure 1. Histograms for Western blots represents western blot from 
Figure 1 (A), Figure 2 (B) and Figure 3 (C,D). It was considered the housekeeping control 
for total proteins, and the ratio between phosphorylated/total forms for phosphorylated 
proteins. Statistical analysis: Figure 1 (A), P<0.05 K562 vs. Lucena-1; Figure 2 (B), P<0.05 
Lucena-1 shScramble vs. Lucena-1 shACP1 and for figure 3 (C,D), P<0.05 Control vs. H2O2 
treatments. 
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Experimental procedures 
Cells line, antibodies, and reagents 
Leukemic cells K562 cells were purchased from the American Type Culture Collection and 
Lucena-1 cells (counterpart of K562 cells with multiresistant phenotype) were provided by 
prof. V.M. Rumjanek [14] – for details, see Table 1. Polyclonal antibodies against α-Tubulin 
(#2144), Beclin (#3738S), phospho-Beclin (Ser 93/96) (#12476S), LC3 (#2775), Catalase 
(#14097), UBC3 (#4997), Caveolin-1 (#3238) and phospho-Caveolin (Tyr 14) (#3251) 
antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). SQSTM1 
(D3) p62 (sc28359) antibody was obtained from Santa Cruz Biotechnology, Inc. (St. Louis, 
MO, USA). LC3 B (MAP1) (18725-1) and SOD2 (1080) antibodies were obtained from Bioss 
(Boston, MA, USA). LMWPTP (ACP1) (ab26232), β-Tubulin (ab15568) antibodies were 
obtained from Abcam (Cambridge, UK). Anti-sheep, anti-rabbit, and anti-mouse peroxidase-
conjugated antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). 
Hydrogen peroxide 30% (H2O2) was purchased from Merck Millipore Corporation 
(Darmstadt, Germany). 
 
Cell culture 
K562 and Lucena-1 cells were routinely cultured as described in [9]. Briefly, cells were 
grown in suspension in Roswell Park Memorial Institute 1640 medium (RPMI 1640) 
supplemented with 2mM glutamine, 100U/mL penicillin, 100µg/ml streptomycin and 10% 
fetal bovine serum (FBS). For Lucena-1 cells, vincristine (final concentration: 60nM) was 
routinely added culture medium. Cells were maintained at 37°C in a 5% CO2 humidified 
atmosphere. In the present study, the basal condition was considered as cell cultured in 
medium contained FBS, glutamine and antibiotics. The stress condition was under 5mM H2O2 
treatment. 
 
Table 1. Cell lines characteristics 
Cell line K562 Lucena-1 
Tissue Bone marrow (human) Bone marrow (human)  
Disease Chronic myeloid leukemia Chronic myeloid leukemia 
MDR profile Negative Positive [16] 
Vincristine 
resistance 
Negative Positive [16] 
Bcr-Abl mutation Positive Positive [9, 16] 
Obtained from  ATCC 
Derived from K562 
Described at Rumjanek et al, 2001 [16] 
Cell culture Suspension Suspension 
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Transmission electron microscopy 
The transmission electron microscopy was performed as described before [22, 23]. Briefly, 
the K562 and Lucena-1 cells were fixed with 2.0% phosphate-buffered glutaraldehyde. The 
cells were then postfixed in 1% phosphate-buffered OsO4, and embedded in Spurr's resin. 
Thin sections (0.12µm) were cut, double stained with UO2(CH3COO)2 (uranyl acetate) and 
Pb3C12H10O14 (lead citrate), and visualized with a Philips TECNA10 transmission electron 
microscope (TEM). Fifty cells from randomly chosen TEM fields were analyzed for each cell 
line. 
 
Immunofluorescence Microscopy 
CML cells were cultured (1x105 cells/well – 1000 µL), on 24-well plate for 3 hours. After, 
cells were fixed with 4% PFA for 10 minutes, washed with PBS, permeabilized with Triton x-
100 (0.1%) for 10 minutes and blocked with 3% BSA for 1 hour. Cells were washed 3X with 
PBS and incubated overnight at 4°C in a humidified chamber with the following antibody 
LC3 (#2775) Cell Signaling Technology (Beverly, MA, USA). After, cells were stained with 
Alexa-Fluor® - Invitrogen (Thermo Fisher Scientific, MA, USA) 488 Rabbit secondary 
antibodies at 1:500 dilution for 1 hour. Cells were subjected to a standard staining with DAPI-
Invitrogen (Thermo Fisher Scientific, MA, USA) at 1:1000 dilution. Cell suspensions were 
mounted onto glass slides covered with poly-lysine (Sigma-Aldrich, Missouri, USA) with a 
coverlips. Images were acquired on a LEICA TCS SP5 II confocal microscope (Leica, 
Wetzlar, Germany) at Life Sciences Core Facility (LaCTAD) from State University of 
Campinas (UNICAMP) - using a 63X objectives. Images format 1024x1024 and 4x optical 
zoom. Images were analyzed using Image J software (NIH, USA). The analysis of expression 
was performed using: Corrected Total Cell Fluorescence = Integrated Density – (Area of 
selected cell X Mean fluorescence of background readings). 
 
Transfection of Lucena-1 cells with LMWPTP siRNA 
The transfection of Lucena-1 cells was performed as described before [9]. Briefly, Lucena-1 
cells (1x105 cells/mL) were grown for 24 hours at 37°C in a 5% CO2 humidified atmosphere 
and subsequently transiently transfected with LMWPTP siRNA (QIAGEN #SI02776851). 
Transfections were done using the Hiperfect transfection kit (QIAGEN) according to the 
manufacturer’s instructions. Briefly, the cells were transfected with LMWPTP siRNA (5nM) 
for 48 hours and then lysed with a specific buffer for Western blotting procedure. The 
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efficiency of transfection was assessed based on the expression of LMWPTP by Western 
blotting analysis. 
 
Cell Viability and Treatment 
CML cells were plated at 1x105 cells/mL density into a 6-well plate and treated with H2O2 
(5mM) for 30 and 60 minutes. After treatment, cell viability was assessed by trypan blue dye 
exclusion. The cells were harvested and western blot samples were prepared. 
 
Western blotting 
Western blotting was performed as described before [10]. Briefly, cells were lysed for 2 hours 
on ice in cell lysis buffer (50mM Tris–HCl pH 7.4, 1% Tween 20, 0.25% sodium 
deoxycholate, 150mM NaCl, 1mM ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-
tetraacetic acid (EGTA), 1mM Na3VO4, 1mM NaF and protease inhibitors [1µg/ml aprotinin, 
10µg/ml leupeptin, and 1mM 4-(2-aminoethyl) benzenesulfonyl-fluorid-hydrochloride]. 
Protein extracts were cleared by centrifugation and protein concentration was determined 
using the Bradford reagent (Sigma-Aldrich, Missouri, USA). Twice the volume of sodium 
dodecyl sulfate (SDS) gel loading buffer (100mM Tris–HCl pH 6.8), 200mM DTT, 4% SDS, 
0.1% bromophenol blue and 20% glycerol) was added to the samples, which were 
subsequently boiled for 5 minutes. Cell extracts were resolved by SDS-polyacrylamide gel 
(12%) electrophoresis (PAGE) and transferred to polyvinylidene difluoride (PVDF) 
membranes. Membranes were blocked in bovine serum albumin (3%) in Tris-buffered saline 
(TBS)-Tween 20 (0.05%) and incubated overnight at 4°C with the appropriate primary 
antibody at 1:1000 dilutions, in bovine serum albumin (1%) in TBS-Tween 20 (0.05%). After 
washing in TBS-Tween 20 (0.05%), membranes were incubated with anti-rabbit, anti-mouse, 
and anti-sheep horseradish peroxidase-conjugated secondary antibodies, at 1:10000 dilutions, 
in bovine serum albumin (1%) in TBS-Tween 20 (0.05%) for 2 hours. Proteins were detected 
using enhanced chemiluminescence in Alliance 6.7 (UVITEC, Cambridge, UK). 
 
Data Analysis 
All experiments were performed in triplicate. Soluble lysates were matched for protein 
content and analyzed by Western blotting and all bands were compared with their respective 
internal control. Student’s t-test was performed (paired, 95% confidence intervals, two tailed) 
using GraphPad software (version 5.0, GraphPad Inc, San Diego, CA, USA). 
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Abstract 
Platelets control hemostasis and play a key role in inflammation and immunity. However, 
platelet function may change during aging, and a role for these versatile cells in many age-
related pathological processes is emerging. In addition to a well-known role in cardiovascular 
disease, platelet activity is now thought to contribute to cancer cell metastasis and tumor-
associated venous thromboembolism (VTE) development. Worldwide, the great majority of 
all patients with cardiovascular disease and some with cancer receive anti-platelet therapy to 
reduce the risk of thrombosis. However, not only do thrombotic diseases remain a leading 
cause of morbidity and mortality, cancer, especially metastasis, is still the second cause of 
death world-wide. Understanding how platelets change during aging and how they may 
contribute to aging-related diseases such as cancer may contribute to steps taken along the 
road towards a ‘healthy aging’ strategy. Here, we review the changes that occur in platelets 
during aging, and investigate how these versatile blood components contribute to cancer 
progression.   
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Platelet function, platelet reactivity, aging, cancer. 
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1. Introduction 
Physiological changes occur in all organ systems during aging, and are a reflection of 
changes that occur on a molecular level in individual cells. Diverse animal and yeast models 
have shown that aging is associated with tissue-specific changes in transcriptomes as well as 
intra- and extracellular metabolite changes [1]. Cellular senescence, a block in cellular 
proliferation as a result of (amongst others) telomere shortening and loss of DNA damage 
repair, plays an important role in the process of aging [2]. In addition to telomere attrition, 
genomic instability, and cellular senescence, other hallmarks of cellular aging include stem 
cell exhaustion, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, and altered intercellular communication [3]. Not all cells become 
senescent, and removal of senescent cells may reduce aging on an organismal level [4]. 
However, cellular communication is mediated in part via the release of vesicles known as 
exosomes, which can carry cellular components from one cell to another across large 
distances. Senescent cells also release such exosomes and these have been speculated to play 
a significant role in age-related phenotypes including age-related diseases [5]. Connecting all 
known cellular alterations to biological aging remains challenging, and finding ways to 
promote “healthy aging” remains a holy grail [3].  
Thus far, aging is often studied in the context of stem cell capacity and longevity, but 
cellular changes in individual cell types have also been investigated for neurons, skin 
fibroblasts and keratinocytes, bone and bone marrow (bone-proximal osteoblastic niche), and 
many other tissues and cell types [6–8]. One more cellular component to be added to this mix 
are platelets, as a role for these blood constituents in aging and age-related diseases is now 
emerging [9]. Like many systems in cellularmetabolismand catabolism, the biology/function 
of platelets appears to be altered in the elderly. In addition, altered platelet function and 
clinical conditions such as cancer create a complex chain of cause and effect, which can 
culminate in systemic responses responsible for the main causes of death in the world, 
namely, (1) inappropriate blood clot formation known as thrombosis and (2) cancer 
metastasis, responsible for more than 90% of cancer-related deaths [9,10]. Thrombotic risk in 
the elderly is associated with genetic factors, but also with lifestyle, obesity, and diseases such 
as cancer [11, 12], creating a complex feedback loop. Other examples of the interrelationship 
between platelet function and pathological conditions can be seen in the acquisition of 
bleeding disorders such as hemophilia or Von Willebrand syndrome [13], or the involvement 
of platelets to neurological disorders such as Alzheimer disease (for review, see [14]). In this 
latter condition, the microenvironment sensitizes platelets to activation and renders them less 
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sensitive to inhibition, most likely due to increased sensitivity to some platelet activation 
agonists, such as thrombin and collagen, leading to an increase in β-amyloid production by 
platelets [15, 16]. Large-scale omics studies have demonstrated age-specific proteomic 
changes in platelets from childhood to adulthood [17], and miRNA patterns associated with 
age in individuals ranging from 18 to 46 years old [18]. It is conceivable that such cellular 
changes may predispose an individual to aging-related diseases. In this review, we summarize 
the impact of aging on platelet function, and investigate how such altered platelet 
functionality can contribute to aging-related diseases, with particular emphasis on cancer. 
 
2. Aging-associated changes in platelet phenotype and function(s) 
Since the lifespan of platelets is around 7 to 10 days in the bloodstream, changes in 
platelet functions may be correlated with megakaryocyte matura t ion, adhes ion, and 
thrombopoiesis, as changes in megakaryocyte maturation during aging lead to altered 
proplatelet formation and release of platelets with an altered content [19]. Some of these 
events appear to be driven by β-adrenergic signals coming from a senescent 
microenvironment [19–21]. As such, megakaryocyte aging, aging of platelets in the 
circulation, and cues from an aged microenvironment to megakaryocytes and nascent platelets 
during organismal aging can all contribute to changes in platelet biology in elderly 
individuals. Under normal conditions, there is a gradual loss of RNA content over the course 
of a platelet lifespan, while in aged organisms, distribution of megakaryocyte content to 
platelets is altered. However, there are also clear differences between “aged platelets” and 
“platelets in aged individuals.” Hepatic clearance of senescent platelets from the circulation of 
adult organisms is dependent on the loss of sialic acid residues of glycoproteins in the cell 
membrane. Activation of the pro-apoptotic BAX–BAK pathway in aged platelets results in 
caspase-dependent surface exposure of phosphatidylserine, which serves as a recognition 
signal for phagocytic cells. In terms of functionality, senescent platelets have impaired 
adhesion and aggregation responses. On the other hand, platelets in senescent organism might 
be primed to increase their responsiveness to agonists (hyper-reactive platelets) [22, 23].  
Several recent studies have investigated the effect of aging on platelet morphology and 
function. During the course of life, platelet size increases [24], which directly affects platelet 
content, including granules and pro-coagulation factors. Other morphological changes seen in 
platelets from older individuals include an irregular, less smooth plasma membrane with more 
frequent ruptures, and an increase of slender pseudopodia [25]. The number of circulating 
platelets is thought to decrease with advanced age. While a study of over 5000 participants 
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suggested that platelet count in individuals of > 65 years is not affected by subsequent age 
differences [26], two large studies investigating over 25,000 and 40,000 individuals, 
respectively, showed that platelet numbers drop from early childhood, are relatively stable in 
adulthood, and drop again over the age of 60 years old, irrespective of gender and ethnicity 
[27, 28]. Careful consideration of the age groups studied is essential, and for the purpose of 
this review, we therefore aimed to compare young adults (18–39 years), middle-aged (40–59 
years), old-aged (60–79 years), and very-old-aged (> 80 years) groups, where possible (Figs. 
1 and 2). While the cause of reduced platelet numbers during aging remains to be clarified, 
some studies have suggested changes in hematopoietic stem cells as a pivotal cause of lower 
platelet counts in advanced age [29–31].  
Despite a lower platelet count in older individuals, bleeding times are reduced during 
aging, which is thought to contribute to an increased risk of blood clot formation [32, 33]. 
Bleeding time (i.e., time before efficient blood clotting occurs) is dependent on platelet count 
and vessel contractibility, as well as platelet function, and platelets in the elderly are indeed 
hyper-reactivated, especially in subjects with associated comorbidities (for review, see [31, 
34]). For instance, spontaneous platelet aggregation is higher in very old subjects as compared 
with old adults [35, 36], and a higher sensitivity to ADP stimulation [10, 37, 38] and thrombin 
receptor–activating protein (TRAP6) [39] is seen. Several other platelet agonists, including 
ristocetin, thrombin, and collagen, have received attention but whether responsiveness of 
platelets towards these agonists is increased or decreased during aging remains disputed (Fig. 
1).  
Whether overactivation of platelets is a failed compensation mechanisms to make up 
for the loss of platelet count remains speculative. The mechanisms contributing to higher 
platelet activity in elderly individuals are still under investigation. It has been suggested that 
age-related inflammatory and metabolic changes contribute to an increased platelet function 
in the elderly [40]. Mouse models have shown an increase of hydrogen peroxide 
concentration in blood, which directly increases platelet activity during aging [41]. In humans, 
oxidative stress markers in platelets increase from young to middle-aged individuals [35, 42, 
43]. Hydrogen peroxide accumulation in platelets could be the result of NADPH oxidase and 
superoxide dismutase activity, which are associated with an increased integrin αIIbβ3 activity 
in platelets [44, 45]. Indeed, the expression of surface markers such as integrin αIIb and 
αIIbβ3 is increased during the course of aging [46, 47]. Thus, overall increased oxidative 
stress is generally seen during the aging process, contr ibuting to the concept that platelet 
alterations in aging are associated with an increasing inflammatory state. The oxidative burst 
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triggers activation of the signaling molecule mTOR, a key regulator of lifespan and aging 
[48]. mTOR activation in turn results in an increased platelet production by megakaryocytes 
[49]. Moreover, mTOR hyper-activation during aging is associated with increased platelet 
aggregability and aging-related venous thrombosis risk in mice [50]. Thus, mTOR plays a 
dual role in platelet hyper-aggregability by increasing the activity of platelets, while oxidative 
stress further increases platelet reactivity, resulting in an enhanced risk of thrombi formation 
in the elderly (Fig. 2).  
Association between activated platelets and monocytes, as would occur during blood 
clotting, enhances the formation of aggregates. While there is no impact of age on platelet-
monocyte aggregation per se in healthy adults [51], higher levels of platelet-monocytes 
aggregates were seen in patients with acute coronary syndrome [52], and platelet hyper-
activation may thus be further exacerbated in disease states. Others have shown that the age-
related increases of platelet- derived β-2-microglobulin levels in the serum cause monocyte 
differentiation towards a less regenerative phenotype, providing a further link between 
platelet changes during aging and the aging process [53].  
A clear association between platelet hyper-reactivity and the occurrence of 
thromboembolic events exists and may contribute to cardiovascular comorbidities in the 
elderly [54]. In addition to the direct effect of aging on platelet aggregation described above, 
this phenomenon has also been attributed to the fact that the production of anti-coagulation 
factors does not follow the increasing pro-coagulation factor production during aging [11]. 
Gleerup and Winther showed that, in addition to an enhancement of platelet aggregability, 
aging provokes a decrease of fibrinolytic activity, further reinforcing the association between 
lower fibrinolytic activity forming stable thrombus formation and accumulation, an imbalance 
between thrombotic versus fibrinolytic events [55]. The same research group described that 
adrenaline and sub-concentration ADP-induced canonical platelet activation is enhanced in 
old and very old individuals, as is the synergistic effect of serotonin on adrenaline-/ADP-
induced platelet activation. Adrenaline levels were also augmented in the old and very old 
groups [56, 57]. This might be a compensatory mechanism for the fact that β-adrenoreceptors 
from older individuals show higher ligand affinity. This receptor reduces platelet aggregation 
through the production of cAMP, and a reduced signaling capacity through this receptor may 
thus contribute to an enhanced platelet aggregation in the elderly; however, the levels of 
cAMP in plasma did not change significantly during aging [56, 57]. Endothelial dysfunction 
during aging may further increase platelet responsiveness [58]. For instance, it has been 
speculated that platelet activation and aggregation caused by dysfunctional lung epithelium in 
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virally infected individuals may cause depletion of thrombocytes, and contribute to the 
thrombocytopenia observed in COVID-19 patients infected with SARS-CoV-2 [59, 60]. 
In addition to blood clotting, it is increasingly recognized that platelets play an 
important role in wound healing. While wound healing is not absolutely impaired, delayed 
closure rates and weaker wound repair are commonly seen in subjects of advanced age [61]. 
During wound healing, many different cell types, including fibroblasts and immune cells such 
as macrophages and lymphocytes, cooperate to restore tissue architecture. Activated platelets 
trapped in the blood clot release mediators to attract these cells and express P-selectin which 
acts as cell adhesion molecule for passing lymphocytes [62]. Furthermore, the secretion of 
several growth factors, such VEGF, PDGF, EGF, and TGFβ, may modulate T cells to induce 
keratinocyte regenerative capacity and enhance proliferation of regenerative cells such as 
fibroblasts [63, 64]. However, while reduced serum levels of these platelet-derived factors 
could theoretically contribute to decreased wound healing rates, age-related variations in 
cytokine levels appear most pronounced in early adulthood, disputing their relevance for 
wound healing delay in the very old individuals [25, 65]. 
Data collection on platelet function during aging is complicated by several issues. For 
one thing, platelet aging may be gender-specific, as studies have indicated that aging-related 
loss of interaction with the adhesion molecule von Willebrand factor (vWF) is more 
pronounced in women as compared to men [28, 66]. Thus, hormonal changes may contribute 
to platelet alterations in older subjects [67]. Levels of steroids such as testosterone and 
dihydrotestosterone in older individuals are negatively associated with platelet activation 
markers, and these steroids can directly inhibit collagen-induced aggregation in vitro [68]. 
Secondly, recent data suggest that changes that occur during aging are complicated and were 
not always found to be continuous during aging. Spontaneous aggregation was increased in 
elderly individuals compared with younger subjects, while ristocetin or collagen-induced 
aggregation was decreased (pointing towards platelet exhaustion) [35]. However, these trends 
did not follow linear relationships with changes most pronounced in the very old (80+ years) 
[35]. Other platelet activation markers (soluble P-selectin, integrin αIIb, caspase 3, oxidative 
stress)were shown to increase from young to old individuals, but decrease again in the very 
old [43]. However, it should be noted that others found no differences in basal membrane-
bound P-selectin between individuals < 45 years and > 65 years old [69, 70], while the 
percentage of platelets expressing P-selectin upon stimulation with TRAP-6 was actually 
higher in younger individuals [39]. Differences in age groups, methods, and stimuli used vary 
per study and may account for conflicting results. It should further be noted that the effects 
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observed are sometimes small, and small group sizes may hamper interpretation of results. 
While many studies point towards disturbances in platelet functionality during aging, the 
direct consequences on coagulation in healthy aging may not always be clear [68, 71], and 
may be more pronounced under pathological conditions.  
 
Platelet bioactive lipids in aging  
A detailed study on platelet lipid production and aging was reported in 1986 [72]. This 
study investigated platelet cholesterol and phospholipids content, and observed a slight 
increase of cholesterol/phospholipids molar ratio upon aging within a range of 20 to 69 years 
old [72, 73]. It is important to highlight that platelets are not able to produce their own 
cholesterol, which must be obtained during their genesis (from megakaryocytes) or derived 
from plasma. The cholesterol/phospholipid molar ratio is important to maintain platelet 
membrane fluidity, and, consequently, the platelet capacity to change its shape during 
activation. In addition, activation of platelets via agonist-receptor activation in many cases 
requires localization of receptors and downstream signaling molecules in cholesterol-rich 
lipid rafts [74]. The lipid composition is also affected by aging [75], with increased fatty acids 
16:0 phosphatidylcholine and sphingomyelin, and a decrease of linoleic acids 18:2, 20:4, and 
20:3 in older subjects [72]. It is important to note that lipid oxidation occurs on platelet LDL, 
and this phenomenon may have severe consequences for cardiovascular diseases. One study 
showed that older males at risk for coronary heart disease due to dietary habits (55–73 years 
old) showed higher platelet aggregation in response to epinephrine as compared with younger 
individuals (28–54 years old) and males at lower risk for heart disease, indicating that age-
related platelet changes associated with phospholipid content may be a risk factor for 
cardiovascular diseases [76].  
Besides the platelet membrane lipid composition, the most important bioactive lipids 
relevant to platelet function are the signaling lipids derived from the eicosanoid pathway. 
Briefly, upon stimulation of cells, membrane-anchored arachidonic acids (AA) are released 
from the membrane phospholipids by phospholipases (phospholipase A2), after which they 
are enzymatically converted to prostanoids by COX1/2 enzymes. This process results in 
production of platelet stimulatory thromboxane (TxA2, mainly produced via COX1 [77]) or 
platelet antagonistic prostaglandins (PG), PGI2, prostacyclin), PGD2, and PGE2 (mainly via 
COX2) [78, 79]. Alternatively, AA can be converted to leukotrienes through lipoxygenases 
activity. Eicosanoids are impor tant mediators of inflammation, and, indeed, eicosanoid 
biosynthesis is higher on advanced age [57, 80, 81], which in turn may contribute to enhanced 
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inflammatory state during aging [78, 80, 82]. Platelet interaction with peripheral blood 
mononuclear cells directly modulates inflammatory responses, potentially through their 
production of PGE2 [62, 63]. In this case, PGE2 decreases the effectiveness of myeloid cell 
differentiation and affects their responses [83].  
However, both increased TxA2 as well as PGE2 and prostacyclin excretion were seen 
in older humans or rats, which begs the question of how this balance would affect platelet 
activity [57, 84, 85]. While TxA2 is produced by platelets, the major source of prostacyclins 
is endothelial cells. While some studies showed no differences in prostacyclin secretion by 
arterial endothelial cells for donors of different ages [83], others demonstrated reduced 
prostacyclin expression in aorta endothelia from older individuals, suggesting that perhaps the 
TxA2 effectwins out during aging. It is of interest to know that dietary restriction, known to 
prolong healthy aging, is associated with an enhanced prostacyclin/TxA2 ratio in rats [86, 87]. 
Indeed, increased TxA2 excretion appears to be associated not only with age-related diseases 
such as atherothrombosis but also with metabolic disease [88, 89]. Obesity and 
decompensated glucose metabolism increase not only platelet activation but also 
inflammation (for review, see [90]). In this case, the persistent TxA2-dependent platelet 
activation increases systemic inflammation [89, 91]. Inflammation-induced endothelial events 
may play a major role in aging comorbidities. For instance, glycemia-mediated TxA2-receptor 
activation was associated to disturbed blood-brain barrier integrity in diabetes [92]. 
Furthermore, TxA2 is a P2X1 ion channel agonist and both platelets and P2X1 are required to 
maintain vascular integrity in a mouse colitis model [93, 94]. 
Taken together, a clear change in platelet morphology and function is seen during 
aging, which may have severe consequences for aging-related physiology. The most relevant 
changes in platelet biology were highlighted in Figs. 1 and 2. 
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Figure 1. Age-associated changes in platelets function. Platelet function of aggregation, 
tissue repair and remodeling changes discriminated on age-groups. The concept of age-groups 
is based on young adults (18-39 years), middle-age (40–59 years), old-age (60–79 years), 
very-old-age group (>80 years). 
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Figure 2. Age-associated changed in platelet markers. Platelets present several changes 
during the aging process on their content (cytosolic and membrane) and release thereof. The 
concept of age-groups is based on young adults (18-39 years), middle-age (40–59 years), old-
age (60–79 years), very-old-age group (>80 years). 
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3. Platelets in cancer – “double edged sword”? 
As described above, platelet hyper-reactivity during aging is associated with an 
increased risk of formation of embolisms. Nevertheless, despite cancer being an age-related 
disease, thrombocytopenia is a common event in these patients. The risk of bleeding in 
thrombocytopenic cancer patients is difficult to predict [95], and platelet counts must be 
carefully monitored. In particular, cancers of the bone marrow (platelet production from 
megakaryocytes) or spleen (platelet clearance), where hematopoiesis is affected, are prone to 
lead to loss of platelet counts. For instance, thrombocytopenia in patients with bone dyscrasias 
is directly related to bleeding events [96]. However, the most common cause of bleeding due 
to platelet loss in cancer patients arises as a result of  
myeloablative chemotherapy [97] and cytopenia may therefore be a bystander effect rather 
than a pathogenic event. In fact, the role of platelets in cancer appears to be ambiguous, as 
enhanced blood clotting represents a major risk factor in cancer patients. 
Patients with cancer (but also those with cardiovascular diseases including diabetes, 
hyper-cholesterolemia, and hypertension) can develop an increased platelet activity, which 
may be either age-related or disease-specific. The hyper-aggregability observed in these 
diseases appears to be related to higher platelet reactivity towards agonists or in- creased 
circulation of these agonists (such as thrombin and factor Xa), and is a primary cause of 
thrombotic events, in particular venous thromboembolismevents (VTE) and arterial 
thrombosis (AT) [98, 99]. These events partially overlap, with shared risk factors, and similar 
incidence in cancer patients [100, 101].  
The first report of a platelet-related disorder in cancer came from Armand Trousseau, 
who described a higher risk of thrombotic events in cancer patients [102], which has 
subsequently been termed Trousseau syndrome. As the second cause of death, VTE poses a 
significant comorbidity in cancer patients, and a common cause of hospitalizations, thereby 
significantly contributing to cancer-associated health care costs [103]. Several cancers are 
associated with increased VTE risk, including renal carcinoma [104]; hepatocellular 
carcinoma [105]; lung cancer [106]; and esophageal and stomach cancer [98]. Moreover, VTE 
in esophageal or gastric cancer patients has been associated with decreased survival: patient 
survival without VTE is 18 months compared with 13.9 months with VTE [107]. While the 
risk of VTE appears to be especially high in patients suffering from stomach and pancreatic 
cancer, up to 20% of all cancer patients may develop thromboembolisms, including 
pulmonary and venous events. For AT, the overall incidence of events in patients with cancer 
is increased 2-fold [101].  
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Enhanced platelet activation as determined by mean platelet volume (MPV) is seen in 
cancer patients, andmay correlate with tumor stage [108, 109]. BothMPV and increased 
soluble P-selectin levels correlate with VTE development in cancer patients [110–112]. Age 
does not predict VTE risk for all cancer types, suggesting that at least for some cancer types, 
tumor cells themselves increase platelet reactivity and VTE risk [113]. Indeed, higher platelet 
P-selectin expression was found in mouse models of breast cancer, which in turn was 
associated to lung metastasis [114]. In addition, MPV, which is enhanced in malignant 
tumors, drops upon treatment [115], enforcing the direct link between tumor burden and 
platelet activation. Thus, cancer cell–mediated platelet hyper-reactivity contributes to 
increased VTE risk. While to date, there is no method available and validated to monitor the 
clinical implication of platelet hyper-aggregability in cancer patients; this may be a promising 
avenue of investigation [116].  
Multiple mechanisms may underlie the tendency of platelets from cancer patients to 
aggregate. Tumor cells can stimulate platelet aggregation through direct interaction via 
adhesion molecules or via the delivery of extracellular vesicles and/or secreted factors. This 
phenomenon, described as tumor cell–induced platelet activation (TCIPA), was already 
identified decades ago [116]. It has now been shown that single tumor cells are capable of 
attracting and activating platelets to form fibrin clots [117]. Furthermore, platelets from 
cancer patients differ from platelets from healthy controls in their mRNA profiles, with 
mRNA transcripts undergoing alternative splicing under influence of tumor-derived stimuli 
[118,119]. Platelets are also capable of taking up tumor content, as determined by the fact that 
tumor-specific mutations can be identified in platelets upon co-culture with tumor cells. This 
process appears to be regulated by extracellular vesicles released by the tumor cells, which are 
subsequently taken up by co-cultured platelets [120]. This alteration of platelets by tumor 
cells, i.e., tumor education, was shown to contribute to an increased adhesive propensity of 
platelets [121–123]. Furthermore, cancer cells shed extracellular vesicles containing the 
adhesion molecule tissue factor (TF), which may contribute to VTE at sites of vessel damage 
[120, 124]. 
 
4. Platelets drive tumor growth, angiogenesis, and metastasis in cancer 
Specifically in solid tumors, the interaction of tumor cells and platelets leads to a 
condition called paraneoplastic thrombocytosis, in which malignant tumors not only hijack or 
mimic platelet functions but can also increase their production. A cyclic picture emerges, 
which contributes to the most feared outcome of a malignant neoplasm: metastasis [125]. 
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Metastasis is the principal cause of death in cancer patients and investigation of the molecular 
mechanisms that coordinate this process is therefore crucial. The process of metastasis 
requires several steps: invasion of cells in the surrounding matrix, intravasation to the blood 
circulation, survival at the circulation, extravasation at the secondary site (tissue or organ), 
micrometastasis formation and colonization [126]. The primary tumor can shed many cells 
during the growth phase; however, only a few cells are able to colonize a secondary site 
[121]. Much depends on the survival of these tumor cells in the blood circulation, survival of 
detachment, and the hemodynamic flux force, as well as escaping the immune system. One of 
the principal strategies of cancer cells to survive in the circulation is interaction with platelets, 
and nearly all processes of cancer metastasis appear to be facilitated by interaction of tumor 
cells with platelets.  
Platelets can stimulate expression of metalloproteinases in tumor cells, which in turn 
contributes to tumor cell invasion by facilitating extracellular matrix degradation [127, 128]. 
Tumor cell metastasis often requires the acquisition of a different phenotype, termed 
epithelial-to-mesenchymal transition (EMT). This process is characterized by upregulation of 
several molecular markers (e.g., expression of SNAIL, vimentin cadherin, and MMPs), and 
platelet-released TGFβ can significantly enhance the upregulation of these markers in cancer 
cells [129, 130]. In addition, direct contact between cancer cells and platelets contributes to 
TGFβ/Smad and NFκB pathway activation, culminating in EMT stimulation. Adherence of 
cells to the extracellular matrix provides survival signals, which are disrupted upon 
detachment of cells, thereby leading to anoikis: detachment-induced apoptosis. While cancer 
cells have several mechanisms to overcome anoikis, it has been demonstrated that interaction 
of cancer cells with platelets further induces tumor cell resistance against anoikis [115]. Thus, 
platelet-induced alteration of cancer cell intracellular programs contributes to tumor 
invasiveness and metastasis [121, 130, 131].  
Extravasation of tumor cells from tissue to bloodstream is facilitated by platelet-
derived ADP stimulation of P2Y2 receptors on endothelial cells [132]. Once the cancer cell 
enters the blood circulation, the dissemination efficiency also depends on the interaction with 
platelets, with many studies showing that platelets facilitate the metastatic process via 
hematogenous dissemination [129, 133]. Survival of tumor cells in the blood stream is not 
only enhanced by platelets through mechanic protection from shear force but also by 
protecting the cancer cells from circulating immune cells, which may target neoantigens, 
expressed by tumor cells. Interestingly, it has been demonstrated that cancer cells may mimic 
platelets by expressing megakaryocytic genes and expressing platelet surface markers, 
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including adhesion molecules such as integrins and selectins [125, 134]. Additionally, coating 
of tumor cells with platelets allows transferring their major histocompatibility complex 
(MHC) class I to tumor cells, thereby giving these cells a false “pseudonormal” exterior, and 
allowing escape from immunosurveillence by natural killer cells [135]. TGFβ released by 
platelets also downregulates the NK receptor NKG2D on tumor cells, further shielding them 
from immunosurveillence [136, 137]. Lastly, extravasation of the tumor cells from the blood 
stream is facilitated by platelets, and appears to require binding of platelets to Integrin ανβ3 
expressed on tumor cells [138].  
As a solid tumor grows and its oxygen and nutrient demands increase, angiogenesis, 
the formation of new blood vessels, is essential for its survival. Tumor-induced angiogenesis 
often results in an abnormal vasculature with suboptimal perfusion. Nevertheless, tumor cells 
may benefit from this, as this may reduce delivery of therapies and tumor-targeted immune 
cells [136]. Furthermore, tumor cells may adapt to such ineffective vascularization, and the 
ensuing hypoxia may favor tumorigenesis by selecting for aggressive and metastatic clones 
[139]. Supplementation of platelets or their released products stimulates angiogenesis induced 
by breast tumor cells in vitro [122, 140]. In glioblastoma patients, release of VEGF by 
platelets was shown to contribute to vessel formation [141], although other studies indicated 
that platelet-induced angiogenesis was independent of VEGF but most likely relied on release 
of several other factors, including IL6, thrombopoietin, and angiopoietin [142, 143]. 
Furthermore, animal models indicate that tumor-educated platelets are more efficient at 
inducing angiogenesis than healthy platelets, suggesting a more efficient delivery of pro-
angiogenic factors by tumor-educated platelets [144]. This appears to be supported by 
findings in humans, showing that levels of VEGF are increased in platelets fromprostate, 
breast, and colorectal cancer patients [145, 146]. It is of interest to note that vasculogenic 
mimicry, where tumor cells themselves rather than endothelial cells form vessels, is inhibited 
by platelets. While counterintuitive, this process is thought to promote metastasis [147]. Thus, 
platelets tightly coordinate the vascularization process in the context of cancer, and may 
thereby potentiate malignancies.  
Thus far, platelet participation in cancer progression has been associated with 
vascularization, delivery of growth factors, and hematogenous dissemination [129]. In 
addition, platelets may directly stimulate cancer cell proliferation through upregulation of 
oncogenic genes, as was demonstrated for colorectal cancer cells [117]. Thus, platelets play a 
role in all aspects of cancer progression, something we may do well to take into account when 
addressing these diseases.  
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Taking the above into account, it is perhaps surprising to realize that fibrinolysis, the 
process of dissolving a blood clot, can also play a tumor-promoting role [148]. The main 
enzyme promoting fibrinolysis is plasmin, while the platelet-derived plasminogen activator 
inhibitor (PAI) is the main suppressor of this system. Elevated PAI-1 levels are associated 
with VTE [149], and may explain VTE in pancreatic and glioma cancer patients [150, 151]. 
As such, inhibition of fibrinolysis is detrimental to cancer patients. On the other hand, 
plasminogen itself contributes to metastasis by degradation of the extracellular matrix 
surrounding tumor cells. In addition, the fibrinolytic system contributes to inflammation, 
angiogenesis, the release of tumor growth factors, and other tumor-promoting functions [148]. 
Thus, coagulation and fibrinolysis play double roles in cancer, highlighting platelet 
performance as double-edged sword [152].  
In order to target these interactions in healthy aging as well as age-related diseases, 
detailed knowledge regarding the molecular mechanisms involved may prove essential (Fig. 
3). Many of the molecular interactions between cancer cells and platelets depend on their 
molecular cell surface composition. Platelets can interact with cancer cells via tissue factor 
(TF), selectins, integrins, and glycoproteins receptors, all of which may activate signaling 
pathways leading to platelet activation. Thus, platelet membrane components havemultiple 
functions: they contribute directly to hemostasis during thrombus formation, but can also 
contribute to multifactorial cancer dissemination. TF expressed by cancer cells stimulates 
platelet activation and initiation of the coagulation cascade. The fibrin produced by platelets 
subsequently interacts with integrins from cancer cells as well as platelets themselves, 
inducing formation of cancer cell–fibrin–platelet clusters, which may enter the circulation 
[153, 154]. Overexpression of TF on breast cancer cells has been reported, and appears to be 
linked to the release of TGFβ from activated platelets [155]. Furthermore, in ovarian cancer, 
platelet-induced increase in TF acts as a metastasis initiator [156]. 
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Figure 3. The crosstalk between cancer cells and platelets support metastasis, 
angiogenesis and tumor growth. Platelets release factors such as TGFβ and VEGF that 
stimulate epithelial-to-mesenchymal transition (EMT) and angiogenesis. Additionally, 
platelets contribute to escape from immunosurveillance by covering cancer cells and shielding 
them from the immune system. 
 
The contribution of integrins to cancer cell–platelet interactions is broad and 
bidirectional. Platelets express integrins αIIbβ3, αvβ3, α2β1, α5β1, and α6β1, which bind 
preferentially fibrinogen, vitronectin, collagen, fibronectin, and laminins, respectively, all of 
which have been described to have adhesive proprieties [136]. Mammadova-Bach and 
colleagues described that integrin α6β1 from platelets directly binds ADAM9 from tumor 
cells, a member of the disintegrin and metalloproteinase family. As a consequence of this 
interaction, platelets are activated and support hematogenous dissemination of cancer cells 
[157]. Conversely, as already mentioned above, interaction of αvβ3 on platelets was 
associated with extravasation in aggressive breast cancer [138]. A last class of molecules 
facilitating the interaction between cancer cells and platelets are selectins, membrane-
localized glycoproteins that bind carbohydrates from glycoproteins, glycolipids, and 
glycosaminoglycan/proteoglycans. Of the selectin family, P-selectin is expressed on platelets 
and endothelial cells and has already been mentioned above. Platelet dysfunction as a result of 
P-selectin deficiency limits colon carcinoma and metastasis progression [158, 159]. E-
selectin, which is produced by endothelial cells, binds to sialyl-Lewis-x/an, otherwise known 
as CA19-9, a common tumor marker. The ensuing interaction promotes hematogenous 
dissemination of colorectal cancer cells [160].  
Platelet bioactive lipids are also associated to cancer metastasis (for review, see [161]), 
and prostanoid synthesis inhibition as a strategy for cancer treatment has been suggested since 
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1972 [162]. Leukemic cell–induced platelet aggregation is associated with increased TxA2 
and decreased leukotriene B4 (LTB-4) production by platelets [163]. TxA2 in turn 
promotesmetastasis of various tumor models by increasing TCIPA, endothelial cell activation, 
and recruitment of innate immune cells, all contributing to creating a pre-metastatic niche 
[164]. Targeting COX1/TxA2 appears efficient to reduce tumor cell metastasis [165, 166]. 
Conversely, prostacyclin, one of the most potent platelet inhibitors, prevents metastasis in a 
melanoma model [162, 164]. Endothelial function, essential to tumor 
cellintravasation/extravasation, is also modulated by prostacyclins. Interestingly, endothelial 
dysfunction, as characterized (amongst others) by decreased prostacyclin and increased P-
selectin levels, was associated with more severe lung cancer stage, but also to patient age 
[167]. PGD2 can also decrease tumor MMP-2 expression, inhibit EMT inhibition, and reduce 
tumor cell proliferation [168, 169]. While these latter functions appear to be independent of 
platelets, some of the prostacyclin-mediated anti-tumor effects may come from inactivation of 
platelet hyper-reactivity in response to cancer cells, as was shown for melanoma, lung cancer, 
and breast cancer [165]. However, the anti-tumorigenic effects of prostacyclin and PGD2 may 
be specific to these prostanoids, as PGE2 did not reduce TCIPA, and COX2 and PGE2 have 
been associated with enhanced rather than reduced cancer metastasis [170, 171]. Thus, while 
COX2 inhibitors have been advocated as anti-cancer treatments in the context of 
inflammation (i.e., prostaglandins are important mediators of inflammation, which in turn 
may have carcinogenic effects), caution should be taken [172, 173]. Complicatingmatters 
further is the fact that platelets and their products may actually protect endothelial cells, in 
particular under inflamed conditions (e.g., platelet dysfunction has been suggested to 
contribute to endothelial dysfunction in COVID-19 patients) [174]. By strengthening the 
endothelial barrier, platelets may prevent intra/extravasation of tumor cells, thereby limiting 
tumor metastasis (reviewed in [175]). 
All in all, many different molecular associations underlie platelet–cancer cell 
interactions and a better insight into these pathways may provide targets for treatment of both 
cancer and its associated VTE risk in elderly patients. With platelets playing multiple roles in 
cancer progression, care needs to be taken when using platelet inhibitors [175]. 
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5. Conclusions 
It is becoming increasingly clear that aging is associated with changes in platelet 
ontogenesis/biogenesis and function, and that this may have consequences for physiological 
aging. With the (relatively late) recognition of the importance of platelets, it has also become 
evident that age-related diseases such as cancer and cardiovascular disease are associated with 
platelet alterations (Fig. 4). However, to what extent this is driven by age-related changes or 
whether these alterations are disease-specific is perhaps unclear and age-matching in platelet 
investigation is imperative. Nevertheless, evidence showing that tumor cells directly modulate 
platelet content and functions suggests that while aging may predispose towards platelet 
dysfunction, specific disease states may further exacerbate platelet dysfunction to a 
pathological extent. Finding ways to break this pathological interaction while maintaining the 
balance of hemostasis may prove an important step towards healthy aging. 
 
 
Figure 4. Aging related changes in platelet function and their association with aging 
related diseases (e.g. cancer). As a crosslink between aging and cancer, oxidative stress, 
wound healing disturbed, inflammation, lower platelet count and senescent cells delivery 
factors is highlighted. Platelets support metastasis by augmentation of integrin activity, 
increasing expression of metalloproteinases and the release of growth factors, which also 
augment angiogenesis. Furthermore kinase activation, including mTOR pathways, increase 
platelet activation. Production of reactive oxygen species enhances platelet production.  
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Abstract 
Over the last decades, several members of the tyrosine phosphatase family have emerged as 
cancer promoters. Among them, the low molecular weight protein tyrosine phosphatase 
(LMWPTP) has been described to be associated with colorectal cancer liver metastasis and 
poor prostate cancer prognosis. Of importance in the process of cancer progression and 
metastasis is the interaction between tumor cells and platelets, as the latter are thought to 
promote several tumor hallmarks. Here, we examine to what extent LMWPTP expression in 
tumor cells affects their interaction with platelets. We demonstrate that the gene encoding 
LMWPTP is overexpressed in upper gastrointestinal (GI) cancer cell as well as colorectal 
cancer, and subsequently employ cell line models to show that this expression may be further 
upregulated by platelets. We demonstrate that tumor-platelet interaction promotes GI tumor 
cell proliferation and show that LMWPTP expression within the tumor cell contributes to a 
more efficient interaction with platelets by using knock down models. These data are the first 
to demonstrate that phosphatases play a positive role in the tumor-promoting activities of 
platelets. Further elucidation the molecular mechanisms underlying these interactions may 
provide novel treatment strategies for gastrointestinal cancer.  
 
Keywords 
Gastric cancer, colorectal cancer, LMWPTP, ACP1, tyrosine phosphatases, gastrointestinal 
cancer, platelets, tumor microenvironment. 
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1. Introduction 
Over the last few years, an important role for platelets in cancer progression has emerged. 
Platelets can interact with cancer cells, either directly, or via tumor-cell released factors [1]. 
This can have several tumor-promoting effects. Firstly, the dynamic crosstalk between 
platelets and cancer cells promotes cancer cell survival in the blood circulation. Coating of the 
cancer cell surface with platelets not only protects cancer cells from hemodynamic flux, but 
may also allow cancer cells to escape immunosurveillance through shielding of tumor 
antigens and platelet-induced shedding of immune cell ligands from the tumor cell surface 
[2]. Secondly, owing to their growth factor content, platelets can directly stimulate cancer 
growth [3,4]. For instance, co-culture of ovarian cancer cells with platelets increased tumor 
cell proliferation via binding of transforming growth factor beta (TGFβ) released by platelets 
to its receptor present on tumor cells [5]. Thirdly, a role for platelets in metastasis and cancer 
angiogenesis has thus far been demonstrated for breast, ovarian and prostate cancers, through 
platelet-tumor cell interaction and/or factors released by platelets [4,6,7]. Thus, it is clear that 
tumor cells may derive beneficial effects from interaction with platelets. This interaction 
appears to be bidirectional, as tumor cells may also cause tumor cell-induced platelet 
aggregation (TCIPA) [8].  
The exact molecular mechanisms governing platelet-tumor cell interactions are still unclear. 
The receptors contributing to this interaction are relatively well described [9], as is the role of 
the kinases which promote oncogenic signaling in tumor cells [10]. However, while over the 
past decade it has become clear that tumor cell over-expression of protein tyrosine 
phosphatases (PTPs) contributes to tumorigenesis [11]; their roles in platelet-tumor cell 
interactions are scarcely investigated. We and others have previously shown that the low 
molecular weight protein tyrosine phosphatase (LMWPTP) is upregulated in various human 
cancers [12-14], and in turn, contributes to tumor cell invasiveness and chemotherapy 
resistance [15,16]. In addition, we showed that LMWPTP expression follows a step-wise 
increase through different levels of dysplasia in colorectal cancer (CRC) [14]. However, it is 
unclear whether this phosphatase also affects tumor progression by promoting interactions 
with platelets. Therefore, in the present study, we aimed to increase our understanding of the 
relevance of a high expression of LMWPTP in colorectal as well as upper gastrointestinal 
(GI) cancer. We show that LMWPTP expression in tumor cells affects their ability to interact 
with platelets and proliferate in the presence of platelets, while platelets themselves affect 
LMWPTP expression in cancer cells, creating a feedback loop. These data show for the first 
time that cellular levels of LMWPTP may affect tumor-platelet interactions, suggesting that 
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targeting such phosphatases may not only reduce primary cancer growth, but may also affect 
tumor survival.    
 
2. Material and methods 
2.1. Antibodies and reagents 
Antibodies were purchased from Santa Cruz (Dallas, TX), Cell Signaling Technology 
(Danvers, MA) or SignalWay (College Park, MD). For details, see Table 1. Other reagents 
were purchased from Sigma Aldrich (Saint Louis, MO), Santa Cruz (Dallas, TX), Merck 
(Kenilworth, NJ), Millipore (Burlington, MA).  
 
Table 1. Antibodies 
Acp1 α/β (LMWPTP) Santa Cruz Biotechnologies sc-100343 
β-actin Santa Cruz Biotechnologies sc-47778 
Phospho-Akt (Ser473) Cell Signaling 4060 
Phospho-Src family (Tyr416) Cell Signaling 2101 
Phospho-FAK (Tyr925) SignalWay Antibodies 11123-2 
Phospho-p38 (Thr180/Tyr182) Cell Signaling 4511 
Phospho-Cofilin (Ser3) SignalWay Antibodies 21164 
Phospho-Paxillin (Tyr118) Cell Signaling 2541 
Phospho-S6K (Ser235/236) Cell Signaling 21225 
Anti-rabbit IRDye® 800CW Odyssey 926–32211 
Anti-mouse IRDye® 680RD Odyssey 926-68070 
 
2.2. Cell culture 
CRC cell (HCT116) was routinely grown in McCoy 5A culture medium (Lonza, Maryland, 
USA). GES-1, HCT116 shScramble, HCT116 shLMWPTP, Caco-2 shScramble, Caco-2 
shLMWPTP, HT29 wild type and HT29 LMWPTP KD were routinely grown in Dulbecco’s 
Modified Eagles Medium (DMEM, Lonza, Basel, Switzerland), 23132/87, KatoIII wild type 
and KatoIII LMWPTP KD cells were routinely grown in Roswell Park Memorial Institute 
medium (RPMI1640, Lonza, Basel, Switzerland). All cell lines were supplemented with 10% 
Fetal Bovine Serum (FBS, Sigma-Aldrich, Missouri, USA), and 1% 100 U/mL penicillin, 
100 μg/mL streptomycin (Life technologies, Bleiswijk, Netherlands) at 37°C in a 5% CO2 
humidified atmosphere. The gastric cancer cell line 23132/87 was a kind gift from Prof. Dr. 
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Winand Dinjens of the department of pathology of the Erasmus University Medical Center. 
The immortalized gastric epithelial cell line GES-1 was a kind gift from Prof. Dr. Yun Yu of 
the department of Gastroenterology and Hepatology of the Chinese University of Hong Kong. 
CRC cells were obtained from BCRJ (Rio de Janeiro, RJ, Brasil). HCT116 and Caco-2 
(shScramble and shLMWPTP) cells were generated and described by Hoekstra [14]. HT29 
wild type, HT29 LMWPTP KD, KatoIII wild type and KatoIII LMWPTP KD were generated 
through Crispr/Cas9 gene editing using forward oligo CACCGACACACAAACAGCACGGACT 
and reverse oligo AAACAGTCCGTGCTGTTTGTGTGTc which were annealed and ligated into 
pX330 vector which was subsequently electroporated into competent NEB5x bacteria. After 
sequencing individual colonies for verification of correct insertion of the oligo, plasmids were 
isolated by midiprep (Qiagen, Germany). Cell lines were plated in 6 well plates, grown to 
50% confluency and transfected with pX330-ACP1 and GFP-empty vector using Fugene 
transfection reagent (Promega, USA) according to manufacturer’s protocol. After 48h, single 
GFP-positive cells were sorted into 96 well plates containing 50% conditioned medium and 
individual cell colonies were tested for the presence of LMWPTP by Western blot analysis to 
confirm successful knock out of LMWPTP. Clones without successful knockout were taken 
as control lines, having undergone the exact same procedure as the knock out lines. All lines 
were routinely checked for mycoplasma.  
 
2.3.  Immunohistochemistry 
Immunohistochemistry was performed as described before [14]. Briefly, 5μm formalin fixed 
paraffin embedded (FFPE) tissue sections were deparaffinized in xylene and rehydrated 
through graded alcohols. Antigen-retrieval was performed by boiling the slides in citrate 
buffer pH 6.0 for 15 minutes. Endogenous peroxidases were blocked by immersing the slides 
for 10 minutes in 3% H2O2 in phosphate buffered saline (PBS). Next, slides were blocked by 
incubation in PBS containing 10% goat serum in for 1 hour at RT. Primary antibody Acp1 α/β 
was added 1:100 in blocking buffer (BSA 5% in PBS) - (for primary antibody, see 
specification in Table 1) and incubated overnight at 4°C. Envision goat anti-mouse-
horseradish peroxidase (Dako, Heverlee, Belgium) was used as secondary antibody. The slide 
scoring was based on Allred score (Allred et al, 1998, Hoekstra et al, 2015), taking the sum of 
intensity of staining (scored 0 to 5) and proportion of positively stained cells (scored from 0 to 
3) [14,17].  
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2.4. Oncomine™ and GEOdata analysis 
The Oncomine™ and GEOdata analysis was performed as described before [14]. Expression 
profiles from publicly available Oncomine™ were used to assess ACP1 mRNA expression in 
colorectal, gastric and esophageal cancer, while GEO databases were searched for additional 
databases not already represented in Oncomine™. Information on ACP1 expression in gastric 
cancer was available in 3 additional arrays. GEO Dataset Record GSE13861 based on the 
Illumina HumanWG-6 v3.0 expression beadchip (Illumina, Inc., California, USA) was used to 
compare 71 gastric cancer and 19 normal tissue samples [18]. Oncomine™ platform was used 
in dataset record (transcript 201630_s_at) based on the GeneChip Human Genome U133 Plus 
2.0 Array (Affymetrix, California, USA) to compare 3 gastric cancer and 10 normal tissue 
samples [19]. Oncomine™ platform was used in dataset record (transcript U25849_at) based 
on the GeneChip HuGeneFL array (Affymetrix, California, USA) to compare 22 gastric 
cancer and 8 normal tissue samples [20]. Oncomine™ searching was based on: gene: ACP1; 
analysis type: gastric cancer vs normal analysis; concept type: over-expression (oncomine 
concepts). GEOdata analysis searching was based on raw RNA data available with RNA 
discrimination, and search on ACP1 gene on each file. For colorectal cancer GEO Dataset 
Record GSE24514 (transcript 201630_s_at) based on the GeneChip Human Genome U133 
Plus 2.0 Array (Affymetrix, California, USA) was used to compare 34 colorectal cancer and 
15 normal tissue samples [21].  
 
2.5. Platelet preparation  
To obtain Platelet Rich Plasma (PRP), peripheral blood was obtained after signing informed 
consent (Ethical committee Project NL66029.078.18 approved by Erasmus MC medical and 
ethical committee, confirming that all methods were carried out in accordance with relevant 
guidelines and regulations and all experimental protocols were approved by this committee). 
Platelet isolation was performed as described before [22]. Briefly, whole blood was collected 
from healthy, drug-free volunteers into 3.2% sodium citrate tubes (BD, New Jersey, USA). 
Whole blood was centrifuged at 1500 rpm, 10 minutes, 22°C, and PRP was collected. The 
remaining blood was centrifuged at 2500 rpm, 10 minutes, 22°C, and Platelet-Poor Plasma 
(PPP) was collected. This platelet preparation was used in co-culture (2D and 3D), colony 
formation assay, MTT assay, adhesion assay, platelet-cancer cells interaction assays, and 
confocal microscopy.  
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2.6. Platelet-Cancer Cells Interaction Assays 
Platelet isolation was performed as described before [22]. Briefly, Caco-2 cell lines 
(shScramble and shLMWPTP) were detached with trypsin-EDTA and washed several times 
with NaCl 0.9% to remove the excess of trypsin-EDTA. 500 uL of PRP was incubated with 
tumor cells (1.5 × 104 cells/test in NaCl 0.9%)—(protocol described before [23] with some 
modifications) at 37°C for 5 minutes. Subsequently, the agonist collagen (2 µg/mL) was 
added to the samples. An aggregation curve was recorded for 10 minutes after the addition of 
agonist. Light transmission changes (an indicator of aggregation) were monitored with an 
aggregometer (Chrono-Log Corp., Pennsylvania, USA) following the method described 
before [24]. Quality controls of platelets were assessed by aggregation response at the 
beginning and end of experiments. 
 
2.7. Co-culture 
Gastric cells (GES-1 and 23132/87) and CRC cells (Caco-2 shScramble, Caco-2 shLMWPTP, 
HT29 wild type, HT29 LMWPTP KD) were plated at 4x104 cells/cm2 at 24-well plate for 24 
hours. After that, cells were washed with PBS, and the following conditions were applied: 
control (without platelets), 5% PRP (platelet stimulation) or 10% FBS (growth factor positive 
control). After 24 hours, microscopy analyses were made for CRC cells, as described in [22]. 
Briefly, microscopic images obtained by EVOS XL Core Cell Imaging System 
(ThermoFischer Scientific, Massachusetts, USA), using 10x magnification, focusing on cells 
and platelets differently. For gastric cells, platelets were removed by NaCl (0.9%) washing, 
and only tumor cells were collected for western blot sample preparation.  
 
2.8. Western blot assay 
Western blot was performed as described before [25]. In short, cells were plated at a density 
of 4x104 cells/cm2 for GES-1,23132/87, KatoIII wild type, KatoIII LMWPTP KD HT29 wild 
type and HT29 LMWPTP KD. After 24 hours, cells were washed with NaCl 0.9% and lysed 
in 2× concentrated Laemmli buffer (100 mM Tris-HCl [pH 6.8], 200 mM dithiothreitol, 4% 
SDS, 0.1% bromophenol blue and 20% glycerol) and samples were boiled for 10 minutes. 
Cell extracts were resolved by SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis) and transferred to polyvinylidene difluoride membranes (Merck chemicals 
BV, Darmstadt, Germany). Membranes were blocked in 50% odyssey blocking buffer (LI-
COR Biosciences, Nebraska, USA) in TBS and incubated overnight at 4°C with a primary 
antibody, dilution 1:1000. After washing in TBS-T (TBS with 0.5% Tween 20), membranes 
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were incubated with IRDye antibodies (LI-COR Biosciences, Lincoln, USA) for 1 hour. 
Detection was performed using Odyssey reader and analyzed using the manufacturer’s 
software. For antibodies used, see Table 1. 
 
2.9. Colony formation assay 
Cells (GC and CRC) were plated at 2.0x103 cells/well in 6-well plates. After 24h, 250µL of 
culture medium or PRP was added to the appropriate wells. After 10 days, the incubated 
medium was removed, and the cells were stained using crystal violet (0.5% water:methanol) 
for 40 minutes. After, the crystal violet was discarded and the wells were washed 3 times with 
tap water. Microscopic images were acquired using a Zoom Stereomicroscope (scale bar: 
2000µm) - (2x, Nikon, Japan) and the colonies were counted using ImageJ software (NIH, 
USA). 
 
2.10.  MTT assay 
Cells were plated at 4.0x104 cells/cm2 (GES-1, KatoIII wild type and KatoIII LMWPTP KD) 
and 5.0x104 cells/cm2 (23132/87) at 96-well plate for 24 hours. After that, culture medium 
(control) or PRP (5%) were added at each corresponding well for 24 hours. After, the 
supernatant with platelets was removed and MTT (0.5 mg/mL) was added, and incubated for 
3 hours. Next, cells were resuspended in 100 μL of Dimethyl sulfoxide (DMSO, Sigma-
Aldrich, Montana, USA) and optical density (OD) was measured using a spectrophotometer at 
595 nm (BioRad, California, USA).  
 
2.11. Adhesion assay 
Cells in serum-free medium were allowed to adhere to plates for 30 and 120 minutes in the 
presence and absence of platelets. The attached cells were stained with DAPI, and the 
attached cells were counted from microscopic images obtained by EVOS XL Core Cell 
Imaging System (Thermo Fischer Scientific, Massachusetts, USA). 
 
2.12. Confocal Microscopy 
HCT116 were cultured under density 4.5x104 cells/well – 500 µL on glass coverslips for 24 
hours. Subsequently, cells were incubated with platelets (5%) in medium without FBS, and 
medium with FBS (control), and cultured for another 24 hours. HT29 cells were grown in 3D 
cultured based on Souza [26]. Cells were seeded in 6-wells microplates and grown in a 2D 
model for 24 hours after which they were statically incubated for 24 hours with 60µl of 
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NanoShuttle (Nano3D Biosciences, Texas, USA) at a proportion of 2µL/1x104 cells. After 24 
hours of magnetization, cells were washed twice with PBS and enzymatically detached with 
350 µL of trypsin. Detached cells were suspended with 750 µL of McCoy 5A medium and 
seeded at 1x104 cells/well – 100 µL on a 96-wells cell repellent microplate. Platelets were 
mixed with cancer cells, seeded on 96-microplate and placed atop a magnetic drive of 96 
neodymium magnets (Nano3D Biosciences, Greiner Bio-One, Brazil) to induce spheroid 
formation. After 24 hours, the magnetic drive was removed. Images were taken by Luma 
Scope microscope (Etaluma Inc, California, USA) in a 10X magnification after 120 hours of 
culturing. Next, the protocol followed as described here [27] with some modifications. Cells 
were fixed with 4% PFA for 10 minutes, washed with PBS, permeabilized with Triton X-100 
(0.1%) and blocked with 3% BSA for 1 hour. Cells were washed with PBS and incubated 
overnight at 4°C in a humidified chamber with the following antibodies (For primary 
antibodies, see Table 1). Coverslips were stained with Alexa-Fluor® - Invitrogen (Thermo 
Fisher Scientific, Massachusetts, USA) 488 Mouse secondary antibody at 1:500 dilution for 1 
hour. Coverslips were subjected to a standard staining with DAPI-Invitrogen (Thermo Fisher 
Scientific, Massachusetts, USA) at 1:1000 dilution  and it were mounted onto glass slides. 
Images were acquired on a LEICA TCS SP5 II confocal microscope (Leica, Wetzlar, 
Germany) at Life Sciences Core Facility (LaCTAD) from State University of Campinas 
(UNICAMP) - using 100X objectives (scale bar: 25µm). Images format 1024x1024. Images 
were analyzed using ImageJ software (NIH, USA).  
 
2.13. Statistical analysis 
The data is represented by means ± SEM. Statistical analysis was performed using t-student 
(paired, 95% confidence intervals, two tailed) for Figure 1(A-C,E), 2(E), 3(B,C,E,F,G,I,J), 
4(A,C,D,F,H,I,K,M), S2(D) and One-way ANOVA with post-test corrected for multiple 
testing for Figure 3(K) and 5(C,D,G,H,K) and * = P≤0.05; ** = P≤0.01; *** = P≤0.001 using 
GraphPad (version 5.0, GraphPad Inc, California, USA). All experiments were performed a 
minimum of three independent times. 
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3. Results 
3.1. High LMWPTP protein expression in gastric cancer cells affects oncogenic 
hallmarks 
Having previously established a role for LMWPTP in CRC, we first investigated whether 
these findings also extend to upper GI cancers. Oncomine™ was used to investigate ACP1 
mRNA expression/copy number gain in gastric cancer tissues. GEO database was searched 
for additional expression databases not already represented in Oncomine™. A comparison of 
the 15 datasets present in Oncomine™ for gastric cancer showed a borderline significant 
increase in ACP1 expression in gastric tumors as compared to normal gastric mucosa 
(p=0.055, Supplementary Figure S1A), which was strengthened by a significant 
upregulation of ACP1 mRNA expression in gastric tumors observed in three available 
additional GEO datasets [18-21] (Figure 1A-C). As a proof of concept to demonstrate that 
enhanced ACP1 levels also translate to enhanced protein expression, we analyzed LMWPTP 
by immunohistochemistry and showed a significant overexpression of LMWPTP in a small 
sample set of gastric cancer tissues as compared to normal gastric epithelium (Figure 1D, E). 
Investigation of three esophageal squamous cell carcinoma (ESCC) studies present in 
Oncomine™ indicated an enhanced expression in tumor tissue as compared to controls 
(P=0.001), while a non-significant trend towards ACP1 upregulation was seen in in 
esophageal adenocarcinoma (EAC) (P=0.174). No additional GEO datasets were discovered 
(Supplementary Figure S2A, B). As a proof of concept, we also show significantly 
enhanced expression of LMWPTP by immunohistochemistry in esophageal adenocarcinoma 
(n=8) as compared to normal squamous epithelium (n=7) (Supplementary Figure S2C, D). 
These data indicate that upregulation of ACP1 expression extends to upper GI cancers as well 
as CRC. 
Having established an overexpression of LMWPTP in upper GI cancers, we employed gastric 
cell lines as a model system to investigate the molecular contribution of this tyrosine 
phosphatase to carcinogenesis (Figure 2A). First we compared LMWPTP expression in the 
gastric cancer cell line 23132/87 and the non-transformed cell line GES-1, and showed that, 
corresponding to the immunohistochemistry data, LMWPTP expression is enhanced in 
23132/87 cells compared to non-transformed cells (Figure 2B). Next, we investigated the 
phosphorylation pattern of several kinases related to cell proliferation and cytoskeletal 
remodeling, such Src, FAK and Cofilin, and observed an enhanced activation of these kinases 
in gastric cancer cells (Figure 2C-E). To confirm whether a higher expression of LMWPTP 
directly contributes to activation of proliferative signaling pathways, we performed genetic 
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knockout of LMWPTP in the gastric cancer cell line KatoIII. A reduced phosphorylation of 
cytoskeletal proteins (Figure 1D), as well as decreased proliferation (Figure 1E) was 
observed upon knockout of LMWPTP in these gastric cancer cells. Thus, these data imply 
that LMWPTP overexpression leads to stimulation of oncogenic signaling in gastric cancer 
cells. 
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Figure 1. ACP1/LMWPTP expression is increased in gastric cancer. (A-C) Oncomine and GEOdata analysis from three different studies A 
[18], B[19], C[20] studies. (D, E) Normal gastric (n=9) was compared to gastric carcinoma (n=5) and representative samples (20X) as well as 
quantifications are shown. The intensity and proportion of the staining were scored and control and carcinoma groups were compared. Dots 
indicate individual patients or experiments, and mean +/- SEM is shown.  
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Figure 2. LMWPTP contributes to 
proliferative and cytoskeletal 
signaling in gastric cancer cells. (A) 
LMWPTP expression in the non-
transformed GES-1 cell line and gastric 
cancer cell line 23132/87 as determined 
by Western blot analysis. β-actin was 
used as loading control. (B-C) 
Phosphorylation of signaling molecules 
related to cytoskeletal remodeling (B) 
and survival (C) were investigated in 
normal and cancer gastric cell lines. β-
actin served as loading control. (D) 
Phosphorylation status of kinases 
comparing KatoIII wild type (WT) and 
LMWPTP knockout (KD) cells. (E) 
Proliferation rate using MTT assay 
comparing KatoIII WT and LMWPTP 
KD. Dots indicate individual 
experiments, and mean ± SEM is shown. 
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3.2. LMWPTP protein expression in gastric cancer cells affects tumor-platelet 
interactions 
Next, we investigated whether LMWPTP-mediated signaling affects gastric cell interactions 
with platelets. To better understand the molecular mechanisms related to stimulation of cell 
survival and LMWPTP expression, we first analyzed the protein expression and/or activation 
in gastric cells co-cultured with platelets. As expected, survival-associated kinases were not 
activated in GES-1 cells, while in GC cells cultured with platelets, Src and p38 were activated 
(Figure 3A). Interestingly, co-culturing gastric cancer cells with platelets further increased 
their LMWPTP protein expression, something which was not observed in non-transformed 
cells (Figure 3A-C). When detached gastric cells were incubated with platelets prior to 
plating, attachment of 23132/87 cells, but not GES-1 cells was reduced (Figure 3D, E), 
suggesting that direct interaction between gastric cells and platelets is more pronounced in 
tumor cells. Next, we assessed gastric cell proliferation in the presence or absence of platelets 
by MTT assays. While normal gastric cells (GES-1) were not affected by co-culture with 
platelets, proliferation of GC cells (23132/87) was significantly increased in the presence of 
platelets (Figure 3F,G). To validate these findings, we further investigated proliferation by 
colony formation assay. While the size of cancer cell colonies was significantly increased 
upon co-culture, non-transformed cells showed a decrease rather than increase in size of 
colonies (Figure 3H-J). To investigate whether LMWPTP might directly drive platelet-
induced tumor cell proliferation, we knocked out LMWPTP in the gastric cell line KatoIII and 
investigated their colony formation potential. KatoIII cells form bigger colonies when 
expressing LMWPTP (Figure 3K). More importantly, however, LMWPTP-expressing 
KatoIII cells form bigger colonies in the presence of platelets as compared to LMWPTP KD 
cells, and the increase in colony size induced by the presence of platelets was no longer 
present upon knockdown of LMWPTP (Figure 3K-L). Together, these data suggest that 
LMWPTP in gastric cancer cells increases their interaction with platelets, which is associated 
with cancer cell proliferation signaling. 
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(Legend on next page) 
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Figure 3. Platelets stimulate LMWPTP expression and proliferation in gastric cancer 
cells. (A-B) Kinase activation (Src and p38), and LMWPTP expression in normal and cancer 
gastric cell line in the presence or absence of platelets. Densitometry analysis for LMWPTP 
expression is represented in (B). β-actin was used as loading control. (D-E) Adhesion assay of 
GES-1 (D) and 23132/87 (E) cells in absence and presence of platelets. (F-G) MTT assay of 
GES-1 (F) and 23132/87 (G) cells in the absence or presence of platelets.  (H-J) Colony 
formation of GES-1 and 23132/87 cells in the absence or presence of platelets. The size of 
GES-1 (I) and 23132/87 (J) colonies are presented. (F) Representative microscopic images of 
colony formation. (K-L) Colony formation of KatoIII wild type and KatoIII LMWPTP KD 
cells in the absence or presence of platelets. The size (L) of KatoIII wild type and KatoIII 
LMWPTP KD colonies are presented. Dots indicate individual experiments, and mean ± SEM 
is shown. 
 
3.3. LMWPTP is overexpressed in colorectal cancer and supports cell migration and 
proliferation in presence of platelets 
Our previous data suggested that LMWPTP is increased in colorectal cancer [14]. Here, we 
sought to validate and these findings in a new cohort of cases. A comparison of the 33 
datasets present in Oncomine for colorectal cancer, showed an upregulation of ACP1 in 
cancerous tissues as compared to normal colonic mucosa (p=0.001) (Figure S1B), which was 
confirmed by an additional GEO dataset comparing 34 colorectal cancer and 15 normal tissue 
samples [21] (Figure 4A). Employing immunohistochemistry, we further validated a 
significantly increased protein expression of LMWPTP in CRC tissues compared to their 
normal counterpart (Figure 4B). We subsequently investigated to what extent LMWPTP 
expression is modulated by platelets in colorectal cancer cell line models. As for GC cells, we 
observed that co-culture of CRC cells with platelets causes a distinct growth pattern (Figure 
4D, F), which is accompanied by a significantly enhanced protein expression level of 
LMWPTP in HCT116 cells (Figure 4D-E, H-I) as well as HT29 cell models (Figure 4F-G, 
J-K), grown under 2D or 3D conditions, respectively.  
Next, we aimed to determine whether LMWPTP also plays a role in platelet-mediated 
oncogenic potential of colorectal cancer cells. To this end, we employed shRNA to reduce 
LMWPTP expression in HCT116 cells (Figure 5A). Partial knock down of LMWPTP cells 
(18%) resulted in a ~30% reduction of the number of colonies (Figure 5B,D), confirming a 
role for LMWPTP in inherent tumorigenesis. The number of colonies was enhanced in the 
presence of platelets, but this was no longer the case when LMWPTP expression was reduced 
(Figure 5D). The size of the colonies, while not affected in control cells, was reduced in 
LMWPTP knock-down cells in the presence of platelets (Figure 5D), implying that 
LMWPTP is required to maintain colony size in the presence of platelets. To confirm the role 
of LMWPTP in platelet-induced cell growth in a separate cell model we investigated HT29 
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cell with genetic knock out of LMWPTP. Upon co-culture with platelets, a significantly 
higher colony size was seen upon in the presence of LMWPTP (Figure 5A-B), while colony 
number per se was not affected. As an increase in tumor cell proliferation may be effected by 
growth factors released by platelets, we next sought to investigate to what extent LMWPTP 
contributes to direct interaction between platelets and tumor cells. To this end, we 
investigated platelet aggregation, which may be promoted by tumor cells, but requires 
physical interaction between these two cells, as tumor cell-conditioned medium does not elicit 
the same effect [25]. We showed that knock down of LMWPTP in a third CRC cell model 
(Caco2, Figure 5I) significantly reduces platelet aggregation in the presence of tumor cells as 
determined by microscopy and aggregometry (Figure 5J,K), which was confirmed in the 
HT29 knock-out model by microscopy (Figure 5L). Together, these data demonstrate that in 
CRC as well as upper GI cancer, LMWPTP upregulated in cancer cells may be further 
enhanced by platelet interaction with tumor cells, and that LMWPTP contributes significantly 
to platelet-tumor interaction and tumor proliferation.  
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Figure 4. Platelets support CRC cell migration and proliferation in the context of 
LMWPTP. (A) GEOdata analysis of [21] indicates reduced ACP1 mRNA expression in 
colorectal cancer tissues. (B-C) LMWPTP expression was determined by 
immunohistochemistry in CRC tumors. Normal colorectal specimens (n=11) and 
adenocarcinoma (n=11) were compared. Representative samples (20X) and quantifications 
are shown. The intensity and proportion of the staining were scored and analysis was 
performed comparing control and carcinoma groups. (D-E) Fluorescence microscopy 
comparing LMWPTP intensity (quantification in E) in HCT116 cells after co-culture with 
platelets. Nuclei are stained in blue (DAPI) and LMWPTP in red at 100X magnification. (F-
G) LMWPTP expression in HCT116 as determined by Western blot analysis (densitometry 
analysis – G). β-actin was used as loading control. (H-I) 3D growth of HT29 cells in the 
presence of platelets leads to altered growth pattern and increased LMWPTP expression 
(quantification in I) as determined by fluorescence microscopy staining. Nuclei are stained in 
blue (DAPI) and LMWPTP in red at 10X magnification. (J-K) LMWPTP expression in HT29 
as determined by Western blot analysis (densitometry analysis – K). β-actin was used as 
loading control. Legend: dots indicate individual experiments, and mean +/- SEM is shown. 
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Figure 5. LMWPTP expression in CRC cells affects their interaction with platelets and 
promoted proliferation. (A) LMWPTP expression in HCT116 cells treated with either 
shScramble or shLMWPTP indicates an 18% reduction of LMWPTP expression in 
shLMWPTP cells. β-actin served as loading control.  (B-D) Colony formation assay of 
shScramble or shLMWPTP HCT116 cells in the absence or presence of platelets indicated a 
reduced number of colonies in the absence of LMWPTP as well as a loss in platelet-induced 
increase thereof. Quantification of the size (C) and number (D) of colonies in shScramble and 
shLMWPTP cultured in the absence or presence of platelets are shown. (E) LMWPTP knock-
out in HT29 cells. β-actin served as loading control. (F-H) Colony formation assay of wild 
type (WT) and LMWPTP knockout (KD) HT29 cells in the absence or presence of platelets 
indicated a reduced platelet-induced colony size increase in the absence of LMWPTP. 
Quantification of the size (G) and number (H) of colonies in WT and LMWPTP KD cells 
cultured in the absence or presence of platelets are shown. (I) LMWPTP expression in Caco-2 
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cells treated with either shScramble or shLMWPTP indicates a 44% reduction of LMWPTP 
expression in shLMWPTP cells. β-actin served as loading control. (J) Light microscopy 
images of Caco-2 cells showing reduced platelet aggregates upon shLMWPTP. (K) 
Aggregometry analysis of platelet aggregation shows that cancer cell-induced increase in 
platelet aggregation is reduced upon shLMWPTP in Caco-2 cells. (L) Light microscopy 
images of HT29 cells showing reduced platelet aggregates upon KD of LMWPTP. 
Representative pictures are shown at 10x magnification and the aggregate is highlighted by 
black arrow. 
 
4. Discussion 
Despite improvements in alimentary tract cancer detection and treatment, prognosis of these 
cancers remains abysmal with a 5-year survival rate of around 30% and 12% for GC and 
CRC, respectively [28,29]. While over the last decades, our knowledge regarding kinase 
signaling in cancer cells has expanded, the role of tyrosine phosphatase signaling in cancer 
remains poorly understood [11]. These enzymes are commonly regarded to be tumor 
suppressors, as their primary function of de-phosphorylating proteins and lipids is generally 
thought to inactivate signaling pathways. However, we have previously shown that 
dephosphorylation of the inhibitory site of the kinase Src by the phosphatase PTP1B can 
contribute to activation of oncogenic signaling [30]. Scr is also a target for LMWPTP, and 
activation of Src signaling upon activation of LMWPTP has been demonstrated in leukemia 
cells [15]. Thus removal inhibitory phosphorylation patterns by phosphatases may account for 
the enhanced phosphorylation of downstream oncogenic targets, as seen in the current study 
as well as others upon knock down of LMWPTP [11,24,31-34].  
With this new knowledge, protein tyrosine phosphatases are now emerging as potential cancer 
biomarkers and targets for treatment [16]. Here, we show that LMWPTP is overexpressed in 
gastric and esophageal cancer, as well as CRC, suggesting that upregulation of phosphatase 
expression is a common feature amongst intestinal cancers and opening up the tantalizing 
possibility of a common target for treatment of these diseases. Using several different cell 
models, we demonstrate that platelets significantly enhance tumor cell proliferation and that 
this process is at least partially dependent on LMWPTP expression in tumor cells. 
Interestingly, co-culture of tumor cells with platelets further increases their expression of 
LWMPTP in this study. With LMWPTP directly conferring several tumorigenic properties 
[11,14], it is tempting to speculate that upon extravasation of tumor cells to the blood stream 
and their subsequent interaction with platelets, a further platelet-mediated upregulation of 
LWMPTP in part mediates the platelet-induced proliferative advantage. Indeed, our data show 
that tumor cell-expressed LMWPTP directly affects association of tumor cells with platelets, 
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which is in line with data showing that Integrin β3 on the surface of platelets can promote 
phosphatidylinositol 3-OH kinase (PI3K) signaling and proliferation of 
hemangioendothelioma cells [35]. However, platelets also produce substantial amounts of 
growth factors, and it is conceivable that these also contribute to LMWPTP expression and 
proliferation of tumor cells in situ. Indeed, supernatant obtained from stimulated platelets was 
able to stimulate breast cancer cells by activating the pro-survival kinases 
phosphatidylinositol 3-OH kinase (PI3K) and protein kinase C [10].  
In summary, we demonstrate that LMWPTP expression in intestinal cancers takes part in the 
crosstalk between platelets and cancer cells, with platelets significantly enhancing GI cancer 
cell proliferation. Future research will have to extend these findings to additional cell line and 
pre-clinical models, to investigate to what extent LMWPTP may affect other platelet-
mediated oncogenic properties and provide a target for treatment of GI cancers.    
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Supplemental Figures:  
Figure S1. Oncomine analysis for 
gastric cancer and CRC. (A) Gastric 
cancer tissues showed a borderline 
significant increase in ACP1 expression 
as compared to normal gastric mucosa in 
15 datasets available. (B) A comparison 
of datasets present in Oncomine for 
colorectal cancer, an update of our 
previous investigation of public 
repositories [14], confirmed an 
upregulation of ACP1 in cancerous 
tissues as compared to normal colonic 
mucosa across 33 studies. 
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Figure S2. LMWPTP expression is increased in esophageal cancer. (A-B) Oncomine analysis from Esophageal Squamous Cell Carcinoma 
(A) and Esophageal Adenocarcinoma (B). (C-D) Normal esophageal (n=7) was compared to esophageal carcinoma (n=8) and representative 
samples (10X) as well as quantifications are shown. The intensity and proportion of the staining were scored and control and carcinoma groups 
were compared (D). Legend: dots indicate individual experiments, and mean +/- SEM is shown. 
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Abstract 
Platelets are small enucleated cell fragments specialized in the control of hemostasis, but also 
playing a role in angiogenesis, inflammation and immunity. This plasticity demands a broad 
range of physiological processes. Platelet functions are mediated through a variety of 
receptors, the concerted action of which must be tightly regulated, in order to allow specific 
and timely responses to different stimuli. Protein phosphorylation is one of the main key 
regulatory mechanisms by which extracellular signals are conveyed. Despite the importance 
of platelets in health and disease, the molecular pathways underlying the activation of these 
cells are still under investigation. Here, we review current literature on signaling platelet 
biology and in particular emphasize the newly emerging role of phosphatases in these 
processes. 
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1. Introduction 
Platelets are derived from megakaryocytes in a complex differentiation process called 
thrombopoiese, in which shedding of cytoplasmic extensions generates small cellular 
fragments lacking genomic DNA [1]. The human body has in the order of 1012 circulating 
platelets. Their average life span is 7-10 days, after which they are removed from the 
circulation and cleared by splenic or hepatic macrophages and hepatocytes. With a size of 
around 2-3μm diameter, a discoid shape, and a minimal displacement volume coupled with a 
highly active cytoskeleton, platelets are well suited to vascular circulation. As the first 
responders to tissue damage, platelets play an important role in hemostasis. But their 
functions extend beyond this. As a supplier of angiogenic and non-angiogenic factors, they 
induce blood vessel formation. They play a pivotal role in wound healing and regenerative 
processes contributing to tissue repair, amongst others by transporting soluble factors that 
contribute to the cell recruitment and phenotype transition required for tissue regeneration. In 
addition, a novel role for platelets in immunity is now emerging. Having retained several of 
the functions associated with their myeloid origin, including their granulocytic characteristics, 
platelets have the ability to internalize environmental factors such pathogens through 
phagocytosis [2]. Binding of bacteria via toll like receptors may facilitate the recruitment and 
subsequent uptake of bacteria by granulocytes [3]. Platelets also contribute to adaptive 
immunity, by activating dendritic cells and enhancing their antigen presentation in the context 
of major histocompatibility complex (MHC)II molecules to T or B cells [4], while MHCI 
molecules taken up from serum can be used to present antigens to T-cells [5]. Thus, platelets 
are versatile cells which play an important role in human physiology. While a protagonist in 
hemostasis, excessive platelet activation is also a major cause of morbidity and mortality in 
western societies. It is therefore not surprising that platelets have become an extensively 
investigated biological cell type. Nevertheless, precisely how platelets become activated 
under physiological and pathophysiological conditions are still under investigation.  
Similar to the megakaryocytes from which they hail, platelets contain proteins and RNA 
transcripts, with up to 3,000–6,000 mRNA transcripts thus far identified. Thus, despite the 
fact that platelets do not contain a nucleus and are hence incapable of newly transcribing 
mRNA molecules, they do retain the capacity to synthetize their own functional proteins from 
the mRNAs inherited from their parental cell. Alternative splicing and signal-dependent 
translation of mRNAs may give rise to new proteins. Furthermore, platelets contain 
proteasomes and ubiquitin complexes, which together with the presence of platelet-derived 
extracellular ERp57, a thiol isomerase enzyme, contributes to protein modifications. 
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However, one of the most important post-translational protein modifications, allowing 
platelets to fulfil their highly dynamic and diverse functions [6,7], comes from protein 
phosphorylation. Reversible phosphorylation of proteins, catalyzed by phosphorylating 
kinases and dephosphorylating phosphatases, plays a role in almost every cellular function of 
eukaryotic cells. Contact of platelets with extracellular ligands causes a fast and transient 
burst in kinase activity and a substantial augmentation of intracellular phosphorylation. 
However, although much is known about the kinases present in platelets, comparatively little 
is known about phosphatases in the context of platelet function. While even in the early 90’s 
platelets were recognized to contain at least 6 independent phosphatases with activity towards 
actin-related proteins including myosin light chain, these remained unnamed and were 
speculated to merely reduce platelet activation [8]. Subsequent progresses on platelet studies 
have shown that many phosphatases are present in platelets, and that their role is not always 
so straightforward. Therefore, in this review, we will discuss the recent advancements in our 
knowledge regarding the phosphatases governing platelet plasticity in response to different 
stimuli. 
 
2. Phosphorylation in platelets 
Cellular communication at the micro- and macro-environment depends on cellular adhesion 
molecules as well as the release of cytokines, chemokines and growth factors. Information 
delivered to the target cell through the interaction between these molecules and a ligand-
dependent receptor at the cellular membrane results in intracellular signaling, ensuring 
amplification of the received information and execution of a specific cellular response. 
Activation or inhibition of a protein during signal transduction is often determined by their 
phosphorylation status. Zahedi and colleagues investigated the phosphoproteome from 
healthy human platelets, and demonstrated that almost 280 proteins were phosphorylated on 
different sites, with 55% of these proteins related to signaling pathways and cytoskeletal 
dynamics [9]. Thus, phospho-signaling in platelets is evidently important, and a better 
understanding of these signaling events may provide insight into platelet biology in health as 
well as pathological conditions (Figure 1). Protein phosphorylation is restricted to only a few 
amino acid residues, and according to their specificity, function and structure, kinases and 
phosphatases are classified as being tyrosine, serine/threonine or dual specificity enzymes. 
Over 500 protein kinases are encoded by the human kinome, many of which are expressed in 
platelets. Although full functional characterization is mainly limited to a few main signaling 
pathways, our knowledge of these pathways is relatively well advanced [10-12]. In contrast, 
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the human genome contains far fewer phosphatase genes, with a total of 107 protein tyrosine 
phosphatase (PTP) and ~30 serine/threonine phosphatases thus far identified [13]. Sixteen of 
these have been identified in platelets using a specialized PTP-proteomics approach [14] with 
several others identified by conventional proteomics, making a total tally to date of 10 
receptor-like and 10 non-receptor PTPs present in platelets [15]. Over the past few years, 
more and more studies have revealed that PTPs are relevant modulators of platelet function, 
although the underlying mechanisms are still poorly understood. It is of interest to note that 
pan tyrosine phosphatase activity is increased in platelets in response to collagen stimulation, 
suggesting their role in adhesive processes (Figure 2). However, in contrast to collagen, 
thrombin stimulation reduces total phosphatase activity (Figure 2). Thus, specific regulation 
of phosphatase activity exists in platelets. Below, we summarize the ligand-receptor-signaling 
events involved in hemostasis and review what is currently known regarding the best 
described of these phosphatases in platelet activity.  
 
3. Platelet receptors and their ligands 
In order to perform their functions, platelets carry an array of membrane receptors allowing 
them to respond to various extracellular ligands. Of the extended family of integrins, platelets 
carry six: αIIβ1 (CD49b/CD29), ανβ1 (CD49e/CD29), α6β1 (CD49f/CD29), αLβ2 
(CD11a/CD18), αΙIbβ3 (CD41/CD61), and ανβ3 (CD51/CD41) [16,17]. Of these, arguable 
the best studied are αIIbβ3 [16] - (the most abundant platelet receptor) recognized by 
fibrinogen, von Willebrand factor (vWF) and the extracellular matrix components fibronectin 
and vitronectin, and the collagen receptor αIIβ1 (otherwise known as glycoprotein GPIa/IIa). 
Collagen is additionally recognized by the platelet receptor GPVI. The second most abundant 
platelet receptor is the glycoprotein receptor complex GP1b-IX-V, which primarily binds to 
vWF, but also recognizes thrombin, P-selectin, and clotting factors XI and XII [18]. Thrombin 
is also able to stimulate platelets via the protease activated receptor (PAR)1 and PAR4. It is of 
interest to note that platelets carry many components capable of enhancing their own 
activation. Amongst many others, the fibrin precursor fibrinogen, GPVI, αIIbβ3, P-selectin, 
and bioactive molecules such vWF, vascular endothelial growth factor (VEGF), platelet 
derived growth factor (PDGF), coagulation factor V and anti-thrombin are contained within 
-granules [19,20]. Dense-granules, lysosome-related organelle with a cargo profile that is 
largely dominated by smaller molecules, contain serotonin, ADP/ATP and Ca2+ [21]. 
Exocytosis of these granules can be triggered by specific platelet agonists and enhance levels 
of already present membrane phospholipids, glycoproteins and integrins, or cause novel 
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expression of granule-specific markers. Many of these membrane components play an 
essential role in platelet adhesion and aggregation, known as primary hemostasis, and their 
release can therefore further platelet activation cascades. Furthermore, as platelets themselves 
carry receptors for many of the vesicle components, including ADP receptors P2Y1, P2Y12 
and the ATP receptor P2X1, release of these factors allows autocrine activation [22].  
 
4. Hemostasis  
As mentioned, the primary role of platelets is to form a platelet plug in response to vascular 
injury. The hemodynamic force of the blood flow ensures the proximity of platelets to the 
vessel wall, allowing a quick response to such tissue damage. The process of thrombus 
formation is complex and depends on rheological circumstances. Under high shear conditions, 
the first step towards thrombus formation is the deceleration of platelets through binding of 
their GPIb-V-IX receptor complex to vWf captured onto collagen fibrils exposed at the sub-
endothelial matrix lining of the vessel upon injury [23,24]. This transient interaction is 
stabilized by subsequent binding of αIIβ1 to collagen and αIIbβ3 binding to vWf/fibrinogen, 
fully anchoring platelets to the vessel wall [16,24,25]. After formation of a monolayer of 
platelets attached to the vessel wall, platelet-platelet interactions, i.e. platelet aggregation, is 
required for growth of the thrombus. These homotypic platelet interactions are mediated by 
GPIb-V-IX and αIIbβ3 binding to their ligands. Subsequent adhesion-dependent signals, 
including GPVI binding to collagen, triggers activation of the platelets [26]. This is further 
extended by locally generated or secreted factors like thrombin, ADP, epinephrine and 
thromboxane A2 (TxA2), amplifying the activation/aggregation process. At this stage, the 
platelet becomes fully activated and changes its morphology from a discoid shape to a 
flattened shape with lamellipodia (Figure 1A) – [27,28]. The ensuing increased platelet 
surface area may provide a scaffold for other aggregating platelets, although whether this 
actually contributes to the aggregation process is unclear [29]. In the last steps of platelet 
activation, intracellular signaling cascades lead to conformational changes in integrin αIIbβ3, 
giving it an enhanced affinity for its ligands. This subsequently allows fibrinogen to act as a 
bridging molecule, tethering platelets together [30,31]. The inside-out signaling required to 
initiate these conformational changes appears to be mediated largely through thrombin-
mediated signaling via PAR1, and depends on actin-binding intermediator proteins such as 
talin, kindlins and the ezrin-radixin-moesin (ERM) family of proteins [32]. In addition to 
forming a platelet plug during primary hemostasis, platelets contribute to secondary 
hemostasis (coagulation cascade) mainly through their degranulation products. Released 
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coagulation Factors V, XI, and XIII, pro-thrombin and fibrinogen all feed into the coagulation 
cascade, a series of catalytic steps involving the cleaving of pro-thrombin to thrombin and 
culminating in the cleaving of fibrinogen by thrombin to form adhesive monomeric fibrin 
fibrils. Polymerization of these fibrils by activated factor XIII further constructs stable bridges 
between platelets [33]. Thus, many interlinked processes initiated and maintained by platelets 
are required for blocking the blood flow from damaged vessels.  
 
5. Signaling during hemostasis 
G-protein coupled receptor signaling 
Extracellular signals are relayed primarily via two types of signaling receptors; tyrosine 
kinase-associated receptors and G-protein coupled receptors (GPCR). Examples of GPCR on 
platelets are the thrombin and ADP receptors. Attached to these serpentine receptors are 
heterotrimeric G-proteins, Gα, Gβ and Gγ, of which in particular the type of Gα subunit 
coupled to the receptor determines its signaling outcome. Four main Gα proteins can be 
distinguished, Gαq, Gαs, Gαi and Gα12/13. Binding of a Gαq-coupled receptor leads to 
activation of phospholipase C, which in turn cleaves the membrane bound inositol lipid 
phosphatidylinositol biphosphate (PIP2) to diacylglycerol (DAG) and inositol 3-phosphate 
(IP3) – [34]. Subsequent binding of IP3 receptors on the endoplasmic reticulum leads to 
release of intracellular Ca2+ stores, while DAG binds and activates the serine/threonine 
Protein Kinase C (PKC), together leading to further intracellular signal transduction and 
cellular responses. In platelets, Gαq receptors include the receptors for thrombin [35], TxA2, 
and the P2Y1 ADP receptor, epinephrine activates Gαs. It was already early recognized that 
thrombin-mediated platelet aggregation relies on signaling via PLC, PKC (including PKC-α, -
β, -δ, and –θ isoforms) as well as activation of tyrosine- and serine/threonine phosphatases 
[36]. While the exact phosphatases remained to be elucidated at that time, later studies 
demonstrated that activation of diverse PKC isoforms inhibits the myosin light chain 
phosphatase (MLCP), thereby stimulating the formation of actin stress fibers required for 
platelet secretion [37]. Modulation of actin cytoskeletal rearrangement in response to 
thrombin is also mediated by dephosphorylation of cofilin, in a signaling scheme that is 
dependent on Ca2+ and the Ca2+/calmodulin-dependent phosphatase calcineurin, but 
independent of PKC [38]. 
Gαs and Gαi proteins act by stimulating or inhibiting the enzyme adenylate cyclase (AC), 
respectively. AC activity triggers the formation of second messenger cyclic-AMP (cAMP) 
resulting in activation of cAMP-dependent Protein Kinase A (PKA), a potent inhibitor of 
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platelet function [39]. While prostaglandins and adenosines increase cAMP levels via Gαs, 
the thrombin receptors PAR1, as well as the ADP receptor P2Y12, signal through Gαi (as well 
as Gq), thereby reducing activation of the serine/threonine PKA kinase [40]. Phosphotyrosine 
profiling showed that total cellular tyrosine phosphorylation was increased upon stimulation 
with ATP, which was near completely abolished by concurrent treatment of cells with PKA-
activating prostacyclin analogue iloprost [41]. This suggests that kinase activity does not 
indiscriminately result in enhancement of platelet functions, as is often thought. Indeed 
phosphorylation of GP1bβSer166 by PKA can reduce its binding to vWF under flow conditions 
[42]. Large scale phosphoproteomics confirmed that inhibition of platelet functions through 
stimulation with prostacyclin (activating cAMP/PKA signaling) is indeed accompanied by 
upregulation of phosphorylation of several kinases, including GRP2Ser587, SrcTyr530, 
VASPSer157, VASPSer239, GSK3αSer21, GSK3βSer9, ZyxinSer142/143, Filamin-ASer2152, LASPSer14. 
However, many of these phosphorylations reduce activity of the associated protein, which 
may in part account for the inhibition of platelet functioning [43,44]. In addition, 
phosphorylation of 3 phosphatases, namely PTPRJSer1311 (increased), CTDSPLSer32 
(decreased), and PTPN12Ser332 (decreased) were affected by prostacyclin stimulation. To what 
extent these contribute to inhibition of platelet signaling in response to Gαs signaling remains 
to be established (for more details on PTPRJ, see below) – [39]. Furthermore, in contrast to 
the thrombin-Gq-activated MLCP inhibition described above, prostaglandin-activated PKA 
enhances MLCP activity, thereby inhibiting the actin cytoskeleton rearrangements required 
for platelet shape changes [45]. On the other hand however, thrombin signaling through Gαi 
does cause phosphorylation and activation of the Src homology region 2 domain-containing 
phosphatase-1 SHP1), as well as its translocation to the cytoskeleton (see below for further 
discussion of SHP1 in platelets) – [46]. Thus, a complex series of activating and inactivating 
phosphorylation of both kinases and phosphatases contribute to PKC/PKA-mediated 
modulation of platelet functions. It should be noted that different isoforms of PKA also exist, 
which may localize to different cellular compartments and play different roles in platelet 
activation [47] suggesting that PKA signaling in platelets is complex and multifunctional [40].  
Lastly, signaling via Gα12/13 occurs via PAR4 and the TxA2 receptors, and activates 
cytoskeletal rearrangement and platelet shape changes [48]. Recently, Pyk2 (a member of the 
focal adhesion kinase [FAK] family) was described to be a direct target of PAR-4-mediated 
Gα12/13 activity, regulating platelet aggregation and dense granule release [49]. Again, 
signaling via MLCP appears also to be affected by Pyk2 signaling through this G-protein [49]. 
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Tyrosine kinase (associated) receptor signaling 
The main tyrosine kinase-associated receptors involved in platelet activation are GPIb/IX/V 
and GPVI. Neither of these contain intrinsic kinase activity; instead, they rely on a family of 
protein-tyrosine kinases (PTKs) that are either associated with or in close proximity to their 
cytoplasmic tails, to transmit signals. For GPVI, this is provided by coupling with Fcγ-
receptors, which have an intracellular domain containing an immunoreceptor tyrosine 
activation motif (ITAM). Upon ligand binding, ITAM motifs become phosphorylated by the 
Src family of kinases (SFK, including Src, Syk, Fyn, Lck, Btk, Fgr, Lyn, Yes), which results 
in tyrosine phosphorylation of the membrane adaptor protein LAT (linker of activation of T-
cells (LAT), which in turn activates multiple signal transduction pathways including PLCγ 
and the lipid kinase phosphatidyl-inositol 3-OH kinase (PI3K) – [50,51]. For GPIb/IX/V, the 
associated tyrosine kinase appear to be less well known, and signaling could be either via 
FcγRII, directly through Src, or via PI3K [52]. It has also been suggested that FcγRII-ITAM 
signaling contributes to outside-in signaling of integrins, with in particular Fyn and Syk 
contributing to phosphorylation of αΙIbβ3 integrin, leading to PLCγ activity [48]. Other 
tyrosine kinase receptors present on the surface of human platelets include thrombopoietin 
receptor (or c-MPL), TAM family (Tyro3, Axl, and Mer), ephrins and IGF-1 receptor. The 
contribution of each of receptor and its signal in thrombus formation or its bleeding risk, 
when absent, is under active study, but their involved intracellular signaling, are broadly 
speaking the same as for the tyrosine kinase-associated receptors [53].  
Downstream signaling of tyrosine kinase (associated) receptors is complex, and in platelets 
appears to depend to a large extent on SFK activity (for review see [11]). vWF interaction 
with GPIb-V-IX leads to activation of SFK as well as Phospholipase A2, initiating platelet 
activation by changing its cytoskeletal arrangement [11,50]. Collagen stimulation of the 
receptors GPIIb/IIIa, GPIb, GPIIb/IIIa, GPVI and FcγR also results in SFK activation [50]. 
Furthermore, in platelets activated by thrombin, Ca2+-mediated activation of the SFK results 
in Pyk activation [54], and Src and FAK proteins have described as master regulators of 
cytoskeletal remodeling in response to thrombin, showing that GPCR signaling also 
converges on tyrosine phosphorylation signaling [55]. Activation of SFK in platelets leads to 
activation of other intracellular kinases, including PI3K/protein kinase A (Akt). For instance, 
GPIa/IIa and GPIIb/IIIa activate SFK and PLC signaling, which coordinates PI3K/Akt 
activation [10,56]. PI3K was associated with platelet aggregation in response to ADP 
stimulation [57], but is also activated by thrombin [55]. Downstream of Src-PI3K signaling, 
Akt phosphorylation was confirmed to play an important role in collagen- and ADP-induced 
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platelet aggregation [58]. In addition to Src and PI3K signaling, members of MAPK family 
(ERK and p38) have generally been considered positive modulators of platelet function. 
Binding of vWF or thrombin to GPIb-IX-V results in activation of integrin αIIbβ3, an 
example of inside-out-signaling, and this process depends on both PKC and ERK activities 
[59]. Activated ERK is described to play an important role in platelet aggregation, 
morphological changes and clot retraction [60]. p38 is also known to be activated by Src 
phosphorylation during collagen- and thrombin-stimuli. The principal mechanism coordinated 
by p38 is cytoskeleton remodeling and Ca2+ release, and consequently, amplification of 
platelet aggregation [61].  
The general kinase receptor-induced pathways described here are common among many 
different cell types, and phosphatases modulating these pathways have been identified in 
several cellular settings. Below, we describe in more detail what is known about these 
phosphatases in phosphate signaling in platelets.  
 
6. The role of phosphatases in hemostasis 
ITIMs, GPCRs and SHP 
Platelet activation via ITAM motif-coupled receptors is counteracted to large extent by 
immunoreceptor tyrosine-based inhibitory domain (ITIM)-containing receptors. The best 
described of these in platelets are PECAM-1, which mainly inhibits collagen-mediated 
activation the GPVI-FcRγ-chain complex, and G6b-B, which reduces signaling from GPVI-
FcRγ-as well as CLEC-2, the hemi-ITAM-containing receptor for podoplanin. In addition to 
an ITIM motif, PECAM-1 and G6b-B contain an immunoreceptor tyrosine-based switch 
motif (ITSM) – [62,63]. Phosphorylation of both ITAM and ITIM/ITSM by SFKs creates 
docking sites for SH2-domain containing proteins. But while for ITAM this results in 
recruitment of protein-tyrosine kinase Syk and downstream activation of (tyrosine) kinase 
signaling and Ca2+ release, ITIM/ITSMs recruit the SH2-domain containing phosphatases 
SHP1 (i.e. PTP1C, PTPN6) and SHP2 (i.e. PTP1D, PTP2C, PTPN11), which is associated 
with inhibition of platelet function [56,64]. SHP2 may directly dephosphorylate the ITAM 
receptor itself (as was shown for CLEC-2 in the case of G6b-B), but also may target the 
kinase Syk [62,64,65]. Additionally, it has been suggested that PECAM-1 itself may be a 
target (although the role for this in platelets is unclear) and that recruitment of PI3K to SHP-1 
prevents its activation by molecules associated with LAT (although this appears to be 
independent of its phosphatase activity) – [66,67].  
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The role of SHP1 and SHP2 has also been investigated in non-ITIM-mediated signaling in 
platelets. As already alluded to above, GPCR signaling activates kinase signaling and 
phosphorylation patterns which are also subject to phosphatase regulation. One study showed 
that PKC-mediated phosphorylation of SHP1Ser591 in response to thrombin-PAR1/4 
stimulation inhibits SHP1 activity, which subsequently increases phosphorylation of its 
substrate, the guanine-nucleotide exchange factor Vav, a regulator of cytoskeletal 
rearrangement [68]. Indeed, overall, the general consensus appears to favor a negative 
modulatory role for SHP phosphatase activity in platelet adhesion [69]. However, several 
studies indicate that the role of SHP phosphatases may be more complicated. SHP1Tyr536 and 
SHP1Tyr564 phosphorylation in response to thrombin were shown to activate SHP-1 enzymatic 
activity [70], independently from integrin and PKC signaling [46] (Li et al, 1995). As the Scr 
kinase is a direct substrate of SHP1, this would paradoxically dampen thrombin-mediated 
responses. However, some studies showed that this may be a late event during thrombin 
signaling (upon 45 minutes stimulation), and therefore a means to prevent over-activation of 
thrombus formation [71]. Furthermore, by targeting the negative tyrosine regulatory site of 
Src kinase, SHP1 activity may actually enhance Src activity and platelet function [72]. 
Additionally, it was demonstrated that Gq-mediated signaling causes rapid (within seconds) 
degradation of a protein complex which keeps resting platelets inactivated, and this process is 
dependent on phosphorylation and activation of SHP1 [73]. Overall, both positive and 
negative roles for SHP-1 have been described in platelets and the exact role for SHP-1 in 
platelet function therefore, remains elusive [73,74]. Experiments in knock-out mice have 
demonstrated that SHP-1 deficiency leads to reduced platelet spreading, while SHP-2 
deficiency increases platelet spreading on fibrinogen, demonstrating opposite effects of these 
phosphatases on at least some platelet functions. Both gain-of-function and loss-of-function of 
SHP-2 are found in humans: gain-of function mutations as seen in patients with Noonan 
syndrome (often associated with bleeding) cause reduced collagen-induced (but not thrombin 
or ristocetin-induced) platelet aggregation, while loss-of-function of SHP2 in patients with 
Noonan syndrome with multiple lentigines show normal aggregation, but increased collagen-
adherence under shear stress [75]. Thus, overall, SHP2 activity appears mostly to reduce the 
hemostatic process in humans.  
 
Positive modulation of SFK via CD148 and PTP1B 
One of the first transmembrane PTPs identified in platelets is the receptor-like protein-
tyrosine phosphatase (PTP) CD148, also known as PTPRJ, which is expressed in all 
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hematopoietic cells. It is known to dephosphorylate PLCγ1 and LAT, thereby inactivating 
signaling through the T-cell receptor CD3 in T-cells, while dephosphorylation of SFKs 
contributes to neutrophil migration [76,77]. It is tempting to speculate that it may contribute 
to the immunological functions of platelets as well. While one of the main substrates of this 
phosphatase is the platelet derived growth factor receptors (PDGFR), in platelets this 
phosphatase is best known for its ability to modulate activity of the SFK [78]. Knockdown of 
CD148 in mouse models was shown to increase Lyn and Src phosphorylation at their 
inhibitory sites, while reducing phosphorylation in their activation loops. In turn, this resulted 
in impaired platelet spreading on fibrinogen, suggesting a requirement of this phosphatase in 
integrin αIIbβ3 signaling. GPVI-dependent platelet aggregation and ATP secretion were also 
dependent on CD148 activity. Thrombin-induced aggregation and ATP secretion as well as 
CLEC-2-mediated platelet activation were only partly affected by CD148 knock-down, while 
ADP-induced responses were not affected at all, showing selective requirement of this 
phosphatase by specific platelet agonists [79]. In humans, it has recently been shown that loss 
of function mutations in CD148 cause a form of hereditary thrombocytopenia, with patients 
showing reduced pro-platelet formation as well as reduced GPVI-mediated Src activation and 
platelet responses [80]. Thus, the general consensus is that CD148 contributes to platelet 
activation by releasing inhibitory phosphorylation on SFK. However, a recent study suggests 
that CD148 may also reduce phosphorylation of SFK at its activation loop. However, this is 
likely required to limit platelet over-activation, and indeed over-activation of SFK signaling 
may provide a negative feedback loop [81]. While CD148 was shown to be essential for 
platelet activity, full aggregate formation also requires the phosphatase PTP1B, another 
positive modulator of SFK [82]. 
Expression of the non-transmembrane PTP1B (also known as PTPN1) was already described 
decades ago. This phosphatase can become activated upon proteolytic cleavage by calpain in 
response to αIIbβ3 integrin stimulation [83]. This in turn can reduce the FcyRIIa-mediated 
phosphorylation of LAT, resulting in cytoskeletal rearrangement and irreversible platelet 
aggregation [84]. This suggests that PTP1B activity is required for full platelet responses, and 
indeed, PTP1B deficient platelets fail to form full aggregates on collagen [79]. Upon 
fibrinogen stimulation of platelets, PTP1B is recruited to interact with αIIbβ3 and promotes 
Src kinase activation by dephosphorylation of its inhibitory site [79,85]. This results in αIIbβ3 
outside-in signaling and adhesion of platelets to fibrinogen. These functions are very similar 
as those reported for CD148, but while CD148 appears to regulate SFK more generally, 
PTP1B involvement is more specific to αIIbβ3 integrin signaling [78,86]. It should be noted 
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however, that calpain knockout mice were described to exhibit increased platelet PTP1B 
levels as well as activity, which was associated with reduced thrombin-induced platelet 
aggregation, showing that PTP1B signaling is perhaps more complex [87]. Crosstalk between 
PTP1B and the serine/threonine phosphatase PP2A has also been shown. While PTP1B-
mediated Src activation is required for αIIbβ3-mediated platelet adhesion, PP2A inhibits this 
process, adding a layer of regulation and complexity [88]. Indeed, serine phosphatases may 
contribute to tyrosine phosphorylation patterns in platelets [89]. For instance, αIIbβ3-
activated PP2A inhibits ERK signaling in response to ATP [90]. Thus, not all phosphatases 
are alike and it is their concerted actions that decide platelet fate.  
 
LMWPTP is activated upon collagen-dependent signaling 
The presence of Low Molecular Weight Protein Tyrosine Phosphatase (LMWPTP) was first 
described in platelets by Mancini and colleagues as late as 2007 [91]. They showed that while 
this phosphatase is less abundant in platelets as compared to PTP1B, it is nevertheless 
functional in causing dephosphorylation of the FcγRII receptor ITAM motif, as well as LAT, 
causing inactivation of Syk and PLCγ and inhibition of platelet function. Interestingly, despite 
the fact that Scr kinases have been shown to be an important target for LMWPTP in other cell 
types [92,93], pp60src phosphorylation in response thrombin, convulxin or FcγRIIA 
clustering did not appear to be affected by LMWPTP in this study. On the other hand, another 
study showed that collagen induced LMWPTP, PTP1B and Src kinase activity, and that 
inhibition of this phosphatase activity was associated with reduced Src activity and inhibition 
of platelet aggregation [94]. In addition, LAT is also a substrate for the kinases Syk and 
ZAP70, both of which are activated by LMWPTP [95,96]. Thus, the end result of LMWPTP 
activity in platelets may be activation rather than inactivation of platelet signaling, depending 
on the platelet agonist. While LMWPTP may play an important role at platelet activation, the 
molecular contribution of this phosphatase remains poorly understood. 
 
Other tyrosine phosphatases 
Very limited information is available concerning the other phosphatases expressed in 
platelets. PTEN (phosphatase and tensin homologue deleted on chromosome 10) is a well-
known tumor suppressor, which, when down-regulated or mutated, is correlated to cancer 
development and obesity. In platelets, a function for PTEN was described by Weng and 
colleagues (2010) showing that platelets deficient for PTEN demonstrate increased collagen-
induced aggregation and ATP secretion, as a result of enhanced activation of the PI3K-Akt 
 
164 
pathway [97]. Thus, knock-down of PTEN reduced bleeding times in mice [97]. In contrast, 
knock-down of the protein tyrosine phosphatase PTPN7 (or hematopoietic protein tyrosine 
phosphatase (HePTP)), which acts as a negative modulator of ERK, regulating GPCR-
signaling rather than GPVI signaling, only modestly affected bleeding times [98]. ERK is also 
targeted by the Vaccinia H1‐related (VHR) phosphatase, or dual‐specificity phosphatase 
(DUSP) 3. In platelets, DUSP3 knockdown or inhibition causes a decrease of platelet 
aggregation efficiency [99]. Thus, conflicting results are obtained with knockdown of 
phosphatases despite partial overlap in their signaling activity.  
 
7. Conclusions 
Platelets play an important role in many physiological processes, including hemostasis, 
wound healing and immunity. Impaired platelet function may contribute to several diseases, 
with over-activation of platelets having been related to, for instance, cardiovascular diseases 
and their complications. Thus, the elucidation of the molecular mechanism governing platelet 
functionality in health and disease may improve the treatment of such diseases. The role of 
phosphatases in these processes is slowly gaining attention, but their roles are as complex as 
the multitude of signaling events regulating platelet functions themselves. Both positive and 
negative modulatory roles for these enzymes have been described, and it is clear that 
selectivity towards agonists exists for these proteins in platelets. However, differences in 
agonists used, read-outs for platelet reactivity and methods of studying phosphatase activity 
and their downstream targets hamper interpretation of the limited experimental evidence. 
Thus the role of phosphatases in platelet biology warrants further investigation. A better 
understanding of these phosphatases, the way they themselves are regulated and the pathways 
they modulate, may contribute to the discovery of new potential pharmacological targets. 
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Figure 1. Platelet function. Platelet activation is modulated by the interaction of several agonists with specific receptors. After the activation 
through diverse stimuli, platelets change their shape to spread and expose adhesion molecules, which supports adherence and triggers granule 
release, further amplifying the aggregation process. Following the platelet activation, platelets releases pro-inflammatory factors for wound 
healing, tissue regenerations and angiogenesis by transporting and delivering factors. The pivotal signaling pathways associated to platelet 
activation are described in (A) coordinated to contribution for platelet function (B). 
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Figure 2. Total tyrosine phosphatase activity assay in stimulated platelets. After signed 
informed consent was obtained (Ethical committee Project NL66029.078.18 approved by 
Erasmus MC medical and ethical committee), venous blood from healthy donors (n=3) (all of 
them drug-free) was collected into conical plastic tubes containing 3.8% trisodium citrate 1:10 
(v/v). Whole blood was centrifuged at 1500 rpm, 10 min, 22°C, and Platelet-Rich Plasma 
(PRP) was collected. NaCl (0.9%) was used to wash the platelets. Washed platelets were 
incubated with a final concentration of 2µg/mL Collagen or 1U/mL Thrombin for 10 minutes. 
All experiments were performed using 200-300 x 103platelets/µL. Platelets were lysed with 
100 μL of lysis buffer (20 mM HEPES, pH7.4 with 2.5 mM MgCl2, 0.1 mM EDTA) on ice 
for 2 h. After clarifying by centrifugation, protein-normalized platelets extracts were 
incubated in acetate buffer and the enzyme activity was assessed as followed: reaction 
medium (100 μL) contained 100 mM acetate buffer, 5 mM p-nitrophenyl phosphate (pNPP). 
After 60 min, at 37°C and under agitation (600rpm) the reaction was stopped by adding 100 
μL 1M NaOH. The absorbance was measured at 405 nm (spectrophotometer - BioRad, 
California, USA). Statistical analysis was performed using t-student (paired, 95% confidence 
intervals, one-tailed) using GraphPad (GraphPad Inc, version 5.0, California, USA). 
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Abstract 
Venous thromboembolism (VTE) is one of the most common causes of cancer related 
mortality. It has been speculated that hypercoagulation in cancer patients is triggered by direct 
or indirect contact of platelets with tumor cells, however the underlying molecular 
mechanisms involved are currently unknown. Unraveling these mechanisms may provide 
potential avenues for preventing platelet-tumor cell aggregation. Here, we investigated the 
role of protein tyrosine phosphatases in the functionality of platelets in both healthy 
individuals and patients with gastrointestinal cancer, and determined their use as a target to 
inhibit platelet hyperactivity. This is the first study to demonstrate that platelet agonists 
selectively activate low molecular weight protein tyrosine phosphatase (LMWPTP) and 
PTP1B, resulting in activation of Src, a tyrosine kinase known to contribute to several platelet 
functions. Furthermore, we demonstrate that these phosphatases are a target for 3-
bromopyruvate (3-BP), a lactic acid analog currently investigated for its use in the treatment 
of various metabolic tumors. Our data indicate that 3-BP reduces Src activity, platelet 
aggregation, expression of platelet activation makers and platelet-tumor cell interaction. Thus, 
in addition to its anti-carcinogenic effects, 3-BP may also be effective in preventing platelet-
tumor cell aggregationin cancer patients and therefore may reduce cancer mortality by 
limiting VTE in patients.   
 
Keywords: platelet function; gastrointestinal cancer; venous thromboembolism; tyrosine 
phosphatases; LMWPTP; ACP1; PTP1B 
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1. Introduction 
In 2018, over 18 million new cases of cancer were diagnosed worldwide. Despite 
improvements in cancer treatment, mortality rates are still high [1]. One of the most common 
comorbidities of cancer is thrombosis. Overall, 20% of cancer patients experience a 
thrombotic event, and in patients with gastrointestinal (GI) cancers the risk of developing a 
venous thromboembolism (VTE) is particularly high [2,3]. The association between cancer 
and thromboembolism events is termed Trousseau Syndrome, after Armand Trousseau [4], 
who first described the high occurrence of superficial migratory thrombophlebitis [5]. 
Because thrombosis is a common comorbidity in cancer, treatment strategies have been 
devised to include the use of anti-thrombotic drugs, such as low molecular weight heparin 
(LMWH), aspirin and warfarin, for co-adjuvant therapy in cancer treatment [6]. However, 
these drugs decrease the overall thrombus formation, and as a consequence, side effects pose 
a challenge [7]. Finding new compounds that combat VTE as well as primary cancer cells 
could mean a step forward in cancer treatment. In cancer patients, platelets appear to be more 
easily activated by agonists as compared to platelets from healthy individuals, and this 
hyperactivity may relate to VTE risk. However, despite the high impact of VTE in cancer 
morbidity, it is as yet unclear how platelet phenotype and inherent function are modulated in 
patients with cancer [8–11]. Thus, elucidating the molecular mechanisms related to cancer-
associated VTE remains crucial. 
Platelets contain a vast array of proteins, such as membrane proteins (e.g., 
glycoprotein IIb/IIIa integrins, P-Selectin, CD36), adhesive proteins (e.g., von Willebrand 
factor, fibrinogen, vitronectin), growth factors (PDGF, VEGF, EGF, TGF-B, and others) and 
clotting factors (V, IX, and XIII) [11]. Upon tissue damage, soluble von Willebrand factor 
binds to the exposed collagen and subsequently tethers platelets by binding to their 
glycoprotein Ib receptors (GPIbR) [12], thereby providing a scaffold for the generation of 
thrombin and formation of fibrin fibers. Coagulation in thrombosis and hemostasis is well 
described [13]. One important emerging regulator of collagen receptor and integrin-mediated 
platelet function is the Src family of kinases [14,15], although how these kinases themselves 
are regulated in platelets remains relatively unclear [16]. We and others have previously 
demonstrated that in hematopoietic and GI tumor cells, modulation of Src is dependent on 
protein tyrosine phosphatase activity, and inhibition of these phosphatases attenuates Src-
dependent cancer cell growth and metastasis [17]. One potential modulator of this 
intracellular signaling pathway is the small molecule 3-bromopyruvate (3-BP), which is 
known to kill metabolically active tumor cells through inhibition of glycolysis. The use of 3-
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BP for cancer treatment has been advocated [18,19]. Here, we investigate whether this 
compound may also hold promise for the prevention of platelet-tumor cell aggregation in 
cancer patients. We demonstrate for the first time that activity of Low Molecular Weight 
Protein Tyrosine Phosphatase (LMWPTP) as well as Protein Tyrosine Phosphatase 1B 
(PTP1B) in platelets is selectively modulated by platelet agonists. We show that these 
phosphatases are a target for 3-BP, which also inhibits Src activity in platelets. Furthermore, 
3-BP reduces collagen-induced aggregation and activation of platelets from both healthy 
controls and GI cancer patients, demonstrating the potential anti-thrombotic effect of this 
compound. Thus, 3-BP-like molecules may hold promise as an anti-tumor agent which 
simultaneously prevents platelet-tumor cell aggregation.  
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2. Material and methods 
2.1. Antibodies and Reagents 
Antibodies were purchased from Santa Cruz Biotechnology (Dallas, TX, USA), Cell 
Signaling Technology (Danvers, MA, USA), SignalWay (College Park, , MD, USA). For 
details, see Supplemental File Table 1. Reagents were purchased from Sigma Aldrich, Santa 
Cruz, Merck Millipore, Chronolog. For details, see Supplemental File Table 2. 
 
2.2. Cell Culture 
HT29, HCT116 and Caco-2 cells were obtained from ATCC (American Type Culture 
Collection, VA, USA) and routinely maintained in Dulbeco’s Modified Eagles Medium 
(DMEM, Lonza, Basel, Switzerland) supplemented with 100U/mL penicillin, 100mg/mL 
streptomycin (Life technologies, Bleiswijk, NL) and 10% Fetal Calf serum (FCS, Sigma-
Aldrich, St. Louis, MO, USA) at 37°C under a 5% CO2 humidified atmosphere. See 
Supplemental File Table 3 for characteristics of these lines. 
 
2.3. Platelet Preparation  
After signed informed consent was obtained (Ethical committee Project NL66029.078.18 
approved by Erasmus MC medical and ethical committee), venous blood from healthy donors 
(n = 19) and gastrointestinal cancer patients (n = 3) was collected into conical plastic tubes 
containing 3.8% trisodium citrate 1:10 (v/v). Whole blood was centrifuged at 1500 rpm, 10 
min, 22°C, and Platelet-Rich Plasma (PRP) was collected. For specific analysis NaCl (0.9%) 
was used to wash the platelets as previously described before [20]. All experiments were 
performed using 200–300×103 platelets/µL. Due to logistical restraints, not all experiments 
were performed on all donors. The number of times an experiment was performed is indicated 
in the figure legends. 
 
2.4. Patient Information  
Blood was obtained at diagnosis from three patients suffering from malignant esophageal 
neoplasia. The mean age was 73 ± 10 years, and two of them were male. Two patients used 
salbutamol, two patients took gastric pH modulators (Esomeprazol, Famotidine), and two 
patients used antidiabetics (hydrochlorothiazide). One patient took paracetamol, and one 
patient took metoclopramide as well as beclomethasone. None of these drugs were described 
to have an antiplatelet effect according to Chronolog (Chronolog Corp., city, PA, USA). All 
cancer patients were gender-matched to a healthy control. 
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2.5. Platelet Aggregation Assay by Light Transmission 
A 500 µL aliquot of PRP was placed in an aggregometer cuvette and incubated at 37°C for 5 
min in the presence or absence of compounds (100µM 3-bromopyruvate, 10µM CinnGEL, 
100µM NSC87887). Subsequently, the agonist collagen (2µg/mL) was added to the samples. 
An aggregation curve was recorded for 10 min after the addition of agonist. Light 
transmission changes (an indicator of aggregation) were monitored with an aggregometer 
(Chrono-Log Corp.) under shear stress conditions by stirring at 1200 rpm following the 
method described before [21]. Quality controls of platelets were assessed by aggregation 
response at the beginning and end of experiments. 
 
2.6. Platelet Activation Assay 
Washed platelets were incubated with a final concentration of 100µM 3-bromopyruvate, 
10µM CinnGEL, or 100µM NSC87887, for 60 min at room temperature, followed by 
stimulation of platelets with 2µg/mL Collagen or 1.25mg/mL Ristocetin for 10 minutes. After 
treatment, samples were incubated with antibodies CD41b (92800/040408 M1674); CD42b 
(65117/151106 M1729); CD62 (AK4) (304910-B239360 Becton, Dickinson and Company, 
Franklin Lakes, NJ, USA) for 15 min and data was acquired using a MACSQuant® Analyzer 
10. Data analysis was performed with FlowJo, LLC v10 (Becton, Dickinson and Company, 
Franklin  Lakes , NJ, USA).  
 
2.7. Platelet-Cancer Cells Interaction Assays 
For co-culture experiments, colorectal cancer cells (HCT116, Caco-2 and HT29) (1.0×104 
cells/cm2) were plated in 24-well plates for 24 h. After that, cells were washed with PBS, and 
PRP was added to each well for 6 h, together with either collagen (2µg/mL), 3-BP (100µM), 
or no agonists. After co-culture, the cells were either imaged by microscopy (Nikon), and the 
platelet-tumor cell aggregates were counted using a 10X magnification, at the well center 
quadrant, or platelets were harvested and analyzed by western blot as described before [22].   
For aggregation assays in the presence of cancer cells, cancer cell lines were detached with 
trypsin-EDTA and washed several times with NaCl 0.9% to remove the excess of trypsin-
EDTA. 500 uL of PRP was incubated with tumor cells (1.5×104 cells/test in NaCl 0.9%)—
(protocol described before [23] with some modifications) at 37°C for 5 min in the presence or 
absence of 100µM 3-BP. Subsequently, the agonist collagen (2µg/mL) was added to the 
samples. An aggregation curve was recorded for 10 min after the addition of agonist. Light 
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transmission changes (an indicator of aggregation) were monitored with an aggregometer 
(Chrono-Log Corp.) following the method described before [21]. Quality controls of platelets 
were assessed by aggregation response at the beginning and end of experiments. 
 
2.8. Western Blot  
Two different platelet treatments were performed: (A) washed platelets (20,000,000-
30,000,000) were incubated for 5 min in the absence or presence of compounds (final 
concentration: 100µM 3-BP, 10µM CinnGEL, 100µM NSC87887). Subsequently, platelet 
agonist collagen (2µg/mL) was added to the samples and after 10 min, the platelets were 
collected, washed and lysed as described below; (B) Platelets collected from co-cultures with 
colorectal cancer cells were washed with NaCl 0.9% and lysed in 2X concentrated Laemmli 
buffer (100mM Tris–HCl [pH 6.8], 200mM dithiothreitol, 4% SDS, 0.1% bromophenol blue 
and 20% glycerol) and samples were boiled for 10 min. Cell extracts were resolved by SDS-
PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) and transferred to 
polyvinylidene difluoride membranes (Merck chemicals BV, Darmstadt, Germany). 
Membranes were blocked in 50% odyssey blocking buffer (LI-COR Biosciences, Lincoln, 
NE, USA) in TBS and incubated overnight at 4°C with a primary antibody. After washing in 
TBS-T (TBS with 0.5% Tween 20), membranes were incubated with IRDye antibodies (LI-
COR Biosciences, Lincoln, NE, USA) for 1 h. Detection was performed using Odyssey reader 
and analyzed using the manufacturer’s software. For the primary antibodies used, see 
Supplementary Table 1. 
 
2.9. Immunoprecipitation Phosphatases 
Platelets were treated with test compounds and subsequently stimulated with agonists as 
described above. Immunoprecipitation was performed for LMWPTP and PTP1B as described 
previously [24,25]. Briefly, cells were lysed with 100μL lysis buffer (20mM HEPES, pH7.4 
with 2.5mM MgCl2, 0.1 mM EDTA) on ice for 2 h. After clarifying by centrifugation and pre-
clearing with uncoupled G-Sepharose beads (Thermo Fisher Scientific, Waltham, MA, USA), 
the platelet extracts were incubated overnight at 4°C under rotation with antibodies against 
LMWPTP (Acp1) or PTP1B. G-Sepharose beads were added to lysate and incubated for 3 h 
at 4°C. Samples were washed 3 times with acetate buffer (100mM pH5.5) before performing 
phosphatase activity assays.  
 
2.10. Phosphatase Activity Assay 
 
182 
After immunoprecipitation (IP), the pellet was re-suspended in acetate buffer and the 
enzymatic activity was assessed as follows: reaction medium (100μL) containing 100mM 
acetate buffer, 5 mM p-nitrophenyl phosphate (PNPP) was added to the precipitated 
phosphatase. After 60 min at 37°C and under agitation (600 rpm) the reaction was stopped by 
adding 100 μL 1M NaOH. The absorbance was measured at 405 nm (spectrophotometer-
BioRad, Hercules, CA, USA), and results are indicated as optical density measured 
normalized for bead controls (OD). 
The effect of 3-BP and CinnGEL on LMWPTP activity was examined after 10 min of pre-
incubation with LMWPTP immunopreciptated as described above. Subsequently, the 
substrate was added to the reaction medium. 
The effect of 3-BP and CinnGEL on PTP1B activity was examined after 10 min of pre-
incubation with recombinant PTP1B (0010896, lot 04529). Subsequently, the substrate was 
added to the reaction medium. 
 
2.11. MTT Assay 
MTT assay was performed as described before [26]. Briefly, platelets were seeded into a 96-
wells plate for 3 h (total volume per well 180µL). 20µL of MTT (Sigma Aldrich) solution (5 
mg/mL in PBS) was added to each well. After incubating for 4 h at 37°C, the plate was 
centrifuged 2500 rpm, 10 min, the MTT solution was removed and the formed formazan 
crystals were solubilized in 100μL of ethanol. The absorbance was measured at λ = 585 nm 
with a microplate reader (BioRad). 
 
2.12. Statistical Analysis 
The data is represented by means ± SEM. Statistical analysis was performed using t-student 
(paired, 95% confidence intervals, two tailed) using GraphPad (version 5.0, GraphPad Inc, 
city, California, USA). 
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3. Results 
3.1. Protein Tyrosine Phosphatases Are Selectively Activated by Classic Platelet 
Agonists in Healthy Blood Donors 
The role of kinases in platelet biology has received much more attention than 
phosphatases. We therefore set out to investigate the expression and activity of two tyrosine 
phosphatases known to be overexpressed in gastrointestinal cancer; LMWPTP and PTP1B. 
Our findings show that both of these phosphatases are expressed in human platelets (Figure 
1A). Next, we investigated the activity of these phosphatases in the presence of either the 
physiological agonist collagen or the synthetic agonist ristocetin, both of which activate a 
robust platelet aggregation response (supplemental Figure S1). As demonstrated in Figure 1B, 
constitutive activity of LMWPTP was present in platelets, which could be further increased 
by stimulation of cells with collagen (2µg/mL), but not with ristocetin. In contrast, 
constitutive activity of PTP1B in platelets was lower, but drastically enhanced by treatment 
with either collagen or ristocetin (Figure 1C). These data suggest that PTP1B activity is a 
general response to platelet activation, whereas LMWPTP activity is dependent on the 
selective agonist used. As tyrosine phosphatase activity generally affects cellular protein 
phosphorylation levels, we next determined the phosphorylation status of several known 
targets of LMWPTP and PTP1B [24,25]. Constitutive phosphorylation of FAK, Integrinβ3 
and p38 was present in platelets, but the most noticeable activation of signaling upon collagen 
stimulation was seen for the Src family kinases, as determined by their phosphorylation at 
tyrosine residue Y416 (Figure 1D). To confirm the importance of Src for platelet function, we 
performed aggregation assays in the presence of the selective Src family kinase inhibitor PP2. 
Interestingly, only collagen-stimulated aggregation was reduced in the presence of PP2 
(Figure 1E, Figure S1-I), while ristocetin-induced aggregation was not (Figure 1F, Figure S1-
I), suggesting that collagen activation of platelets in particular depends on Src signaling.  
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Figure 1. Platelets contain LMWPTP and PTP1B activity, which are selectively 
activated by platelet agonists. (A) Western blot analysis of platelets from two independent 
donors indicates protein expression of LMWPTP and PTP1B in these cells. (B, C) Platelets 
were stimulated with either collagen (2µg/mL) or ristocetin (1.25mg/mL) and LMWPTP (B) 
and PTP1B (C) were immunoprecipitated from the platelet lysates and subjected to 
phosphatase activity assay. Statistical analysis was performed using t-student (paired, 95% 
confidence intervals, two tailed) (n = 4). (D) Platelets were stimulated with collagen (2 
μg/mL) and subjected to western blot analysis of the indicated (phospho-)proteins. β-actin 
served as a loading control. (-) Without collagen; (+) With collagen. The numbers under the 
blot indicate densitometry values corrected for loading controls. A representative blot of at 
least two independent experiments is shown. (E, F) Following pre-incubation with PP2 for 5 
min, platelets were stimulated with either collagen (2μg/mL) (E) or ristocetin (1.25 mg/mL) 
(F) and the aggregation was measured for 10 min. Each data point corresponds to an 
individual single experiment, indicated by: Circle – 0μM; Square – 50μM and Triangle – 
100μM condition. 
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3.2. Collagen-Induced Intracellular Signaling in Platelets from Healthy Donors is 
Inhibited by 3-BP 
3-BP has been suggested as a promising antitumor agent by targeting a set of key 
metabolic enzymes, including kinases [27]. Therefore, we investigated the effect of this 
compound on cellular signaling in platelets. Interestingly, both collagen-induced LMWPTP 
activity and PTP1B activity were significantly reduced by 3-BP (Figure 2A). Furthermore, 
pretreatment of platelets with 3-BP drastically reduced both constitutive (Figure 2B) and 
collagen-stimulated levels (Figure 2C) of Src, FAK, and Integrinβ3 phosphorylation. 
However, the MAPK p38 was activated as demonstrated by an increase of the 
phosphorylation of T180 and Y182 residues (Figure 2C). Taken together, these data suggest 
that stimulation of platelets with collagen stimulates phosphatase activity and enhances Src 
activity, both of which are reduced by 3-BP treatment.  
  
Figure 2. 3-BP inhibits intracellular signaling in platelets. (A) Platelets were stimulated 
with collagen (2μg/mL) and LMWPTP was immunoprecipitated. For PTP1B activity assay, 
active human recombinant protein was used. Following treatment with 3-BP, precipitates 
were subjected to phosphatase activity assays. Statistical analysis was performed using t-
student (paired, 95% confidence intervals, two tailed) (n = 4). (B, C) Platelets were pretreated 
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with 3-BP for 30 min and left either unstimulated (B) or were treated with collagen (C). 
Western blot analysis was performed for the indicated proteins, with β-actin serving as 
loading control. The numbers under the blot indicate densitometry values that were corrected 
for loading controls. A representative blot of at least two independent experiments is shown. 
 
3.3. 3-BP Abrogates Collagen-Induced Platelet Aggregation  
Based on the inhibitory effect of 3-BP on both kinases and phosphatases in platelets, 
we set out to investigate the functionality of these cells in the presence of this compound. We 
first confirmed that 3-BP was not cytotoxic to platelets, by demonstrating that neither 
caspase-3 nor caspase-8 integrity, both of which are cleaved upon apoptosis induction [28,29], 
were changed upon 3-BP treatment (Figure 3A). Furthermore, expression levels of pro-
apoptotic BAX and the anti-apoptotic Bcl-2 proteins (Figure 3B) were unaffected by 3-BP 
treatment of platelets. 
The glycolytic pathway has been described as an important mediator of platelet 
function [30,31,32]. 3-BP is able to inhibit enzymes from this metabolic pathway [32]. This 
was confirmed by our finding that 3-BP reduces tetrazolium formation, known to be 
dependent on cellular glucose metabolism, by platelets (Figure 3C) [33].  
In light of the involvement of Src in collagen-mediated platelet aggregation and the 
inhibitory effect of 3-BP on Scr signaling, we next investigated whether 3-BP could disturb 
platelet activation and aggregation-specific events. As shown in Figure 3D and Figure S1-II, 
3-BP at a concentration of 100 μM was able to inhibit platelet aggregation induced by 
collagen, which binds to integrin α1β2 and glycoprotein GpVI on the platelet surface [34,35]. 
In contrast, platelet aggregation induced by ristocetin and mediated via vWF binding to Gp1b 
receptors [36], was not reduced by pretreatment of platelets with 3-BP (Figure 3E, Figure S1-
II). Activation of platelets was accompanied by increased expression of Integrinβ3, vWF 
receptor and P-Selectin on the cell surface, and 3-BP treatment of platelets significantly 
reduced collagen-induced expression of both Integrinβ3 and vWF receptor on these cells as 
determined by FACS analysis (Figure 3F), while the expression of these receptors in the 
presence of ristocetin was not affected (Figure 3G). Thus, we conclude that 3-BP induces 
selective inactivation of platelets, without causing wide-scale apoptosis. 
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Figure 3. 3-BP decrease affects platelet metabolic activity and function. (A, B) Platelets 
were subjected to 50μM and 100μM 3-BP for the indicated time points, and expression of 
Bcl2 and BAX (A) as well as caspase cleaving (B) were determined by Western blot analysis. 
β-actin served as loading control. The numbers under the blot indicate densitometry values 
corrected for loading controls. A representative blot of at least two independent experiments 
is shown. (C) Isolated platelets were subjected to the indicated concentrations of 3-BP, and 
cell metabolic activity was followed by MTT assay (mean ± SEM shown). (D, E). 
Aggregation assay using 3-BP as inhibitor of platelet function. Following preincubation with 
3-BP (5 min) platelets were stimulated with either collagen (2μg/mL) (D) or ristocetin 
(1.25mg/mL) (E) and the aggregation was measured for 10 min. Circle indicates 0μM; Square 
indicates 50μM and Triangle indicates 100μM condition. (F, G) Expression of platelet 
activation markers in the presence of 3-BP. Platelets were stimulated with either collagen 
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(2μg/mL) (F) or ristocetin (1.25mg/mL) (G) and stained using CD41b-FITC, CD42b-PE and 
CD62-APC antibodies to detect surface expression of vWF-receptor, Integrinβ3 and P-
Selectin, respectively. Statistical analysis was performed using t-student (paired, 95% 
confidence intervals, two tailed). Each data point (special shapes) corresponds to an 
individual experiment and indicates the data as: Circle – Integrinβ3 without 3BP, Square – 
Integrinβ3 with 3BP, Up-triangle – vWF-receptor without 3BP, Down-triangle – vWF-
receptor with 3BP, Diamond – P-Selectin without 3BP, Hollow circle – P-Selectin with 3BP. 
  
3.4. Platelet function is Dependent on Specific Phosphatases 
3-BP is not a specific inhibitor of PTPs. Therefore, to confirm the involvement of 
phosphatases in platelet activation, we employed the PTP1B inhibitor CinnGEL. As expected, 
CinnGEL specifically inhibits PTP1B (Figure 4A, upper panel), but not LMWPTP (Figure 
4A, lower panel). Furthermore, inhibition of PTP1B was accompanied by a reduced activation 
of Src (Figure 4B). Investigation of platelet activation in the presence of CinnGEL 
demonstrated that platelet aggregation was significantly diminished upon PTP1B inhibition 
(Figure 4C). In addition, collagen-induced expression of platelet activation markers 
Integrinβ3, vWF receptor and P-Selectin were significantly reduced upon inhibition of PTP1B 
activity (Figure 4D). None of these platelet functions were affected by treatment with a 
selective inhibitor of the protein tyrosine phosphatase SHP1 (NSC87887) (Figure S1-III and 
Figure S2), demonstrating that specific protein tyrosine phosphatase activity is required for 
platelet functionality.  
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Figure 4. Platelet function is inhibited by selective PTP1B inhibition. (A) PTP1B activity 
assays were performed using active recombinant human protein. For LMWPTP activity 
assays, platelets were stimulated with collagen (2μg/mL) and LMWPTP was 
immunoprecipitated. Following treatment with CinnGEL (PTP1B inhibitor), recombinant 
proteins and precipitates were subjected to phosphatase activity assays. (B) Platelets were 
pretreated with CinnGEL or left untreated for 5 min. Cells were subsequently left either 
unstimulated or were treated with collagen. Western blot analysis was performed for the 
indicated proteins, with β-actin serving as loading control. The numbers under the blot 
indicate densitometry values corrected for loading controls. A representative blot of at least 
two independent experiments is shown. (C) Aggregation assays were performed for collagen-
stimulated platelets after pretreatment with CinnGEL. (D) Cell surface expression of vWF-
receptor (CD41-FITC), Integrinβ3 (CD42-PE) and P-Selectin (CD62-APC) was investigated 
on collagen-stimulated platelets that were pre-treated with CinnGEL. Each data point (special 
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shapes) corresponds to an individual experiment and indicates the data as: Circle – Integrinβ3 
without 3BP, Square – Integrinβ3 with 3BP, Up-triangle – vWF-receptor without 3BP, Down-
triangle – vWF-receptor with 3BP, Diamond – P-Selectin without 3BP, Hollow circle – P-
Selectin with 3BP. 
 
3.5. 3-BP Decreases the Capacity of Colorectal Cancer Cell Lines to Activate Platelets 
Since the risk of VTE in cancer patients is in part mediated through platelet activation 
by tumor cells, we investigated the behavior of platelets using co-culture with colorectal 
cancer cells (HCT116, HT29, and Caco-2) as a model system. As shown in Figure 5A and 
Figure S1-IV, CRC cells were able to increase collagen-dependent platelet aggregation. 
Furthermore, treatment of co-cultures with 3-BP significantly reduced both platelet 
aggregation as determined by lumi-aggrogometry (Figure 5A, Figure S1-IV) and platelet 
aggregation as suggested by limited counting of aggregates using microscopy (Figure 5B and 
C). An increased presence of LMWPTP and PTP1B was observed in platelets co-cultured 
with either HCT116 or Caco-2 cells, with a concomitant upregulation of Integrinβ3 and Src 
phosphorylation. This effect was mediated through cell-cell contact, as conditioned medium 
from tumor cells did not elicit the same effect (Figure 5D). As a validation of our findings, we 
assessed the cell surface expression of platelet activation markers (vWF-receptor, integrin β3 
and P-Selectin) in the presence of tumor cells, and showed a significant reduction of these 
markers upon treatment of co-cultures with 3-BP (Figure 5E–G). Taken together, these data 
demonstrate that platelet activity can be directly modulated through the physical contact with 
cancer cells, and show the potential of 3-BP to disturb this cancer cell-platelet interaction. 
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Figure 5. Tumor-cell induced aggregation, thrombus formation and activation are 
decreased by 3-BP. (A) Platelets were pre-incubated with CRC cells (1.5×104 cells) and 3-
BP (100μM) for 5 min, and subsequently stimulated using collagen (2μg/mL). Aggregation 
was measured for 10 min. Platelets stimulated with collagen only served as controls for the 
experiment. Each data point (special shapes) corresponds to an individual experiment and 
indicates the data for platelets marked with: Circle – only platelets, Square – with HCT116, 
Up-triangle – with HCT116 and 3BP, Down-triangle – with HT29, Diamond – with HT29 and 
3BP, Hollow circle – with Caco-2, Hollow Square – with Caco-2 and 3BP. (B) Co-cultures of 
tumor cells and platelets were visualized by microscopy. Platelet aggregation as assessed by 
microscopy is indicated with arrows and quantified (C). (D) Platelets from co-culture with 
CRC cells (HCT116 and Caco-2) were lysed and loaded for western blot analysis of platelet 
activation markers and phosphatases. β-actin served as loading control. Densitometric values, 
corrected for loading control, are indicated. A representative blot of at least 2 independent 
experiments is shown. (E–G) Platelets co-cultured with HT29 (E), HCT116 (F) or Caco-2 (G) 
cells in the absence or presence of 3-BP were subsequently subjected to FACS analysis to 
determine cell surface expression of vWF-receptor (CD41-FITC), Integrinβ3 (CD42-PE) and 
P-Selectin (CD62-APC). Each data point (special shapes) corresponds to an individual 
experiment and indicates the data as: Circle – Integrinβ3 without 3BP, Square – Integrinβ3 
with 3BP, Up-triangle – vWF-receptor without 3BP, Down-triangle – vWF-receptor with 
3BP, Diamond – P-Selectin without 3BP, Hollow circle – P-Selectin with 3BP. 
  
3.6. Hyperactivity of Platelets from Gastrointestinal Cancer Patients Is Reduced upon 
Treatment with 3-BP 
We performed a small proof-of-concept study to investigate the capacity of 3-BP to 
decrease platelet aggregation in blood samples from three patients with gastrointestinal 
cancer. It has previously been described that platelets from cancer patients are more sensitive 
to in vitro collagen stimulation as compared to healthy controls. While our group is too small 
to make claims regarding significance as interpersonal variation may exist, we did observe a 
similar trend (% of light transmission of 95.67 ± 3.167 for patients vs 59.67 ± 21.40 for 
controls, Figure 6A, Figure S1–V). However, within the same experimental set-up, ristocetin-
triggered aggregation was less different between three patients and three controls, which may 
suggest that specific molecular dysfunctions of adhesion processes are present in these 
patients (82.83 ± 7.949 for patients vs. 61.33 ± 24.93 for controls). Accordingly, P-Selectin 
levels on platelets from cancer patients appeared to be higher as compared to control, 
although again, we only assessed few patients (Figure 6B). Interestingly, expression of 
LMWPTP, but not PTP1B, was enhanced in all three patients studied, as compared to the 
experimental control subjects (Figure 6C). Importantly, 3-BP significantly decreased 
collagen-stimulated platelet function (Figure 6D, Figure S1-VI). Together, these data suggest 
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that phosphatases are key players in platelet function and aggregation in cancer patients and 
may be targeted by 3-BP. 
 
 
Figure 6. Platelets from patients with gastrointestinal cancer show hyperaggregation 
which can be inhibited by 3-BP. (A) Platelets from 3 gastrointestinal (GI) cancer patients 
(TEP) and 3 healthy controls (TEPH) were stimulated with either collagen (0.5μg/mL) or 
ristocetin (1.25mg/mL) and the aggregation was measured for 10 min. (B) Cell surface 
expression of vWF-receptor (CD41-FITC), Integrinβ3 (CD42-PE) and P-Selectin (CD62-
APC) was investigated on platelets from GI cancer patients (TEP) and healthy controls 
(TEPH). (C) Platelets obtained from GI cancer patients and controls were lysed and subjected 
to western blot analysis of the indicated (phospho-)proteins. Densitometric analysis of 
LMWPTP, PTP1B and p-Src expression are shown. (D) Aggregation assay using 3-BP 
(100μM) as inhibitor of platelet function in 2 healthy controls and 3 GI cancer patients. 3-BP 
was incubated at pre-test step for 5 min, and after platelets were stimulated using collagen 
(1μg/mL). 
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4. Discussion 
Cancer patients, in particular those suffering from gastrointestinal tumors, have a 
severely increased risk of developing VTE. Although the cause of this increased risk has not 
yet been fully elucidated, it has been described that tumor cells are capable of enhancing 
platelet aggregation in a process known as tumor cell-induced platelet aggregation (TCIPA) 
[37,38]. We investigated the molecular mechanisms associated with platelet hyper-
aggregability. In the present study, we confirmed the importance of Src activity for collagen-
induced platelet function, and demonstrated that both Src and Integrinβ3 activation are 
enhanced upon co-culture of platelets with cancer cells. Furthermore, we show here that 
phosphatases modulating Src activity, i.e., LMWPTP and PTP1B, are present and active in 
platelets, and that the levels of these phosphatases are enhanced upon co-culture with CRC 
cells. While it may seem surprising that inhibition of these phosphatases reduces platelet 
activation which relies so heavily on Src activity, both PTP1B and LMWPTP have previously 
been shown to be essential for Src activation, which is dependent on the balance between its 
phosphorylation sites [17,39]. 
In the present study, we observed differences in phosphatase activation upon 
stimulation of platelets with different agonists. Unlike collagen, ristocetin was not able to 
induce LMWPTP activity, suggesting that collagen-induced platelet activation relies more on 
LMWPTP activity than ristocetin-induced activity. Furthermore, in the cancer patients tested 
in this study, LMWPTP expression and collagen-induced aggregation, but not ristocetin-
induced activity, were increased in comparison to healthy controls. Interestingly, increased 
LMWPTP mRNA profiles have been identified in platelets from colorectal, pancreatic, breast 
and hepatobiliary cancer patients [40] which, in light of our current data, suggests that this 
phosphatase may be related to tumor cell-induced platelet aggregation risk.  
A growing body of evidence point towards an important role of PTPs in platelet 
biology [41,42]. Recently, it was shown that platelets contain the dual specificity phosphatase 
DUSP3, and that inhibition of this phosphatase reduces arterial thrombosis in mice [43,44]. A 
functional role for PTP1B has also been suggested in platelets [45,46]. Here, we show for the 
first time, that platelet LMWPTP activity is modulated by collagen, but not by ristocetin, and 
identified this phosphatase as a druggable target for platelet hyperactivity. Importantly, we 
found that 3-BP diminished the reactivity of platelets from healthy individuals as well as 
gastrointestinal cancer patients, at least in part through the inhibition of LMWPTP, PTP1B 
and Src kinaseds. However, the fact that ristocetin-induced aggregation and activation marker 
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expression was not inhibited by 3-BP treatment might suggest that, even though in vitro 3-BP 
is able to inhibit PTP1B activity, cellular LMWPTP is more affected by 3-BP (Figure 7). 
Despite the great progress in the development of cancer treatment protocols, the 
treatment of several tumors is still a challenge, especially in metastatic cases. The use of 
antithrombotic treatment as a co-adjuvant strategy in cancer treatment was already suggested 
in 1982, in particular in its capacity to decrease metastasis [47]. Indeed, it has been described 
that antithrombotic therapy improves survival in patients with colorectal cancer [48]. We have 
previously shown that LMWPTP and PTP1B contribute to metastatic potential of (intestinal) 
cancer cells [24,25]. Here, we demonstrate the important role of these phosphatases in platelet 
biology. Thus, targeting these phosphatases through 3-BP and its derivatives may provide a 
potential strategy to reduce both VTE risk and tumor metastasis in GI cancer patients.  
We acknowledge several limitations in this study. Platelet aggregation is a complex, 
multistep process, requiring many agonists at different time points of the process. Here, we 
limited our investigations to collagen and ristocetin-induced platelet functions, as previous 
studies have indicated that in particular collagen-induced platelet aggregation was increased 
in cancer patients in in vitro experiments [49], and that this correlates well to VTE risk scores 
[50]. However, in vivo, Tissue Factor may be a more relevant cancer-derived platelet agonist 
[51], and further studies will have to elucidate the role of phosphatases in the activation of 
platelets with this and other agonists. Furthermore, these in vitro experiments such as these do 
not take into account fibrinogen and the plethora of other factors encountered by platelets in 
vivo, and therefore care should be taken when trying to extrapolate these findings to an in 
vivo setting. Secondly, platelets are notoriously easily activated in in vitro experiments, and 
several different isolation and washing protocols to reduce unwanted activation have been 
published [52–54]. The protocol used here was taken from Jankowski et al, as this was the 
most compatible with downstream analysis of platelets for phosphatase activity assays. While 
we did not observe unwanted activation in our studies, it is conceivable that other wash 
protocols may have given slightly different results. Lastly, we only included 3 cancer patients 
in our proof-of-concept study, and larger studies using more patients and controls matched for 
age as well as gender, and more different agonists are warranted to further elucidate the role 
of phosphatases in these settings, and the potential of 3BP to affect platelet function in GI 
patients.  
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Figure 7. The 3-BP effect on platelet activation. (A) Platelets can be activated by collagen 
and tumor cells. (B) In the presence of 3-BP, the modulation of phosphatases plays 
contributes to a decreased platelet activity. This can culminate in a decreased aggregation, 
including cancer cell-platelet mist thrombi. 
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Supplemental Figure S1. Representative aggregation graphics from each experiment are 
combined in one file (pdf). I: Treatment of platelets with collagen/ristocetin in the absence or 
presence of the Src inhibitor PP2; II: Treatment of platelets with collagen/ristocetin in the 
absence or presence of 3-BP; Treatment of platelets with collagen in the absence or presence 
of the PTP1B inhibitor CinnGEL or the SHP inhibitor NSC87887; IV: Treatment of platelets 
with collagen in the absence or presence of tumor cells (Caco-2, HT29, HCT116) and 3-BP; 
V: Treatment of patient and control platelets with collagen/ristocetin; VI: Treatment of patient 
and control platelets with collagen/ristocetin in the absence or presence of 3-BP. 
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Supplemental Figure 2. Platelet function is not inhibited by selective SHP inhibitor. (A) 
Aggregation assays were performed for collagen-stimulated platelets after pretreatment with 
specific SHP inhibitor (NSC87887). (B) Cell surface expression of vWF-receptor (CD41-
FITC), Integrinβ3 (CD42-PE) and P-Selectin (CD62-APC) was investigated on collagen-
stimulated platelets that were pre-treated with specific SHP inhibitor (NSC87887). 
 
Supplemental tables 
Table 1. Western blot antibodies  
Antibody Company Code 
Acp1 α/β  Santa Cruz Biotechnologies  sc-100343  
PTP1B  Santa Cruz Biotechnologies  sc-14021  
βactin  Santa Cruz Biotechnologies  sc-47778  
Phospho-Src family (Tyr416)  Cell Signaling  2101  
Phospho-Src (Tyr572)  Cell Signaling  2105  
Src  Cell Signaling 2123 
Phospho-FAK (Tyr925)  SignalWay Antibodies  11123-2  
FAK Cell Signaling 3285S 
Phospho-Integrin βIII (Tyr773)  SignalWay Antibodies  11060-1  
Phospho-Erk (T202/Y204) Cell Signaling 4370 
Erk Cell Signaling 4695 (137F5) 
Phospho-p38 (T180/Y182) Cell Signaling 4511 
p38 Cell Signaling 9228 
Caspase-3 Cell Signaling 9662 
Cleaved Caspase-8 Cell Signaling 9496 
Bax Cell Signaling 2772 
Bcl-2 Cell Signaling 2876 
 
Table 2. Chemicals  
Reagent Company Code 
3-bromopyruvate  Sigma Aldrich  16490-10  
CinnGel  Santa Cruz  205633  
NSC87887  Merck Millipore  565851  
Collagen  Chronolog  385  
Ristocetin Chronolog 396 
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Table 3. Cell line characteristics, as described in [1-9]. 
Cell line HCT116 HT29 Caco-2 
Patient 48-Year-old male 44-Year-old female 72-Year-old male 
Organ Colon ascendens Colon Colon 
Disease colorectal 
carcinoma 
colorectal 
adenocarcinoma 
colorectal 
adenocarcinoma 
Stage Dukes’ D Dukes’ C  
Derived from primary tumor primary tumor  
MSI status MSI MSS MSS 
CIMP panel 1 + + + 
CIMP panel 2 + + - 
CIN - + + 
KRAS G13D WT WT 
BRAF WT V600E WT 
PIK3CA H1047R P449T WT 
PTEN WT WT WT 
TP53 WT R273H E204X 
Abbreviations: CIN, chromosomal instability pathway; MSI, microsatellite instability; MSS, 
microsatellite stable; CIMP, CpG island methylator phenotype 
1. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknæs M, Hektoen M, Lind GE, Lothe 
RA. (2013). Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 16, 
71.  
2. Brattain MG, Brattain DE, Fine WD, Khaled FM, Marks ME, Kimball PM, Arcolano LA, 
Danbury BH. (1981). Initiation and characterization of cultures of human colonic carcinoma 
with different biological characteristics utilizing feeder layers of confluent fibroblasts. 
Oncodev Biol Med. 2(5):355-66. 
3. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. (1981). Heterogeneity of 
malignant cells from a human colonic carcinoma. Cancer Res. 41(5):1751-6. 
4. Eshleman JR, Lang EZ, Bowerfind GK, Parsons R, Vogelstein B, Willson JK, Veigl ML, 
Sedwick WD, Markowitz SD. (1995). Increased mutation rate at the hprt locus accompanies 
microsatellite instability in colon cancer. Oncogene. 10(1):33-7. 
5. Fogh J, Wright WC, Loveless JD. (1977). Absence of HeLa Cell Contamination in 169 Cell 
Lines Derived From Human Tumors. JNCI: Journal of the National Cancer Institute, 58(2), 
209–214. doi:10.1093/jnci/58.2.209  
6. Griffin C, Karnik A, McNulty J, Pandey S. (2011).  Pancratistatin selectively targets cancer 
cell mitochondria and reduces growth of human colon tumor xenografts. Mol. Cancer Ther. 
10; 57-68.  
7. Liu Y, Bodmer WF. (2006). Analysis of P53 mutations and their expression in 56 
colorectal cancer cell lines. Proc Natl Acad Sci U S A. 103; 976-81.  
8. Mouradov D, Sloggett C, Jorissen RN, Love CG, Li S, Burgess AW, Arango D, Strausberg 
RL, Buchanan D, Wormald S, O'Connor L, Wilding JL, Bicknell D, Tomlinson IP, Bodmer 
WF, Mariadason JM, Sieber OM. (2014). Colorectal cancer cell lines are representative 
models of the main molecular subtypes of primary cancer. Cancer Res. 74, 3238-47.  
9. Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, 
Yamane Y, Maejima K, Field HI, Kobayashi T, Akasu T, Sugiyama M, Tsuchiya E, Atomi Y, 
Ponder BA, Nakamura Y, Hamamoto R. (2011). Validation of the histone methyltransferase 
EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. 
Cancer Sci. 102; 1298-305.  
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Summary discussion 
 
Phosphorylation is the most common post-translation modification and regulatory mechanism 
of proteins. Indeed, for many enzymes, phosphorylation leads to a reversible and fast 
modulation of enzymatic activity. Furthermore, protein stability, interactions, and subcellular 
localization are largely dependent on protein phosphorylation (Han et al, 2018; Torresano et 
al, 2020). As such, the phosphorylation system regulates cellular survival, proliferation, 
differentiation, metabolism, and cytoskeletal signaling (Noorolyai et al, 2019). The balance 
between kinases and phosphatases dictates the net cellular phosphor-signaling and has 
emerged as a potential target for overcoming many diseases, such as cancer, cardiovascular 
disease, and (auto)immune diseases (Kumar et al, 2007; Ferguson and Gray, 2018; Kenefick, 
2019). The focus of this thesis was mainly on the role of this aspect of cellular signaling in 
cancer. While cancer treatment has improved over the last decades, so that overall cancer 
death rates are decreasing, this is not equally clear for all cancers. The 5-year survival of, for 
instance, prostate cancer has increased from 67.8% in 1990 to 98.6% in 2016. However, in 
particular, gastrointestinal cancers are still lethal. For instance, the 5-year survival rate for 
colorectal cancer improved only from 50% to 64%, gastric cancer from 15 to 30%, 
esophageal cancer from 5 to 19%, and pancreatic cancer from 2.5 to a dismal 8.2%. Thus, a 
better understanding of the molecular processes underlying carcinogenesis and finding novel 
targets for treatment is still warranted and phospho-signaling may provide such targets 
(Ritchie, 2019). Large-scale kinase activity assays are a valuable tool to discover such 
potential novel targets of treatment or to investigate why some treatments might fail.  
 
Kinome profiling is a pan-kinase analysis tool to elucidate canonical and non-canonical 
pathways in cancer 
A case in point was shown in Chapter 2, where we investigated the canonical and non-
canonical pathways associated with Hedgehog-induced (Hh) signaling in normal mouse 
embryonic fibroblasts. Hh is important for organ formation during embryogenesis, and an 
adult, tissues seem in particular important for stem cell functions. Three Hh ligands are 
known in humans (Sonic Hh, Indian Hh, and Desert Hh), of which SHh is the best studied. 
All Hh members bind to the Patched receptor (Ptch), which under unbound conditions 
represses the activity of the G-protein coupled receptor Smoothened (Smo). Binding of Hh to 
Ptch releases this inhibition, allowing Smo to signal, resulting in activation of GLI 
transcription factors and transcription profiles favoring tumor cell migration, invasion, cell 
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cycle, and stem cell self-renewal. Besides the important effect during tissue development, 
dysregulated SHh signaling has been highlighted as a cancer hallmark in tumor growth and 
progression (Rimkus et al, 2016). Recurrence of cancer through remaining cancer stem cells 
remains a major problem in cancer treatment and targeting tumor cells as well as cancer stem 
cells with Hh inhibitors has been suggested (Sari et al, 2018). Cancer treatment to reduce 
activation of these transcription patterns center mostly around inhibition of Smo, which is 
supposed to completely switch off canonical SHh signaling. Nevertheless, cancer treatment 
with Smo inhibitors such as Vismodegib does not always have the efficacy which one might 
expect (Hansel et al, 2015). In part, this might be explained by the fact that patients who 
develop resistance to vismodigib may acquire mutations in Smo which renders it less 
susceptible to inhibitor binding (Atwood et al, 2015; Sharpe et al, 2015). However, we 
considered that it is also conceivable that alternative, non-canonical signaling of Hh may 
exist, which may account for resistance against Smo inhibitors, something which we 
investigated in Chapter 2. There, we showed that under SHh stimulation (Niyaz et al, 2019), 
kinome pathways associated with survival and cytoskeletal rearrangement were activated. 
However, upon either Smoothened knockdown or Vismodegib inhibitions of Smo, survival 
and cytoskeletal pathways were still activated, as were inflammatory and stemness pathways. 
These results demonstrate that non-canonical signaling based on kinase activity takes place 
downstream of Ptch, independent of Smo signaling. Interestingly, under SHh agonist (SAG) 
treatment, which triggers Smo activity independent of Ptch, survival pathways were not 
activated, while only cytoskeletal pathways were positively modulated. Taking all these 
findings together, independent Ptch-dependent and Smo-dependent signaling exist, but 
cytoskeletal remodeling pathways were activated under all treatment conditions tested. 
Perhaps this finding is not surprising, as cell migration, which is dependent on cytoskeletal 
remodeling, is important for homeostasis and regeneration, especially for building tissues and 
organs during embryonic development (Te Boekhorst and Friedl, 2016).  
Perhaps the most notable finding of this study was that the SHh inhibitor treatment 
(vismodegib) was not able to negatively modulate survival signaling. Thus, despite the main 
effect of Smo inhibitors on canonical pathways, the associated receptor or down-stream 
kinases can be still activated and maintain signaling commonly related to cancer malignancy. 
Indeed, in the presence of vismodegib, SHh-induced Patched-dependent Smoothened-
independent signaling kept cytoskeletal remodeling and Wnt pathways activated, potentially 
compromising the anti-cancer effect of this drug. For instance, cell motility activation is 
associated with metastasis, which in turn is the cause of 90% of cancer deaths (Chaffer and 
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Weinberg, 2015). Our results suggest that co-treatment with kinase inhibitors may provide 
benefit by targeting the non-canonical pathways activated by SHh. Since kinases have been 
highlighted to play a major role in cancer, including in therapeutic resistance, several 
chemotherapeutic drugs were already developed to target kinases, such as Erlotinib targeting 
EGFR, Trametinib targeting MEK1/2, Dasatinib targeting Src kinases (Bhullar et al, 2018). It 
would be of interest to see whether kinase inhibitors targeting non-canonical kinase signaling 
induced by SHh may be of benefit. 
 
The data described in Chapter 2 provide an example of how, using a pan-kinase analysis tool, 
canonical and non-canonical pathways associated with specific signals and/or ligands can be 
investigated, including potential targets for overcome cancer. Using the same pan-kinase 
analysis, in Chapter 3, we turned our attention to drug resistance and compared the kinome 
profile from two chronic myeloid leukemia cell lines: the chemotherapy-sensitive K562 cell 
line and its chemoresistant counterpart Lucena-1. Previous data using western blot analysis of 
individual proteins has shown that Src and BcrAbl were overexpressed/overactivated in 
Lucena-1, as well as, STAT signaling (Ferreira et al, 2012; Mencalha et al, 2014). In Chapter 
3, we aimed for a broader view of signaling changes between these two lines. Interestingly, by 
employing kinome profiling, it was possible to track signaling differences between 
chemosensitive and chemoresistant hematological cancer cells to metabolic changes. Since 
Warburg in 1956 described the importance of mitochondria metabolism in cancer, alternate 
energy metabolism has been highlighted as a cancer hallmark (Warburg, 1956; Hanahan and 
Weinberg, 2011). The Warburg postulation describes how tumor cells show excessive glucose 
uptake, which is converted to lactate through aerobic glycolysis. In this case, the tumor 
glucose metabolism provides energy by glycolysis, even in the presence of sufficient oxygen, 
rather than oxidative-phosphorylation via mitochondria. While glycolysis is faster as 
compared to oxidative phosphorylation (Zheng et al, 2012), it also results in less ATP 
production, thus the exact benefit to the tumor cell remains debated (Liberti et al, 2016). 
Reasons may include the fact that tumor cells may be more often oxygen-deprived and have 
quicker growth rates. However, the pathway might also be deflected to biomolecule 
production, for instance, to nucleotides and reducing agents required for tumor growth 
(Schwartz et al, 2017). Our data indicate that drug-resistant Lucena-1 cells show a higher 
lactate production and lower mitochondria function. Furthermore, it was observed that 
Lucena-1 cells were less sensitive to treatment with oxidants. Changes in glucose metabolism 
have been highlighted as a cancer hallmark, the cancer cell addiction to glycolysis playing a 
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role in two important cell events: (i) crosstalk between pentose phosphate pathway 
predominance flux, in the end, to favor the synthesis of biomolecules; (ii) and lower 
mitochondria function, which directly affect the ROS production by OXPHOS (Amoedo et al, 
2017). Several glycolysis-kinases over-activated in Lucena-1 are associated with 
chemoresistance: Lactate Dehydrogenase, Hexokinase, and mTOR (Zhao et al, 2013), 
suggesting that these processes may be functionally linked.   Thus, kinome profiling in this 
case unexpectedly provided evidence for altered metabolic signaling and provides potential 
targets for interfering with this cancer hallmark. 
 
Novel contributions of LMWPTP to cancer hallmarks  
Interestingly, the chemoresistant Lucena-1 cell line has higher LMWPTP expression and Src 
kinase activity as compared to its K652 counterpart, which directly contributes to its drug 
resistance (Ferreira et al, 2012). Besides several contributions of kinases in cancer, a 
contribution of phosphatases to cancer progression, especially tyrosine phosphatases, has 
emerged during the last decades. Our research group has been investigating the PTPs as 
potential targets and biomarkers for gastrointestinal cancer (Hoekstra et al, 2015; Hoekstra et 
al, 2016) as well as other cancers (Ruela-de-Sousa et al, 2016; this thesis). A role for 
LMWPTP in tumor proliferation, migration, and patient survival is emerging. In Chapter 3, 
we demonstrate for the first time the association between LMWPTP expression and activation 
of glycolytic metabolism in cancer. As a proof-of-concept, using transient LWMPTP 
transfection (silencing or overexpression), it was observed that maintenance of a high 
glycolytic profile was dependent on higher expression of this phosphatase.   
Based on this, in Chapter 4, we further explored the role of LMWPTP in the metabolic 
processes and resistance to environmental stresses in the chronic myeloid leukemia cells 
model. Autophagy is one mechanism of cell fate regulation based on the sequestering of 
molecules and their degradation. Autophagy plays a dual role in cancer. While it can: 
promoting cell survival by removing damaged organelles and proteins and promoting cell 
proliferation by drug neutralization and controlling metabolic stress, prolonged autophagy 
may lead to a ‘point of no return’ at which point ongoing cellular degradation switches to cell 
death (Yang et al, 2011; Lauzier et al, 2019; Li et al, 2020; Mulcahy Levy and Thorburn, 
2020). Furthermore, low O2 concentration is linked to a metabolic switch from oxidative 
metabolism to glycolysis (Ianniciello et al, 2017). Autophagy and ROS accumulation act as a 
differentiation promoter in CML affecting directly chemotherapeutic responsiveness 
(Colosetti et al, 2009; Carrett-Dias et al, 2016; Baquero et al, 2018). The gold-standard CML 
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treatment, imatinib, was described to induce autophagy as part of its mechanism of action 
(Ertmer et al, 2007). We showed that LMWPTP is also linked to autophagy regulation as a 
primary response under antioxidant exposure. Under basal conditions, autophagy was down-
modulated in Lucena-1 cells compared to K562. However, under hydrogen peroxide exposure 
or when LMWPTP expression was reduced, the autophagy process is activated to control the 
excess of ROS, and it is conceivable that this also contributes to the drug resistance profile of 
this cell line. In cumulus cells, autophagy is also required to guarding against oxidative stress 
and it is dependent on DUSP1 expression (Fu et al, 2019). 
Thus, these data have demonstrated that LMWPTP plays a versatile role in cancer, 
contributing to many cancer hallmarks, including glycolysis and modulation of cellular stress 
pathways. A role for phosphatases in cancer is slowly being extended to several different 
enzymes and different processes (see Hoekstra et al, 2012; Ruela-de-Sousa et al, 2010). For 
instance, PTP1B also plays an important role in cancer hallmarks. The higher expression of 
PTP1B was associated with higher cancer cell migration in CRC, and to the invasion process 
in esophageal squamous cell carcinoma (Wang et al, 2012; Hoekstra et al, 2016). 
Furthermore, SHP-2 can also be a cancer predictor, and SHP-2 overexpression leads to cell 
migration (Han et al, 2015). Despite the different phosphatase contributions on several 
processes, most of them appear to play a role in cancer progression. 
 
Tumor and platelets: reciprocal actions in the pre-metastatic niche 
Including the work presented in Chapters 3 and 4, our laboratories have spent considerable 
effort trying to elucidate the effect of LMWPTP on cancer properties. However, cancer cells 
are not solitary - the tumor microenvironment provides support for cancer progression by 
supplying a metabolic network, including nutrients, extracellular matrix (ECM) components, 
and immune cells (Doglioni et al, 2019). While the role of individual ECM components on 
cancer progression is relatively well described (Henke et al, 2019), a new interactive player 
has emerged which deserves more attention: platelets. Platelets are the mandatory element for 
the thrombosis process; however, this anucleated blood component also participates in 
immunologic and inflammatory responses (Morrell et al, 2014; Koupenova et al, 2018). 
Normal platelet function might be disturbed under several conditions, leading to 
cardiovascular complications such as venous thromboembolism (VTE). The aging process has 
been highlighted as a physiological cause for platelet functionality changes. Cancer and 
cardiovascular comorbidities are age-associated diseases that directly affect platelet function. 
Indeed, enhanced risk of VTE is seen in the elderly, but also cancer patients. To what extent 
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VTE risk is related to underlying diseases and whether platelet function in itself is altered by 
the aging process was investigated in Chapter 5. We reviewed the current literature on 
platelet alterations in healthy aging, discussing their contribution to hemostasis and immunity. 
We conclude that while studies vary considerably in terms of methodology and age-groups 
studied, the overall picture emerging is that while platelet count is decreased in the elderly, 
their reactivity towards agonists and general activation pattern appears to be increased, and 
differences start to become more prominent in the 60-80 year age-group. Mechanistically, 
inflammatory processes taking place during aging (e.g. TNFα) appear to age megakaryocytes, 
inducing them to release hyper-activated platelets (Davizon-Castillo et al, 2019). Thus, 
finding safe and affordable ways to interfere with these inflammatory pathways may in the 
future perhaps contribute to healthy aging.  
We go on to discuss the changes in platelets that may account for their association with 
cancer. Tumor cells induce several platelet modifications and can alter their intracellular 
content and function (Menter et al, 2014), which may contribute to increased VTE risk seen in 
cancer. Importantly, some studies have shown that this is independent of aging, suggesting 
that cancer itself is the primary trigger for VTE risk in this case (Heit, 2015). Conversely, 
platelets, and the growth factors they release may trigger tumor cell proliferation and 
metastasis, with extravasation of tumor cells presenting an additional risk to VTE 
development. In this direction, platelets are part of the tumor microenvironment and also 
might support cancer progression. Platelets can facilitate cancer cell proliferation and 
invasion. Platelets might improve vascularization, which directly provides nutrient and 
oxygen supply for cancer growth (Pietramaggiori et al, 2008). In Chapter 6 we further 
investigate the interaction between tumor cells and platelets and investigate the molecular 
mechanisms involved. In particular, we wondered whether LMWPTP in tumor cells, which 
we had already shown to be important for several oncogenic properties, would also mediate 
the tumor-platelet interactions. In Chapter 6, we first demonstrate that LMWPTP is 
overexpressed in the stomach and esophageal cancer, as well as colorectal cancer, suggesting 
that this is a common defect seen in gastrointestinal cancer. When investigating kinase 
activation in gastric cancer cells with high LMWPTP expression compared to non-
transformed gastric cells with lower LMWPTP expression levels, we observed higher Src and 
FAK activation in the stomach cancer cell line. These findings were supported by previous 
studies from our research group (Zambuzzi et al, 2008; Ferreira et al, 2012), showing the 
importance and consistency of the data. We went on to study the importance of platelets on 
tumor progression. While we observed no stimulation by platelets of normal cell line 
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proliferation, stomach tumor cells presented higher proliferation rates, as well as activation of 
Src and p38, in the presence of platelets. Similarly, CRC cell lines also showed enhanced 
proliferation in the presence of platelets. Using various knockdown models, we went on to 
demonstrate that LMWPTP plays an important contribution in this process: knockdown of 
LMWPTP reduced cancer cell interaction with platelets, as well as platelet-mediated 
proliferation effects. Taking this together, platelets and tumors directly improve their 
functions by establishing supporting networks: tumor cells might induce platelet hyper-
activation, but also platelets, in turn, improve tumor growth and local migration by factors 
releasing, events which are dependent on LMWPTP expression. It is of interest to note that 
our data also indicated that LMWPTP itself was upregulated in tumor cells upon interaction 
with platelets, suggesting a positive feedback loop.  
Having investigated the molecular signaling events in cancer cells contributing to platelet-
mediated oncogenic stimulation, we next wondered to what extent signaling in platelets 
themselves might be contributing to this interaction. To this end, we first reviewed 
contemporary literature on signaling in platelets, with particular emphasis on the role of 
phosphatases in platelet activation. In Chapter 7, we show that while the presence of several 
phosphatases has been shown in platelets, their role in platelet functions remains relatively 
poorly understood, in particular in comparison to kinases. For this reason, we turned our 
attention to phosphatase signaling in platelets in Chapter 8. We demonstrated that under 
collagen stimulation, both LMWPTP and PTP1B were activated in platelets, while ristocetin 
only activated PTP1B. These data show the selectivity of phosphatase signaling under 
different conditions. Further, Src kinase was identified as an important player in platelet 
hyper-reactivity using collagen as an agonist. Using a phosphatase inhibitor, the pyruvate 
analog 3-bromopyruvate (3-BP), decreases platelet function on the molecular level, by 
phosphatase and Src kinase family inhibition, as well as on cellular level, by decreasing 
platelet surface activation markers, as Integrin βIII and P-Selectin expression. We next 
investigated the molecular mechanisms of platelet-tumor cell interactions and showed that 
cancer cells were able to enhance platelet function under collagen stimulation, suggesting the 
participation of kinases and phosphatases on this process. Indeed, either collagen or colorectal 
cancer (CRC) cells induced platelet aggregation and expression of activation markers, and this 
interaction was susceptible to 3-BP targeting. In a proof-of-concept experiment, platelets from 
cancer patients were shown to be more responsive to collagen activation compared to normal 
platelets, and 3-BP disturbed this platelet hyper-functionality. Of note, co-culture between 
platelets and cancer cells increased LMWPTP expression in platelets, and a higher LMWPTP 
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expression in patients’ platelets was seen compared to healthy control platelets, confirming 
previous data that platelets may be ‘educated’ by cancer cells (Best et al, 2015).  In summary, 
kinases and phosphatases, especially LMWPTP, play an important role in platelets in health 
and disease. In particular, in the cancer setting, LMWPTP appears to play a central role. This 
enzyme appears to be upregulated in both tumor cells and platelets in cancer, with these cell 
types further reciprocally increasing LMWPTP expression. With this enhanced expression 
subsequently activating both platelets and propagating (platelet-mediated) oncogenic 
properties in tumor cells, this phosphatase might present an interesting target to disrupt both 
VTE risk in cancer as well as cancer growth per se. Additional targets are needed, as targeting 
kinases in cancer may result in bleeding by affecting platelets (Tullemans et al, 2018). 
Overcoming platelet-hyperreactivity in cancer without provoking bleeding requires a careful 
approach. 
 
  
 
220 
Future perspectives 
Protein tyrosine kinases and phosphatases have been investigated as major players on cancer 
hallmarks. Indeed, several cell biology events associated with proliferation and motility are 
associated with FAK/Src and LMWPTP function.  With our studies indicating that non-
canonical signaling and drug resistance are dependent on kinase signaling, making better use 
of available kinase inhibitors may provide a step forward in the treatment of cancer. On the 
other hand, we also demonstrate that a misbalance over-activating LMWPTP leads to 
improved cancer plasticity sustaining proliferative signaling, resisting cell death, deregulating 
cellular energetics, avoiding immune destruction, and activating invasion and metastasis. 
Investigation of the contribution of tyrosine phosphatases in other tissues and organs will 
likely emphasize their importance in diverse diseases. The next step may, therefore, be to 
focus on the development of better inhibitors of phosphatases. Kinases are not only more 
widely studies in disease states, the development of inhibitors for this class of enzymes is also 
facilitated by the fact that they all contain an ATP binding pocket and a relatively high 
selectivity of the catalytic domain for peptide substrates. Many kinase inhibitors thus are ATP 
analogs (Lazo et al, 2017). Unfortunately, the search for phosphatase inhibitors is limited by 
several factors, including lower selectivity and bioavailability (De Munter et al, 2013). Protein 
tyrosine phosphatases are characterized by the PTP motif: (V/H)CX5R (Stanford and Bottini, 
2017), which makes it so complex to evaluate appropriate and selective inhibitors. 
Nevertheless, with more and more evidence suggesting that phosphatases play a stronger role 
in carcinogenesis than previously anticipated and current medicine still losing the battle 
against cancer, exploring this class of enzymes as druggable targets could present a step 
forward in the treatment of these as yet lethal and debilitating diseases.   
 
 
  
 
221 
References 
Amoedo ND, Obre E, Rossignol R. Drug discovery strategies in the field of tumor energy 
metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy. 
Biochim Biophys Acta Bioenerg. 2017;1858(8):674-685. doi:10.1016/j.bbabio.2017.02.005 
Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, Ally MS, Kim J, Yao C, 
Chang AL, Oro AE, Tang JY. Smoothened variants explain the majority of drug resistance in 
basal cell carcinoma. Cancer Cell. 2015;27(3):342-53. doi: 10.1016/j.ccell.2015.02.002.  
Baquero P, Dawson A, Mukhopadhyay A, Kuntz EM, Mitchell R, Olivares O, Ianniciello A, 
Scott MT, Dunn K, Nicastri MC, Winkler JD, Michie AM, Ryan KM, Halsey C, Gottlieb E, 
Keaney EP, Murphy LO, Amaravadi RK, Holyoake TL, Helgason GV. Targeting quiescent 
leukemic stem cells using second generation autophagy inhibitors. Version 2. Leukemia. 
2019;33(4):981-994. doi: 10.1038/s41375-018-0252-4.  
Best MG, Sol N, Kooi I, Tannous J, Westerman BA, Rustenburg F, Schellen P, Verschueren 
H, Post E, Koster J, et al. RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-
Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell 2015;28:666–
676. doi:10.1016/j.ccell.2015.09.018. 
Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, Rupasinghe HPV. 
Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 
2018;17(1):48. doi: 10.1186/s12943-018-0804-2.  
Carrett-Dias M, Almeida LK, Pereira JL, Almeida DV, Filgueira DM, Marins LF, Votto AP, 
Trindade GS. Cell differentiation and the multiple drug resistance phenotype in human 
erythroleukemic cells. Leuk Res. 2016;42:13-20. doi: 10.1016/j.leukres.2016.01.008.  
Chaffer CL, Weinberg RA. (2015). How does multistep tumorigenesis really proceed? Cancer 
Discov. 5(1):22-24. 
Colosetti P, Puissant A, Robert G, Luciano F, Jacquel A, Gounon P, Cassuto JP, Auberger P. 
Autophagy is an important event for megakaryocytic differentiation of the chronic 
myelogenous leukemia K562 cell line. Autophagy. 2009;5(8):1092-8. doi: 
10.4161/auto.5.8.9889.  
Davizon-Castillo P, McMahon B, Aguila S, Bark D, Ashworth K, Allawzi A, Campbell RA, 
Montenont E, Nemkov T, Alessandro A, Clendenen N, Shih L, Sanders NA, Higa K, Cox A, 
Padilla-Romo Z, Hernandez G, Wartchow E, Trahan GD, Nozik-Grayck E, Jones K, Pietras 
EM, DeGregori J, Rondina MT, Di Paola J. TNF-α-driven inflammation and mitochondrial 
dysfunction define the platelet hyperreactivity of aging. Blood. 2019;134(9):727-740. doi: 
10.1182/blood.2019000200. 
De Munter S, Köhn M, Bollen M. Challenges and opportunities in the development of protein 
phosphatase-directed therapeutics. ACS Chem Biol. 2013;8(1):36-45. doi:10.1021/cb300597g 
Doglioni G, Parik S, Fendt SM. Interactions in the (Pre)metastatic Niche Support Metastasis 
Formation. Front Oncol. 2019;9:219. doi: 10.3389/fonc.2019.00219.  
Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer HP, Schätzl HM. The 
anticancer drug imatinib induces cellular autophagy. Leukemia. 2007;21(5):936-42. doi: 
10.1038/sj.leu.2404606.  
Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 
2018;17(5):353-377. doi:10.1038/nrd.2018.21 
Ferreira PA, Ruela-de-Sousa RR, Queiroz KC, Souza AC, Milani R, Pilli RA, Peppelenbosch 
MP, den Hertog J, Ferreira CV. Knocking down low molecular weight protein tyrosine 
phosphatase (LMW-PTP) reverts chemoresistance through inactivation of Src and Bcr-Abl 
proteins. PLoS One. 2012;7(9):e44312.  
Fu XH, Chen CZ, Li S, Han DX, Wang YJ, Yuan B, Gao Y, Zhang JB, Jiang H. Dual-
specificity phosphatase 1 regulates cell cycle progression and apoptosis in cumulus cells by 
 
222 
affecting mitochondrial function, oxidative stress, and autophagy. Am J Physiol Cell Physiol. 
2019;317(6):C1183-C1193. doi:10.1152/ajpcell.00012.2019 
Han T, Xiang DM, Sun W, Liu N, Sun HL, Wen W, et al. PTPN11/Shp2 overexpression 
enhances liver cancer progression and predicts poor prognosis of patients. Journal of 
Hepatology. 2015;63(3):651-660. doi: 10.1016/j.jhep.2015.03.036 
Han ZJ, Feng YH, Gu BH, Li YM, Chen H. The post-translational modification, 
SUMOylation, and cancer (Review). Int J Oncol. 2018;52(4):1081–1094. 
doi:10.3892/ijo.2018.4280 
Hansel G, Tchernev G, Chokoeva AA, Lotti T, Schönlebe J, Wollina U. Failure of 
vismodegib in advanced Basal cell carcinoma. J Biol Regul Homeost Agents. 2015;29(1 
Suppl):11-13. 
Heit JA. Epidemiology of venous thromboembolism. Nat Rev Cardiol. 2015;12(8):464-474. 
doi:10.1038/nrcardio.2015.83 
Henke E, Nandigama R, Ergün S. Extracellular Matrix in the Tumor Microenvironment and 
Its Impact on Cancer Therapy. Front Mol Biosci. 2020;6:160. Published 2020 Jan 31. 
doi:10.3389/fmolb.2019.00160 
Hoekstra E, Das AM, Swets M, Cao W, van der Woude CJ, Bruno MJ, Peppelenbosch MP, 
Kuppen PJ, Ten Hagen TL, Fuhler GM. Increased PTP1B expression and phosphatase activity 
in colorectal cancer results in a more invasive phenotype and worse patient outcome. 
Oncotarget. 2016;7(16):21922-38. doi: 10.18632/oncotarget.7829.  
Hoekstra E, Das AM, Swets M, Cao W, van der Woude CJ, Bruno MJ, Peppelenbosch MP, 
Kuppen PJ, Ten Hagen TL, Fuhler GM. Increased PTP1B expression and phosphatase activity 
in colorectal cancer results in a more invasive phenotype and worse patient outcome. 
Oncotarget. 2016;7(16):21922-38. doi: 10.18632/oncotarget.7829. 
Hoekstra E, Kodach LL, Das AM, Ruela-de-Sousa RR, Ferreira CV, Hardwick JC, van der 
Woude CJ, Peppelenbosch MP, Ten Hagen TL, Fuhler GM. Low molecular weight protein 
tyrosine phosphatase (LMWPTP) upregulation mediates malignant potential in colorectal 
cancer. Oncotarget. 2015;6(10):8300-12. 
Hoekstra E, Peppelenbosch MP, Fuhler GM. The role of protein tyrosine phosphatases in 
colorectal cancer. Biochim Biophys Acta. 2012;1826(1):179-188. 
doi:10.1016/j.bbcan.2012.04.001 
Ianniciello A, Dumas PY, Drullion C, Guitart A, Villacreces A, Peytour Y, Chevaleyre J, 
Brunet de la Grange P, Vigon I, Desplat V, Priault M, Sbarba PD, Ivanovic Z, Mahon FX, 
Pasquet JM. Chronic myeloid leukemia progenitor cells require autophagy when leaving 
hypoxia-induced quiescence. Oncotarget. 2017;8(57):96984-96992. doi: 
10.18632/oncotarget.18904.  
Kenefick K. Kinase Inhibitors as Therapeutics: A Review. Promega. 2019; 
https://www.promegaconnections.com/kinase-inhibitors-as-therapeutics-a-review-2/ 
Koupenova M, Clancy L, Corkrey HA, Freedman JE. Circulating Platelets as Mediators of 
Immunity, Inflammation, and Thrombosis. Circ Res. 2018;122(2):337-351. doi: 
10.1161/CIRCRESAHA.117.310795.  
Kumar R, Singh VP, Baker KM. Kinase inhibitors for cardiovascular disease. J Mol Cell 
Cardiol. 2007;42(1):1-11. doi:10.1016/j.yjmcc.2006.09.005 
Lauzier A, Normandeau-Guimond J, Vaillancourt-Lavigueur V, Boivin V, Charbonneau M, 
Rivard N, Scott MS, Dubois CM, Jean S. Colorectal cancer cells respond differentially to 
autophagy inhibition in vivo. Sci Rep. 2019;9(1):11316. doi: 10.1038/s41598-019-47659-7.  
Lazo JS, McQueeney KE, Sharlow ER. New Approaches to Difficult Drug Targets: The 
Phosphatase Story. SLAS Discov. 2017;22(9):1071-1083. doi:10.1177/2472555217721142 
Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer. Mol Cancer. 
2020;19(1):12. doi:10.1186/s12943-020-1138-4 
 
223 
Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends 
Biochem Sci. 2016;41(3):211-218. doi: 10.1016/j.tibs.2015.12.001. Erratum in: Trends 
Biochem Sci. 2016;41(3):287. Erratum in: Trends Biochem Sci. 2016;41(3):287. 
Mencalha AL, Corrêa S, Salles D, Du Rocher B, Santiago MF, Abdelhay E. Inhibition of 
STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and 
imatinib mesylate resistance in the chronic myeloid leukemia. BMC Cancer. 2014;14:866. 
doi: 10.1186/1471-2407-14-866.  
Menter DG, Tucker SC, Kopetz S, Sood AK, Crissman JD, Honn KV. Platelets and cancer: A 
casual or causal relationship: Revisited. Cancer Metastasis Rev. 2014;33:231–269, 
doi:10.1007/s10555-014-9498-0. 
Morrell CN, Aggrey AA, Chapman LM, Modjeski KL. Emerging roles for platelets as 
immune and inflammatory cells. Blood. 2014;123(18):2759-67. doi: 10.1182/blood-2013-11-
462432.  
Mulcahy Levy JM, Thorburn A. Autophagy in cancer: moving from understanding 
mechanism to improving therapy responses in patients. Cell Death Differ. 2020;27(3):843-
857. doi:10.1038/s41418-019-0474-7 
Niyaz M, Khan MS, Mudassar S. Hedgehog Signaling: An Achilles' Heel in Cancer. Transl 
Oncol. 2019;12(10):1334-1344. doi:10.1016/j.tranon.2019.07.004 
Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between 
PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120-128. doi: 
10.1016/j.gene.2019.02.076. 
Pietramaggiori G, Scherer SS, Cervi D, Klement G, Orgill DP. Tumors stimulate platelet 
delivery of angiogenic factors in vivo: an unexpected benefit. Am J Pathol. 
2008;173(6):1609-16. doi: 10.2353/ajpath.2008.080474. 
Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW. Targeting the Sonic Hedgehog 
Signaling Pathway: Review of Smoothened and GLI Inhibitors. Cancers (Basel). 
2016;8(2):22. doi:10.3390/cancers8020022 
Ritchie H. Cancer death rates are falling; five-year survival rates are rising. Our World in 
Data. 2019; https://ourworldindata.org/cancer-death-rates-are-falling-five-year-survival-rates-
are-rising#licence 
Ruela-de-Sousa RR, Queiroz KC, Peppelenbosch MP, Fuhler GM. Reversible 
phosphorylation in haematological malignancies: potential role for protein tyrosine 
phosphatases in treatment?. Biochim Biophys Acta. 2010;1806(2):287-303. 
doi:10.1016/j.bbcan.2010.07.007 
Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY. Hedgehog Signaling in Cancer: A 
Prospective Therapeutic Target for Eradicating Cancer Stem Cells. Cells. 2018;7(11):208. 
doi:10.3390/cells7110208 
Schwartz L, Supuran CT, Alfarouk KO. The Warburg Effect and the Hallmarks of Cancer. 
Anticancer Agents Med Chem. 2017;17(2):164-170. 
Sharpe HJ, Pau G, Dijkgraaf GJ, Basset-Seguin N, Modrusan Z, Januario T, Tsui V, Durham 
AB, Dlugosz AA, Haverty PM, Bourgon R, Tang JY, Sarin KY, Dirix L, Fisher DC, Rudin 
CM, Sofen H, Migden MR, Yauch RL, de Sauvage FJ. Genomic analysis of smoothened 
inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015;27(3):327-41. doi: 
10.1016/j.ccell.2015.02.001.  
Stanford SM, Bottini N. Targeting Tyrosine Phosphatases: Time to End the Stigma. Trends 
Pharmacol Sci. 2017;38(6):524-540. doi:10.1016/j.tips.2017.03.004 
Te Boekhorst V, Friedl P. Plasticity of Cancer Cell Invasion-Mechanisms and Implications 
for Therapy. Adv Cancer Res. 2016;132:209-264. doi:10.1016/bs.acr.2016.07.005 
 
224 
Torresano L, Nuevo-Tapioles C, Santacatterina F, Cuezva JM. Metabolic reprogramming and 
disease progression in cancer patients. Biochim Biophys Acta Mol Basis Dis. 2020;165721. 
doi:10.1016/j.bbadis.2020.165721 
Tullemans BME, Heemskerk JWM, Kuijpers MJE. Acquired platelet antagonism: off-target 
antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. J Thromb 
Haemost. 2018;16(9):1686-1699. doi: 10.1111/jth.14225.  
Wang J, Liu B, Chen X, Su L, Wu P, Wu J, et al. PTP1B expression contributes to gastric 
cancer progression. Medical Oncology. 2012;29(2):948-956. doi: 10.1007/s12032-011-9911-2 
Warburg O. On respiratory impairment in cancer cells. Science. 1956;124(3215):269-70. 
Yang ZJ, Chee CE, Huang S, Sinicrope FA. The role of autophagy in cancer: therapeutic 
implications. Mol Cancer Ther. 2011;10(9):1533-1541. doi:10.1158/1535-7163.MCT-11-
0047 
Zambuzzi WF, Granjeiro JM, Parikh K, Yuvaraj S, Peppelenbosch MP, Ferreira CV. 
Modulation of Src activity by low molecular weight protein tyrosine phosphatase during 
osteoblast differentiation. Cell Physiol Biochem. 2008;22(5-6):497-506. 
Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. 
Cell Death Dis. 2013;4(3):e532. doi:10.1038/cddis.2013.60 
Zheng J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation 
(Review). Oncol Lett. 2012;4(6):1151-1157. doi:10.3892/ol.2012.928 
  
 
225 
Nederlandse samenvatting 
Eiwit fosforylering is een van de meest voorkomende post-translationele modificaties. Dit 
proces is essentieel voor het moduleren van enzymatische activiteit van eiwitten, hun 
stabiliteit, hun interacties met andere moleculen en hun sub-cellulaire lokalisatie. Als cruciaal 
onderdeel van het doorgeven van omgevingssignalen binnen in de cel, de zogenaamde signaal 
transductie, is fosforylering van eiwitten dan ook essentieel voor alle functies en processen 
die een cel uit moet voeren – van cel deling, overleving en  migratie tot productie van voor het 
lichaam essentiële stoffen. Eiwit fosforylering in de cel wordt bepaald door de acties van twee 
verschillende types van enzymen – de kinasen, die in staat zijn een fosfaatgroep aan een eiwit 
te bevestigen, en de fosfatasen, die fosfaatgroepen van eiwitten kunnen verwijderen. Een 
onbalans tussen deze twee klassen van enzymen en de daarmee gepaard gaande verstoring van 
intracellulaire fosforyleringspatronen kan dan ook verregaande gevolgen hebben. 
Verschillende ziektebeelden zijn geassocieerd met verstoorde activatie van kinasen en 
fosfatasen. In dit proefschrift heb ik mij met name gericht op de verstoorde signaal transductie 
die kenmerkend is voor tumor cellen. De belangrijkste signaleringsroutes zoals deze nu 
bekend zijn in kanker worden beschreven in Hoofdstuk 1.  Hoewel de behandeling van 
kanker in de afgelopen jaren wel verbeterd is, blijft deze ziekte nog steeds voor het overgrote 
deel ongeneselijk, en vaak zelfs dodelijk. Een beter inzicht in de verstoring van intracellulaire 
signaleringsroutes in de cel zou mogelijk kunnen bijdragen tot het identificeren van potentiële 
aangrijpingspunten voor nieuwe medicatie. Een van de methodes die hiervoor bij uitstek 
geschikt is, is het zogenaamde ‘kinome-profiling’, het op grote schaal bekijken van de 
activiteit van vele verschillende kinasen in een cel-lysaat. Met deze techniek zou theoretisch 
in 1 oogopslag kunnen worden gezien welke kinases een belangrijke rol vervullen in het 
oncogene proces, alsmede waarom tumor cellen in sommige gevallen niet reageren op 
behandeling met medicatie of resistent worden tegen zulke medicatie.  
Een goed voorbeeld hiervan laten we zien in Hoofdstuk 2. In dit hoofdstuk onderzoeken we 
hoe het kan dat in sommige gevallen kankerbehandeling met de drug Vismodigib niet werkt. 
Vismodigib blokkeert signalering die aangezet wordt door de stof sonic Hedgehog (SHh). 
SHh is erg belangrijk voor het in stand houden van stamcellen, en speelt daarom een 
belangrijke rol in de embryogenese maar ook in volwassen weefsels die afhankelijk zijn van 
stamcellen voor hun vernieuwing. In verschillende tumoren is aangetoond dat SHh 
signalering overactief is, waardoor de gedachte is ontstaan dat remming van dit signaal 
mogelijk kan bijdragen aan de behandeling van deze kankers. Desondanks is remming van 
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SHh signalering met onder andere Vismodigib toch niet altijd succesvol gebleken. Indien er 
geen SHh aanwezig is, wordt signalering actief geremd doordat de receptor Ptched (Ptch) de 
receptor smoothened (Smo) blokkeert. Binding van SHh aan Ptch heft deze remming op, 
waardoor Smo in staat is gen transcriptie patronen te activeren die leiden tot stamcel activatie. 
Deze cascade van reacties wordt gezien als de bekendste signalering via SHh. In Hoofdstuk 2 
laten wij echter zien dat SHh ook kinase signalering aanzet, en dat Ptch en Smo allebei 
verschillende kinase patronen activeren. Behandeling van cellen met Vismodigib, dat 
specifiek de bekende signalering via Smo blokkeert, remt niet alle kinase activatie patronen 
die door SHh in gang worden gezet. De kinase patronen die nog doorkomen zijn vaak ook 
betrokken bij kankerceldeling. Dit zou een mogelijke verklaring kunnen zijn voor het feit dat 
tumoren met over-activatie van SHh signalering niet altijd goed reageren op behandeling met 
vismodigib,  
Een tweede voorbeeld waarin we laten zien dat kinome profiling behulpzaam kan zijn bij de 
opsporing van resistentiemechanismen van tumoren komt naar voren in Hoofdstuk 3.  In dit 
hoofdstuk onderzochten we de verschillen in kinase activatie patronen tussen de drug-
gevoelige leukemie cellijn K562, en een drug-resistente afgeleide cellijn hiervan, Lucena-1. 
Opmerkelijk genoeg vonden we een kinase patroon dat duidt op veranderingen in 
energiehuishouding in Lucena-1 cellen. Vervolgexperimenten lieten inderdaad zien dat 
mitochondriële functie in Lucena-1 cellen verstoord is, en dat deze cellen meer lactaat 
produceren. Dat wijst erop dat deze cellen in plaats van normale energieproductie via 
mitochondriële oxidatieve fosforylering zijn overgeschakeld op glycolyse, een sneller proces 
om energie te genereren. Een dergelijke omschakeling wordt vaker gezien in tumor cellen, en 
wordt ook wel het Warburg effect genoemd, naar de ontdekker hiervan. Dit is echter de eerste 
keer dat dit aangetoond wordt in de context van drug-resistentie, en de daadwerkelijke link 
tussen deze twee processen behoeft dan ook verdere aandacht.  
Eerder heeft onze onderzoeksgroep laten zien dat Lucena-1 cellen een verhoogde expressie 
hebben van de fosfatase LMWPTP, en dat dit bijdraagt aan de drug resistente eigenschappen 
van deze cel lijn. Om te kijken of LMWPTP ook bijdraagt aan de switch van mitochondriële 
oxidatieve fosforylering naar glycolyse werd dit enzym uitgeschakeld in Lucena-1 cellen. 
Deze proeven toonden aan dat LMWPTP inderdaad gedeeltelijk rechtstreeks bijdraagt aan dit 
proces. Dit lijkt wellicht tegenstrijdig, wetende dat activatie van fosforyleringspatronen 
werden gezien middels kinome profiling. Echter fosforylering van eiwitten kan zowel 
activerende als inactiverende functies hebben, en het verwijderen van remmende 
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fosforyleringspatronen door fosfatasen, waaronder LMWPTP, kan derhalve bijdragen tot 
stimulering van kankerprocessen. Dit concept is echter relatief nieuw, en hoewel kinasen in 
het kankeronderzoek duidelijk verankerd zijn, wordt er nog relatief weinig gekeken naar de 
fosfatasen. In Hoofdstuk 4 hebben wij getracht meer inzicht te verkrijgen in de rol van 
LMWPTP in cellulaire kankerprocessen, en laten ze zien dat deze een belangrijke rol speelt in 
hoe een tumor cel omgaat met de cellulaire stresscondities.  
Hoewel een stimulerende rol voor LMWPTP in kankercellen langzamerhand duidelijk wordt 
(o.a. Hoofdstuk 3 en 4 en eerder onderzoek uit onze groep heeft laten zien dat LMWPTP 
maligniteit van kankercellen versterkt), staan kankercellen niet op zichzelf in het menselijk 
lichaam. Ze zijn verankerd in een extracellulaire matrix en ontvangen veel signalen uit hun 
omgeving, van andere cellen (o.a. immuun cellen) alsmede signaleringsstoffen die worden 
vrijgegeven door andere cellen. Recentelijk is duidelijk geworden dat bloedplaatjes een 
interessante interactie kunnen hebben met tumor cellen. Bloedplaatjes zijn in staat om tumor 
cellen aan te zetten tot celdeling, en kunnen helpen bij de metastasering van tumor cellen via 
de bloedbaan. Omgekeerd kunnen tumor cellen bloedplaatjes activeren. Aangezien de 
belangrijkste fysiologische functie van bloedplaatjes is het helpen stollen van bloed bij een 
verwonding, kan tumorcel gemedieerde activering van bloedplaatjes leiden tot het ontstaan 
van bloedpropjes in de bloedbaan, en trombose is dan ook een veelvoorkomende serieuze 
complicatie van kanker. Trombose wordt echter ook vaker gezien op hogere leeftijd, en 
aangezien kanker ook een ouderdomsziekte is, is het mogelijk dat veroudering bijdraagt aan 
veranderingen in bloedplaatjes die vervolgens hun interactie met tumor cellen versterkt. In 
Hoofdstuk 5 hebben we onderzocht of publicaties in de literatuur deze aannames staven. We 
concludeerden dat het verouderingsproces inderdaad resulteert in verhoogde mate van 
activatie van bloedplaatjes. Echter tumorcellen zelf hebben een direct activerend effect op 
bloedplaatjes dat onafhankelijk is van leeftijd. Inzicht in de moleculaire processen die 
bijdragen aan de interactie tussen bloedplaatjes en kankercellen kan mogelijk resulteren in de 
ontwikkeling van nieuwe therapieën ter bestrijding van zowel trombose in kankerpatiënten 
alsmede bloedplaatjes-gemedieerde kankerceldeling en metastasering.  In Hoofdstuk 6 
hebben we daarom gekeken naar de signaaltransductie routes die worden aangezet in 
kankercellen door bloedplaatjes. Hierbij zagen we activatie van kinases, maar ook een op-
regulatie van de fosfatase LMWPTP wanneer maag- of-darmkanker cellen werden gekweekt 
in de aanwezigheid van bloedplaatjes. Aangezien LMWPTP inderdaad verhoogd aanwezig is 
in tumoren van maag- en darm kankerpatiënten, lijkt dit ook klinisch relevant te zijn. In 
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celkweekexperimenten bleken bloedplaatjes in staat te zijn de celgroei van maag- en -
darmkanker cellen te stimuleren, en dit effect werd significant verminderd indien we 
LMWPTP expressie genetisch verminderden in de tumorcellen.  
Deze resultaten tonen duidelijk aan dat LMWPTP expressie in tumor cellen bijdraagt aan 
oncogene eigenschappen die door bloedplaatjes worden doorgegeven, maar zeggen niets over 
de signaaltransductie in de bloedplaatjes zelf. Om hier een beter inzicht in te krijgen hebben 
we in Hoofdstuk 7 de literatuur onderzocht om inzicht te krijgen in wat er bekend was over 
signalering in bloedplaatjes. We concludeerden dat hoewel er veel informatie beschikbaar is 
over de kinasen die geactiveerd worden door de verschillende receptoren die bloedplaatjes 
bezitten, er maar relatief weinig bekend is over de rol van fosfatasen in activatie van 
bloedplaatjes. Om deze reden onderzochten we in Hoofdstuk 8 of fosfatasen ook actief zijn in 
bloedplaatjes. We toonden voor het eerst aan dat LMWPTP, maar ook de fosfatase PTP1B, 
geactiveerd kunnen worden in bloedplaatjes onder invloed van verschillende stimuli. Een 
remmer van fosfatase activiteit, 3-bromopyuvate (3-BP), blokkeerde de functie van 
bloedplaatjes op moleculair niveau (remming van kinase activiteit) alsmede cellulair niveau 
(remming van activatie en aggregatie). We toonden aan dat incubatie van bloedplaatjes met 
tumor cellen resulteerde in een verhoogde mate van signalering en aggregatie van 
bloedplaatjes, en dat dit geremd kon worden met 3-BP. Opmerkelijk genoeg leek het 
incuberen van bloedplaatjes met tumor cellen ook te leiden tot een verhoging van LMWPTP 
in bloedplaatjes in vitro, iets wat we in een kleine steekproef ook bij kankerpatiënten zagen. 
Al met al lijkt de rol van LMWPTP in de interactie tussen tumor cellen en bloedplaatjes dus 
sterk verankerd te zijn in allebei de celtypes. Mogelijk kan remming van fosfatasen in de 
toekomst bijdragen aan vermindering van het risico op trombose, alsmede een betere 
bestrijding van tumoren.   
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